var title_f26_37_27216="Lichen sclerosus - trunk";
var content_f26_37_27216=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=DERM%2F74154&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=DERM%2F74154&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Lichen sclerosus",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 432px; height: 325px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Oval porcelain-white plaques are present on the trunk of this patient with extragenital lichen sclerosus.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: www.visualdx.com. Copyright Logical Images, Inc.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f26_37_27216=[""].join("\n");
var outline_f26_37_27216=null;
var title_f26_37_27217="Patient information: Congenital syphilis (The Basics)";
var content_f26_37_27217=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"10\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div>",
"   &nbsp;",
"  </div>",
"  <div id=\"basicsTopicMinWidth\">",
"   <div id=\"basicsTopicRight\">",
"    <div id=\"placeholder\">",
"     <div class=\"ieSpacer\">",
"     </div>",
"     <div id=\"basics-more\">",
"      <h4>",
"       <img src=\"file://www.uptodate.com/images/basics-more-title.png\"/>",
"      </h4>",
"      <dl>",
"       <dt class=\"basics\">",
"        The Basics",
"       </dt>",
"       <dd>",
"        <a href=\"UTD.htm?9/61/10195\">",
"         Patient information: Syphilis (The Basics)",
"        </a>",
"       </dd>",
"      </dl>",
"      <div id=\"tooltipper\">",
"      </div>",
"     </div>",
"    </div>",
"   </div>",
"   <div id=\"basicsTopicLeft\">",
"    <div id=\"topicTitle\">",
"     Patient information: Congenital syphilis (The Basics)",
"    </div>",
"    <span class=\"view\">",
"     View in",
"     <a class=\"lang\" href=\"./es-419/congenital-syphilis-the-basics?source=topic_page\">",
"      Spanish",
"     </a>",
"    </span>",
"    <a class=\"contributor contributor_credentials\" href=\"./authors-and-editors/patient-information\">",
"     Written by the doctors and editors at UpToDate",
"    </a>",
"    <div id=\"topicText\">",
"     <p class=\"headingAnchor\" id=\"H25333150\">",
"      <span class=\"h1\">",
"       What is congenital syphilis?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Congenital syphilis is a dangerous infection that babies can get if their mothers have syphilis during pregnancy. The term &ldquo;congenital&rdquo; means a condition a person is born with.",
"     </p>",
"     <p>",
"      Syphilis is an infection you can catch during sex that causes red sores, usually on the penis or around the vagina or anus. Since the sores don&rsquo;t hurt, many people don&rsquo;t get treatment for syphilis. If a woman has syphilis when she is pregnant, the infection can spread to the baby through the placenta. (The placenta is the organ that brings the baby nutrients and oxygen and carries away waste.) Babies can also become infected during birth.",
"     </p>",
"     <p>",
"      Congenital syphilis is very serious. It can cause a baby to be born too early or to die before birth.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H25333165\">",
"      <span class=\"h1\">",
"       What are the symptoms of congenital syphilis?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Most newborns with congenital syphilis do not have symptoms. When they do, symptoms include:",
"     </p>",
"     <p>",
"      <ul class=\"bullet-block\">",
"       <li>",
"        A big liver &ndash; The liver is an organ in the upper right side of the belly.",
"       </li>",
"       <li>",
"        A runny nose &ndash; This is worse than the runny nose from a common cold. Babies with congenital syphilis have mucus that is white and might be bloody.",
"       </li>",
"       <li>",
"        Small, red or pink spots &ndash; These are mostly on the back, the bottom, the back of the upper legs, and the soles of the feet.",
"       </li>",
"       <li>",
"        Swollen lymph nodes &ndash; Lymph nodes are bean-shaped organs found all over the body under the skin. They make and store cells that fight infections.",
"       </li>",
"      </ul>",
"     </p>",
"     <p>",
"      Symptoms in older babies and children include:",
"     </p>",
"     <p>",
"      <ul class=\"bullet-block\">",
"       <li>",
"        A &ldquo;saddle nose&rdquo; &ndash; This means the upper bridge of the nose is flattened",
"       </li>",
"       <li>",
"        A forehead that sticks out more than normal",
"       </li>",
"       <li>",
"        Inflammation of the clear tissue that covers the colored part of the eye, called the &ldquo;cornea&rdquo;",
"       </li>",
"       <li>",
"        Hearing loss",
"       </li>",
"       <li>",
"        Teeth that have notches and gaps between them",
"       </li>",
"       <li>",
"        Scars around the mouth",
"       </li>",
"       <li>",
"        Red, open sores on the skin",
"       </li>",
"       <li>",
"        Problems with the bones and joints, mostly in the legs",
"       </li>",
"       <li>",
"        Trouble thinking and solving problems",
"       </li>",
"      </ul>",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H25333180\">",
"      <span class=\"h1\">",
"       Are there tests for congenital syphilis?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Yes. The doctor might take a sample of the discharge from the baby&rsquo;s nose or from a sore on the baby&rsquo;s body. Then another doctor will look at this fluid under a microscope to check for signs of the infection.",
"     </p>",
"     <p>",
"      Other tests might include:",
"     </p>",
"     <p>",
"      <ul class=\"bulletCompact-block\">",
"       <li>",
"        Blood tests",
"       </li>",
"      </ul>",
"     </p>",
"     <p>",
"      <ul class=\"bulletCompact-block\">",
"       <li>",
"        Lumbar puncture (also known as a &ldquo;spinal tap&rdquo;) &ndash; For this test, a doctor puts a thin needle in the lower back and removes a small amount of spinal fluid. Spinal fluid is the fluid that surrounds the brain and spinal cord. He or she will do lab tests on the spinal fluid.",
"       </li>",
"      </ul>",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H25333195\">",
"      <span class=\"h1\">",
"       How is congenital syphilis treated?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Congenital syphilis is treated with a medicine called penicillin. The medicine can be given as an injection (shot) or through a small tube that goes into a vein, called an &ldquo;IV.&rdquo;",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H25333210\">",
"      <span class=\"h1\">",
"       Can congenital syphilis be prevented?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Preventing and treating syphilis in adults can prevent congenital syphilis. Adults can lower their chances of getting syphilis by:",
"     </p>",
"     <p>",
"      <ul class=\"bulletCompact-block\">",
"       <li>",
"        Using a latex condom every time they have sex",
"       </li>",
"       <li>",
"        Avoiding sex when either person has any symptoms that could be caused by an infection",
"       </li>",
"       <li>",
"        Not having sex",
"       </li>",
"      </ul>",
"     </p>",
"     <p>",
"      Another way to prevent congenital syphilis is to make sure that women who get syphilis are treated. Getting treated before getting pregnant is best, but women can still get treated during pregnancy. It is important to get tested after treatment to make sure that the treatment worked.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H25333236\">",
"      <span class=\"h1\">",
"       More on this topic",
"      </span>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?9/61/10195?source=see_link\">",
"       Patient information: Syphilis (The Basics)",
"      </a>",
"     </p>",
"    </div>",
"    <div id=\"reviewProcess\">",
"     <span>",
"      All topics are updated as new evidence becomes available and our",
"      <a class=\"policy policy_editorialpolicy\" href=\"/home/editorial-policy\">",
"       peer review process",
"      </a>",
"      is complete.",
"     </span>",
"    </div>",
"    <div id=\"topicRetrievedDate\">",
"     <span class=\"emphasis\">",
"      This topic retrieved from UpToDate on:",
"     </span>",
"     Apr 20, 2013.",
"    </div>",
"    <div class=\"patTopicTool\" id=\"patTopicToolBottom\">",
"     <a class=\"toolbutton findicon findInPageLink\" href=\"#\" title=\"Find in Topic\">",
"      Find",
"     </a>",
"     <a class=\"toolbutton printicon\" href=\"UTD.htm?26/37/27217?view=print\" title=\"Print This Topic\">",
"      Print",
"     </a>",
"     <a class=\"toolbutton emailicon etacLink\" href=\"#\" title=\"Email This Topic\">",
"      Email",
"     </a>",
"    </div>",
"    <div id=\"disclaimer\">",
"     The content on the UpToDate website is not intended nor recommended as a substitute for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or other qualified health care professional regarding any medical questions or conditions.",
"The use of UpToDate content is governed by the",
"     <a class=\"legal legal_termsofuse\" href=\"/home/terms-use\" target=\"_blank\">",
"      UpToDate Terms of Use",
"     </a>",
"     . &copy;2013 UpToDate, Inc. All rights reserved.",
"    </div>",
"    <div id=\"topicVersionRevision\">",
"     Topic 83398 Version 2.0",
"    </div>",
"   </div>",
"   <!--  basicsTopicLeft -->",
"  </div>",
"  <!-- basicsTopicMinWidth -->",
" </div>",
" <!-- topicContent -->",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0604-118.195.65.247-9F1D191359-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f26_37_27217=[""].join("\n");
var outline_f26_37_27217=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H25333150\">",
"      What is congenital syphilis?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H25333165\">",
"      What are the symptoms of congenital syphilis?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H25333180\">",
"      Are there tests for congenital syphilis?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H25333195\">",
"      How is congenital syphilis treated?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H25333210\">",
"      Can congenital syphilis be prevented?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H25333236\">",
"      More on this topic",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?9/61/10195?source=related_link\">",
"      Patient information: Syphilis (The Basics)",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f26_37_27218="Tubal recanalization b";
var content_f26_37_27218=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F63310&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F63310&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Pelvic fluoroscopic image",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 392px; height: 403px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    A pelvic fluoroscopic image during fallopian tube recanalization shows a guidewire and microcatheter passed through the left fallopian tube.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f26_37_27218=[""].join("\n");
var outline_f26_37_27218=null;
var title_f26_37_27219="Propantheline: Pediatric drug information";
var content_f26_37_27219=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"1\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Propantheline: Pediatric drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_general\" href=\"UTD.htm?14/4/14404?source=see_link\">",
"    see \"Propantheline: Drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?6/27/6580?source=see_link\">",
"    see \"Propantheline: Patient drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list_set htclist drugH1Div drugBrandNames\" id=\"F1061500\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Therapeutic Category",
"    </span>",
"    <ul>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Anticholinergic Agent",
"      </span>",
"     </li>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Antispasmodic Agent, Gastrointestinal",
"      </span>",
"     </li>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Antispasmodic Agent, Urinary",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block dos drugH1Div\" id=\"F1061495\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Usual",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_general\" href=\"UTD.htm?14/4/14404?source=see_link\">",
"      see \"Propantheline: Drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Antisecretory:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Children: 1-2 mg/kg/day in 3-4 divided doses",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Adults: 15 mg 3 times/day before meals or food and 30 mg at bedtime; for mild manifestations: 7.5 mg 3 times/day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Antispasmodic:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Children: 2-3 mg/kg/day in divided doses every 4-6 hours and at bedtime",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Adults: 15 mg 3 times/day before meals or food and 30 mg at bedtime",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F214400\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Tablet, oral, as bromide: 15 mg",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F214386\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Yes",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F1061503\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Oral: Administer 30 minutes before meals and at bedtime",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F1061502\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Adjunctive treatment of peptic ulcer, irritable bowel syndrome, pancreatitis, ureteral and urinary bladder spasm; to reduce duodenal motility during diagnostic radiologic procedures",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F9959527\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      BEERS Criteria medication:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       This drug may be potentially inappropriate for use in geriatric patients (Quality of evidence - moderate; Strength of recommendation - strong).",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block arm drugH1Div\" id=\"F214440\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Cardiovascular: Palpitation, tachycardia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Central nervous system: Confusion, dizziness, drowsiness, headache, insomnia, nervousness",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Endocrine &amp; metabolic: Suppression of lactation",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Gastrointestinal: Bloated feeling, constipation,  loss of taste, nausea, vomiting, xerostomia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Genitourinary: Impotence, urinary hesitancy, urinary retention",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Neuromuscular &amp; skeletal: Weakness",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Ocular: Blurred vision, cycloplegia, mydriasis, ocular tension increased",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Miscellaneous: Allergic reactions, anaphylaxis, diaphoresis decreased",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F1061507\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to propantheline or any component; narrow-angle glaucoma; ulcerative colitis; toxic megacolon; obstructive disease of the GI or urinary tract",
"    </p>",
"   </div>",
"   <div class=\"block pre drugH1Div\" id=\"F1061494\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Precautions",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Use with caution in febrile patients, patients with hyperthyroidism, hepatic, cardiac, or renal disease, hypertension, GI infections, diarrhea, reflux esophagitis",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F1061493\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Infants, patients with Down's syndrome, and children with spastic paralysis or brain damage may be hypersensitive to antimuscarinic effects",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F13299949\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     None known.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F214395\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     AbobotulinumtoxinA: Anticholinergic Agents may enhance the anticholinergic effect of AbobotulinumtoxinA.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Acetylcholinesterase Inhibitors (Central): Anticholinergics may diminish the therapeutic effect of Acetylcholinesterase Inhibitors (Central). Acetylcholinesterase Inhibitors (Central) may diminish the therapeutic effect of Anticholinergics. If the anticholinergic action is a side effect of the agent, the result may be beneficial.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Aclidinium: May enhance the anticholinergic effect of Anticholinergics.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Anticholinergics: May enhance the adverse/toxic effect of other Anticholinergics.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Levocabastine (Nasal).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Cannabinoids: Anticholinergic Agents may enhance the tachycardic effect of Cannabinoids.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ipratropium (Oral Inhalation): May enhance the anticholinergic effect of Anticholinergics.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     MAO Inhibitors: May enhance the orthostatic hypotensive effect of Orthostatic Hypotension Producing Agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Mirabegron: Anticholinergic Agents may enhance the therapeutic effect of Mirabegron. This may result in acute urinary retention.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     OnabotulinumtoxinA: Anticholinergic Agents may enhance the anticholinergic effect of OnabotulinumtoxinA.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Potassium Chloride: Anticholinergic Agents may enhance the ulcerogenic effect of Potassium Chloride.  Management: Patients on drugs with substantial anticholinergic effects should avoid using any solid oral dosage form of potassium chloride.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pramlintide: May enhance the anticholinergic effect of Anticholinergics. These effects are specific to the GI tract.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     RimabotulinumtoxinB: Anticholinergic Agents may enhance the anticholinergic effect of RimabotulinumtoxinB.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Secretin: Anticholinergic Agents may diminish the therapeutic effect of Secretin.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tiotropium: Anticholinergics may enhance the anticholinergic effect of Tiotropium.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Topiramate: Anticholinergic Agents may enhance the adverse/toxic effect of Topiramate. Specifically, the risk of oligohidrosis and hyperthermia may be enhanced.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F214396\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     C (",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F14079705\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Animal reproduction studies have not been conducted.",
"    </p>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F1061492\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Competitively blocks the action of acetylcholine at postganglionic parasympathetic receptor sites",
"    </p>",
"   </div>",
"   <div class=\"block phd drugH1Div\" id=\"F1061505\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Onset of action: Within 30-45 minutes",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Duration: 4-6 hours",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F1061506\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacokinetics (Adult data unless noted)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Metabolism: In the liver and GI tract",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Elimination: In urine, bile, and other body fluids",
"    </p>",
"   </div>",
"   <div class=\"block pai drugH1Div\" id=\"F1061499\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Patient Information",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?6/27/6580?source=see_link\">",
"      see \"Propantheline: Patient drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;display:inline\">",
"     May cause drowsiness and impair ability to perform activities requiring mental alertness or physical coordination; notify physician if skin rash, flushing, or eye pain occurs; or if difficulty in urinating, constipation, or sensitivity to light becomes severe or persists; may cause dry mouth; maintain good oral hygiene habits, because lack of saliva may increase chance of cavities",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 12739 Version 34.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0604-115.66.252.144-CACC98E3A6-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f26_37_27219=[""].join("\n");
var outline_f26_37_27219=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1061500\">",
"      Therapeutic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1061495\">",
"      Dosing: Usual",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F214400\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F214386\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1061503\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1061502\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9959527\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F214440\">",
"      Adverse Reactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1061507\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1061494\">",
"      Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1061493\">",
"      Warnings",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13299949\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F214395\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F214396\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F14079705\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1061492\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1061505\">",
"      Pharmacodynamics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1061506\">",
"      Pharmacokinetics (Adult data unless noted)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1061499\">",
"      Patient Information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_PED/12739\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_PED/12739|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?14/4/14404?source=related_link\">",
"      Propantheline: Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?6/27/6580?source=related_link\">",
"      Propantheline: Patient drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f26_37_27220="Gallbladder anatomy PI";
var content_f26_37_27220=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PI%2F68129&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PI%2F68129&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 563px\">",
"   <div class=\"ttl\">",
"    Anatomy of the gallbladder",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 543px; height: 396px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The gallbladder (shown in green) is a small, pear-shaped organ that is tucked under the liver. It stores bile, a fluid that is made in the liver and helps the body break down fat. When you eat a meal that has fat in it, your gallbladder empties the bile into a tube called the \"bile duct.\" The bile duct carries the bile into the small intestine to help with digestion.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f26_37_27220=[""].join("\n");
var outline_f26_37_27220=null;
var title_f26_37_27221="Ciclesonide (nasal): Patient drug information";
var content_f26_37_27221=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div id=\"drugTitle\">",
"   Ciclesonide (nasal): Patient drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   <p>",
"    (For additional information",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/25/35220?source=see_link\">",
"     see \"Ciclesonide (nasal): Drug information\"",
"    </a>",
"    and",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?3/33/3604?source=see_link\">",
"     see \"Ciclesonide (nasal): Pediatric drug information\"",
"    </a>",
"    )",
"   </p>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F8002704\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Omnaris&reg;;",
"     </li>",
"     <li>",
"      Zetonna&trade;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F8002705\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Omnaris&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yya-os drugH1Div\" id=\"F10030458\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What is this drug used for?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691981",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to treat nose stuffiness. It may take 2 weeks to see the full effect.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691589",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to ease allergy signs.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt coi-os drugH1Div\" id=\"F10030457\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I need to tell my doctor before I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2701801",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have an allergy to ciclesonide or any other part of this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2705171",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are allergic to any drugs, foods, or other substances. Tell your doctor about the allergy and what signs you had, like rash; hives; itching; shortness of breath; wheezing; cough; swelling of face, lips, tongue, or throat; or any other signs.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yye-os drugH1Div\" id=\"F10030462\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some things I need to know or do while I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697224",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have glaucoma or cataracts, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s3767222",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any nose ulcers or sores, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696717",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Check all drugs you are taking with your doctor. This drug may not mix well with some other drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697641",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are pregnant or plan on getting pregnant. You will need to talk about the benefits and risks of using this drug while you are pregnant.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697636",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are breast-feeding. You will need to talk about any risks to your baby.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyf-os drugH1Div\" id=\"F10030463\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects of this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698119",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Headache.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697983",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Cough.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698257",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Nose stuffiness.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698258",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Nose irritation.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698280",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Nosebleed.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyh-os drugH1Div\" id=\"F10030465\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects that I need to call my doctor about right away?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698721",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you think there has been an overdose, call 1-800-222-1222 (the American Association of Poison Control Centers), your local poison control center (file://www.aapcc.org), or emergency room (ER) right away.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699066",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of an allergic reaction, like rash; hives; itching; red, swollen, blistered, or peeling skin with or without fever; wheezing; tightness in the chest or throat; trouble breathing or talking; unusual hoarseness; or swelling of the mouth, face, lips, tongue, or throat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699077",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of infection. These include a fever of 100.5&deg;F (38&deg;C) or higher, chills, very bad sore throat, ear or sinus pain, cough, more sputum or change in color of sputum, pain with passing urine, mouth sores, wound that will not heal, or anal itching or pain.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699024",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very bad dizziness.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699040",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Bad nose irritation.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s3767199",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Bad nose bleeds.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s3767200",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Whistling sound when you breathe.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s3767201",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Redness or white patches in mouth or throat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699042",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very upset stomach or throwing up.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698658",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Feeling very tired or weak.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698603",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Any rash.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698977",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Side effect or health problem is not better or you are feeling worse.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyc-os drugH1Div\" id=\"F10030460\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How is this drug best taken?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2694774",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not take this drug by mouth. Use in your nose only. Keep out of your mouth and eyes (may burn).",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2694567",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Blow your nose before use.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s3682982",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Spray up the nose only. Do not spray onto the wall joining your two nostrils.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2694631",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Close 1 nostril.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696128",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tilt your head forward a little.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695230",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Put nose spray tube into other nostril.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696276",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       While breathing in, press down once to release spray.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2694569",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Breathe out from your mouth.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"link\">",
"        urn:lims:b498:s3767193",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       <b>",
"        <span style=\"text-decoration: underline\">",
"         Omnaris&trade;:",
"        </span>",
"       </b>",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695636",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Shake well before use.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s3767195",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Prime by spraying 8 sprays before first using or if you have not used for 4 days.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"link\">",
"        urn:lims:b498:s3767194",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       <b>",
"        <span style=\"text-decoration: underline\">",
"         Zetonna&trade;:",
"        </span>",
"       </b>",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s3767196",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Prime by spraying 3 sprays before first using or if you have not used for 10 days.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyd-os drugH1Div\" id=\"F10030461\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I do if I miss a dose?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696583",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Use a missed dose as soon as you think about it.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696496",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If it is close to the time for your next dose, skip the missed dose and go back to your normal time.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696485",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not use 2 doses or extra doses.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696457",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not change the dose or stop this drug. Talk with the doctor.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyi-os drugH1Div\" id=\"F10030466\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How do I store and/or throw out this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"link\">",
"        urn:lims:b498:s3767193",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       <b>",
"        <span style=\"text-decoration: underline\">",
"         Omnaris&trade;:",
"        </span>",
"       </b>",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699336",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store at room temperature.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699638",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Use nose spray within 4 months of opening pouch.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s3767202",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Throw away when actuator says zero.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"link\">",
"        urn:lims:b498:s3767194",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       <b>",
"        <span style=\"text-decoration: underline\">",
"         Zetonna&trade;:",
"        </span>",
"       </b>",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699336",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store at room temperature.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699262",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Protect from heat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s3767203",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not puncture.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s3767202",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Throw away when actuator says zero.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyj-os drugH1Div\" id=\"F10030467\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     General drug facts",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699675",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If your symptoms or health problems do not get better or if they become worse, call your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699673",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not share your drugs with others and do not take anyone else's drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699678",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep all drugs out of the reach of children and pets.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699709",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any questions about this drug, please talk with your doctor, pharmacist, or other health care provider.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s3302581",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       In Canada, take any unused drugs to the pharmacy. Also, visit file://www.hc-sc.gc.ca/hl-vs/iyh-vsv/med/disposal-defaire-eng.php#th to learn about the right way to get rid of unused drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699671",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       These are not all of the side effects that may occur. If you have questions about side effects, call your doctor. Call your doctor for medical advice about side effects.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699683",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with the doctor before starting any new drug, including prescription or OTC, natural products, or vitamins.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 11569 Version 31.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1105-190.92.87.115-3AD7EB5AF7-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f26_37_27221=[""].join("\n");
var outline_f26_37_27221=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8002704\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8002705\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10030458\">",
"      What is this drug used for?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10030457\">",
"      What do I need to tell my doctor before I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10030462\">",
"      What are some things I need to know or do while I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10030463\">",
"      What are some side effects of this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10030465\">",
"      What are some side effects that I need to call my doctor about right away?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10030460\">",
"      How is this drug best taken?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10030461\">",
"      What do I do if I miss a dose?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10030466\">",
"      How do I store and/or throw out this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10030467\">",
"      General drug facts",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?34/25/35220?source=related_link\">",
"      Ciclesonide (nasal): Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?3/33/3604?source=related_link\">",
"      Ciclesonide (nasal): Pediatric drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?34/5/34902?source=related_link\">",
"      Ciclesonide (oral inhalation): Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?34/34/35365?source=related_link\">",
"      Ciclesonide (oral inhalation): Patient drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?22/26/22949?source=related_link\">",
"      Ciclesonide (oral inhalation): Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f26_37_27222="Linagliptin and Metformin: Drug information";
var content_f26_37_27222=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Linagliptin and Metformin: Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?35/22/36197?source=see_link\">",
"    see \"Linagliptin and Metformin: Patient drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"block spa drugH1Div\" id=\"F16339634\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Special Alerts",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      FDA Investigating Unpublished Reports of Pancreatic Toxicity With Incretin Mimetic Drugs",
"     </span>",
"     <span class=\"collapsible-date\">",
"      March 2013",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:0em;margin-top:2em;\">",
"       The Food and Drug Administration (FDA) is evaluating unpublished new findings that suggest an increased risk of pancreatitis and pancreatic duct metaplasia in patients with type 2 diabetes treated with incretin mimetics. These findings are based on pancreatic tissue samples taken from patients who died from unspecified causes. The FDA has requested these samples, as well as information on the methodology used to collect them, and will communicate its final conclusions and recommendations. Healthcare providers should continue to prescribe incretin mimetics according to the drug label recommendations and patients receiving incretin mimetics are advised to continue therapy as directed and to discuss any concerns with their healthcare provider.",
"      </p>",
"      <p style=\"text-indent:0em;margin-top:2em;\">",
"       Further information may be found at the following website:",
"       <a href=\"file://www.fda.gov/Drugs/DrugSafety/ucm343187.htm\" target=\"_blank\">",
"        file://www.fda.gov/Drugs/DrugSafety/ucm343187.htm",
"       </a>",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block black-box-warn drugH1Div\" id=\"F13813081\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     ALERT: U.S. Boxed Warning",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     The FDA-approved labeling includes a boxed warning. See Warnings/Precautions section for a concise summary of this information.  For verbatim wording of the boxed warning, consult the product labeling or",
"     <a href=\"file://www.fda.gov\" target=\"_blank\">",
"      www.fda.gov",
"     </a>",
"     .",
"    </p>",
"   </div>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F13813137\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Jentadueto&trade;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F13759120\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Antidiabetic Agent, Biguanide;",
"     </li>",
"     <li>",
"      Antidiabetic Agent, Dipeptidyl Peptidase IV (DPP-IV) Inhibitor",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F13813120\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;display:inline\">",
"     <b>",
"      Note:",
"     </b>",
"     Patients receiving concomitant insulin and/or insulin secretagogues (eg, sulfonylureas) may require dosage adjustments of these agents.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      Type 2 diabetes mellitus:",
"     </b>",
"     Oral:  Initial doses should be based on current dose of linagliptin and metformin.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     <i>",
"      Patients inadequately controlled on metformin alone:",
"     </i>",
"     Initial dose: Linagliptin 5 mg/day plus current daily dose of metformin given in 2 equally divided doses; maximum: linagliptin 5 mg/metformin 2000 mg daily.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     <i>",
"      Patients inadequately controlled on linagliptin alone:",
"     </i>",
"     Initial dose: Metformin 1000 mg/day plus linagliptin 5 mg/day given in 2 equally divided doses.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      Dosing adjustment:",
"     </b>",
"     Metformin component may be gradually increased up to the maximum dose. Maximum dose: Linagliptin 5 mg/metformin 2000 mg daily",
"    </p>",
"   </div>",
"   <div class=\"block doe drugH1Div\" id=\"F13813121\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Geriatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refer to adult dosing. The initial and maintenance dosing should be conservative, due to the potential for decreased renal function (monitor). Do not use in patients &ge;80 years of age unless normal renal function has been established.",
"    </p>",
"   </div>",
"   <div class=\"block dor drugH1Div\" id=\"F13813123\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Renal Impairment",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Use is contraindicated in patients with renal disease or renal dysfunction (serum creatinine &ge;1.5 mg/dL [&ge;136 micromole/L] in males or &ge;1.4 mg/dL [&ge;124 micromole/L] in females or abnormal clearance)",
"    </p>",
"   </div>",
"   <div class=\"block doh drugH1Div\" id=\"F13813122\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Hepatic Impairment",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Avoid metformin; liver disease is a risk factor for the development of lactic acidosis during metformin therapy.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F13766180\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Tablet, oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Jentadueto&trade; 2.5/500: Linagliptin 2.5 mg and metformin hydrochloride 500 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Jentadueto&trade; 2.5/850: Linagliptin 2.5 mg and metformin hydrochloride 850 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Jentadueto&trade; 2.5/1000: Linagliptin 2.5 mg and metformin hydrochloride 1000 mg",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F13813083\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F13813126\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Administer with meals, at the same time each day.",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F13759122\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Management of type 2 diabetes mellitus (noninsulin dependent, NIDDM) as an adjunct to diet and exercise in patients not adequately controlled on metformin or linagliptin monotherapy",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F13813082\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Sound-alike/look-alike issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       Linagliptin and Metformin may be confused with Sitagliptin and Metformin",
"      </p>",
"     </div>",
"    </div>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      High alert medication:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       The Institute for Safe Medication Practices (ISMP) includes this medication among its list of drug classes which have a heightened risk of causing significant patient harm when used in error.",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F13813100\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Reactions/percentages reported with combination product; also see individual agents.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     1% to 10%:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Gastrointestinal: Diarrhea (6%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Respiratory: Nasopharyngitis (6%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Frequency not defined:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Dermatologic: Pruritus",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Gastrointestinal: Appetite decreased, nausea, pancreatitis, vomiting",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Respiratory: Cough",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Miscellaneous: Hypersensitivity reactions",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F13813089\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to linagliptin, metformin, or any component of the formulation; renal disease or renal dysfunction (serum creatinine &ge;1.5 mg/dL [&ge;136 micromole/L] in males or &ge;1.4 mg/dL [&ge;124 micromole/L] in females), or abnormal creatinine clearance which may also result from conditions such as cardiovascular collapse, acute myocardial infarction, and septicemia; acute or chronic metabolic acidosis including diabetic ketoacidosis (with or without coma).",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F13813090\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      <i>",
"       Concerns related to adverse effects:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Lactic acidosis:",
"     <b>",
"      [U.S. Boxed Warning]: Lactic acidosis is a rare, but potentially severe consequence of therapy with metformin.",
"     </b>",
"     Lactic acidosis should be suspected in any patient with diabetes receiving metformin with evidence of acidosis but without evidence of ketoacidosis. Discontinue metformin in clinical situations predisposing to hypoxemia, including conditions such as cardiovascular collapse, respiratory failure, acute myocardial infarction, acute congestive heart failure, and septicemia. The risk of accumulation and lactic acidosis increases with the degree of impairment of renal function.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      <i>",
"       Disease-related concerns:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Diabetes mellitus (type 1): Not indicated for use in patients with insulin-dependent diabetes mellitus (IDDM) (type 1) due to lack of efficacy in this population.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Heart failure: Use with caution in patients with congestive heart failure requiring pharmacologic management, particularly in patients with unstable or acute heart failure; risk of lactic acidosis may be increased secondary to hypoperfusion.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Hepatic impairment: Avoid metformin use in patients with impaired liver function due to potential for lactic acidosis.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Renal impairment: Metformin is substantially excreted by the kidney; patients with renal function below the limit of normal for their age should not receive therapy. Use of concomitant medications that may affect renal function (ie, affect tubular secretion) may also affect metformin disposition. Metformin should be withheld in patients with dehydration and/or prerenal azotemia.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Stress-related states: It may be necessary to discontinue metformin and administer insulin if the patient is exposed to stress (eg, fever, trauma, infection, surgery).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      <i>",
"       Concurrent drug therapy issues:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Carbonic anhydrase inhibitors: Concomitant use of drugs that inhibit carbonic anhydrase (topiramate, zonisamide, acetazolamide) may cause metabolic acidosis and increase the risk of metformin-induced lactic acidosis; use with caution.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Insulin: Use caution when used in conjunction with insulin; risk of hypoglycemia is increased. Monitor blood glucose closely; insulin dosage adjustments may be necessary.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Insulin secretagogues: Concomitant use of an insulin secretagogue (eg, sulfonylurea) may increase the risk of hypoglycemia. Monitor blood glucose closely; dosage reduction of secretagogues may be required.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      <i>",
"       Special populations:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Elderly: Metformin should not be initiated in patients &ge;80 years of age unless normal renal function is confirmed.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      <i>",
"       Other warnings/precautions:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Ethanol use: Instruct patients to avoid excessive acute or chronic ethanol use; ethanol may potentiate metformin's effect on lactate metabolism.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Iodinated contrast: Metformin therapy should be temporarily discontinued prior to or at the time of intravascular administration of iodinated contrast media (potential for acute alteration in renal function). Metformin should be withheld for 48 hours after the radiologic study and restarted only after renal function has been confirmed as normal.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Patient education: Diabetes self-management education (DSME) is essential to maximize the effectiveness of therapy.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Surgical procedures: Therapy should be suspended for any surgical procedures (resume only after normal intake resumed and normal renal function is verified).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Vitamin B",
"     <sub>",
"      12",
"     </sub>",
"     concentrations: Metformin may impair vitamin B",
"     <sub>",
"      12",
"     </sub>",
"     absorption, particularly in those with inadequate vitamin B",
"     <sub>",
"      12",
"     </sub>",
"     or calcium intake/absorption; very rarely associated with anemia. Rapid reversal of vitamin B",
"     <sub>",
"      12",
"     </sub>",
"     deficiency may be observed with discontinuation of therapy or supplementation. Monitor vitamin B",
"     <sub>",
"      12",
"     </sub>",
"     serum concentrations periodically with long-term therapy.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F13853583\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refer to individual components.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F13853581\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     ACE Inhibitors: DPP-IV Inhibitors may enhance the adverse/toxic effect of ACE Inhibitors. Specifically, the risk of angioedema may be increased.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Carbonic Anhydrase Inhibitors: May enhance the adverse/toxic effect of MetFORMIN. Specifically, the risk of developing lactic acidosis may be increased.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Brinzolamide; Dorzolamide.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Cephalexin: May increase the serum concentration of MetFORMIN.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Cimetidine: May increase the serum concentration of MetFORMIN.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Corticosteroids (Orally Inhaled): May diminish the hypoglycemic effect of Antidiabetic Agents. In some instances, corticosteroid-mediated HPA axis suppression has led to episodes of acute adrenal crisis, which may manifest as enhanced hypoglycemia, particularly in the setting of insulin or other antidiabetic agent use.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Corticosteroids (Systemic): May diminish the hypoglycemic effect of Antidiabetic Agents. In some instances, corticosteroid-mediated HPA axis suppression has led to episodes of acute adrenal crisis, which may manifest as enhanced hypoglycemia, particularly in the setting of insulin or other antidiabetic agent use.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP3A4 Inducers (Strong): May decrease the serum concentration of Linagliptin. Management: Strongly consider using an alternative to any strong CYP3A4 inducer in patients who are being treated with linagliptin. If this combination is used, monitor patients closely for evidence of reduced linagliptin effectiveness.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Dalfampridine: May increase the serum concentration of MetFORMIN. MetFORMIN may increase the serum concentration of Dalfampridine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Deferasirox: May decrease the serum concentration of CYP3A4 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Dofetilide: MetFORMIN may increase the serum concentration of Dofetilide.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Glycopyrrolate: May increase the serum concentration of MetFORMIN.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Herbs (CYP3A4 Inducers): May increase the metabolism of CYP3A4 Substrates. Management: Consider avoiding CYP3A4 inducing herbs in order to avoid therapeutic failure of the substrate. Some combinations may be specifically contraindicated. Consult appropriate manufacturer labeling.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Herbs (Hypoglycemic Properties): May enhance the hypoglycemic effect of Hypoglycemic Agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Hypoglycemic Agents: May enhance the adverse/toxic effect of other Hypoglycemic Agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Iodinated Contrast Agents: May enhance the adverse/toxic effect of MetFORMIN. Renal dysfunction that may be caused by iodinated contrast agents may lead to metformin-associated lactic acidosis. Management: Withhold metformin from all patients receiving intravascular iodinated contrast agents prior to or at the time of the procedure and for at least 48 hrs thereafter.  Document adequate renal function before restarting metformin.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     LamoTRIgine: May increase the serum concentration of MetFORMIN. Management: The lamotrigine Canadian product monograph states that coadministration of these drugs is not recommended.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Loop Diuretics: May diminish the hypoglycemic effect of Hypoglycemic Agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Luteinizing Hormone-Releasing Hormone Analogs: May diminish the therapeutic effect of Antidiabetic Agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     MAO Inhibitors: May enhance the hypoglycemic effect of Hypoglycemic Agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pegvisomant: May enhance the hypoglycemic effect of Antidiabetic Agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     P-glycoprotein/ABCB1 Inducers: May decrease the serum concentration of Linagliptin. Management: Strongly consider using an alternative to any strong P-glycoprotein inducer in patients who are being treated with linagliptin. If this combination is used, monitor patients closely for evidence of reduced linagliptin effectiveness.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     P-glycoprotein/ABCB1 Inhibitors: May increase the serum concentration of P-glycoprotein/ABCB1 Substrates. P-glycoprotein inhibitors may also enhance the distribution of p-glycoprotein substrates to specific cells/tissues/organs where p-glycoprotein is present in large amounts (e.g., brain, T-lymphocytes, testes, etc.).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ritonavir: May increase the serum concentration of Linagliptin.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Salicylates: May enhance the hypoglycemic effect of Hypoglycemic Agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Selective Serotonin Reuptake Inhibitors: May enhance the hypoglycemic effect of Hypoglycemic Agents. Selective Serotonin Reuptake Inhibitors may increase the serum concentration of Hypoglycemic Agents. Management: Consider increased monitoring of glycemic control with concomitant use of a hypoglycemic agent and an SSRI. Dosage adjustments of the hypoglycemic agent may be necessary upon SSRI initiation or discontinuation.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Somatropin: May diminish the hypoglycemic effect of Antidiabetic Agents.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Thiazide Diuretics: May diminish the therapeutic effect of Antidiabetic Agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tocilizumab: May decrease the serum concentration of CYP3A4 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Trimethoprim: May increase the serum concentration of MetFORMIN.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Trospium: MetFORMIN may decrease the serum concentration of Trospium.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block foi drugH1Div\" id=\"F13813103\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Ethanol/Nutrition/Herb Interactions",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Ethanol: Excessive ethanol intake (acute or chronic) may increase risks for metformin accumulation and lactic acidosis.  Management: Avoid excessive ethanol intake.",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F13813085\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     B (",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F13813086\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Adverse events were not observed in animal reproduction studies using this combination. Refer to individual agents.",
"    </p>",
"   </div>",
"   <div class=\"block lac drugH1Div\" id=\"F13813087\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Lactation",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Linagliptin: Excretion in breast milk unknown/use caution",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Metformin: Enters breast milk/not recommended",
"    </p>",
"   </div>",
"   <div class=\"block brc drugH1Div\" id=\"F13813088\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Breast-Feeding Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Small amounts of metformin are excreted into breast milk; excretion of linagliptin is not known. Use of this combination in breast-feeding women is not recommended by the manufacturer. Also refer to individual agents.",
"    </p>",
"   </div>",
"   <div class=\"block dic drugH1Div\" id=\"F13813125\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dietary Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Should be taken with meals (to decrease GI upset). Take at the same time each day. Individualized medical nutrition therapy (MNT) based on ADA recommendations is an integral part of therapy. Monitor for signs and symptoms of vitamin B",
"     <sub>",
"      12",
"     </sub>",
"     and/or folic acid deficiency; supplementation may be required.",
"    </p>",
"   </div>",
"   <div class=\"block fee drugH1Div\" id=\"F16322931\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pricing: U.S. (Medi-Span&reg;)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Tablets",
"     </b>",
"     (Jentadueto Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     2.5-500 mg (60): $290.05",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     2.5-850 mg (60): $290.05",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     2.5-1000 mg (60): $290.05",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F13813128\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hb A",
"     <sub>",
"      1c",
"     </sub>",
"     and serum glucose; hematologic parameters (eg, hemoglobin/hematocrit, red blood cell indices) annually; hepatic function, renal function (prior to initiation of therapy then annually or more frequent if necessary); vitamin B",
"     <sub>",
"      12",
"     </sub>",
"     (periodically with long-term treatment) and folate (if megaloblastic anemia is suspected)",
"    </p>",
"   </div>",
"   <div class=\"block rer drugH1Div\" id=\"F13813107\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Reference Range",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Recommendations for glycemic control in nonpregnant adults with diabetes (ADA, 2012):",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Hb A",
"     <sub>",
"      1c",
"     </sub>",
"     : &lt;7% (a more aggressive [&lt;6.5%] or less aggressive [&lt;8%] Hb A",
"     <sub>",
"      1c",
"     </sub>",
"     goal may be targeted based on patient-specific characteristics)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Preprandial capillary plasma glucose: 70-130 mg/dL",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Peak postprandial capillary blood glucose: &lt;180 mg/dL",
"    </p>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F13813106\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Linagliptin inhibits dipeptidyl peptidase IV (DPP-IV) enzymes resulting in prolonged active incretin levels. Incretin hormones [eg, glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP)] regulate glucose homeostasis by increasing insulin synthesis and release from pancreatic beta cells and decreasing glucagon secretion from pancreatic alpha cells. Decreased glucagon secretion results in decreased hepatic glucose production. Under normal physiologic circumstances, incretin hormones are released by the intestine throughout the day and levels are increased in response to a meal; incretin hormones are rapidly inactivated by DPP-IV enzymes.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;\">",
"     Metformin decreases hepatic glucose production, decreasing intestinal absorption of glucose, and improves insulin sensitivity (increases peripheral glucose uptake and utilization).",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F13813108\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics/Kinetics",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     See individual agents.",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      American Diabetes Association, &ldquo;Standards of Medical Care in Diabetes Mellitus -- 2012,&rdquo;",
"      <i>",
"       Diabetes Care",
"      </i>",
"      , 2012, 35(Suppl 1):11-63.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?26/37/27222/abstract-text/22187469/pubmed\" id=\"22187469\" target=\"_blank\">",
"        22187469",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Canadian Diabetes Association Clinical Practice Guidelines Expert Committee, \"Canadian Diabetes Association 2008 Clinical Practice Guidelines for the Prevention and Management of Diabetes in Canada,\"",
"      <i>",
"       Can J Diabetes",
"      </i>",
"      , 20078, 32(suppl 1):1-201.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Handelsman Y, Mechanick JI, Blonde L, et al, &ldquo;American Association of Clinical Endocrinologists Medical Guidelines for Clinical Practice for Developing a Diabetes Mellitus Comprehensive Care Plan,&rdquo;",
"      <i>",
"       Endocr Pract",
"      </i>",
"      , 2011, 17(Suppl 2):1-53.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?26/37/27222/abstract-text/21474420/pubmed\" id=\"21474420\" target=\"_blank\">",
"        21474420",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Qaseem A, Humphrey LL, Sweet DE, et al,&ldquo;Oral Pharmacologic Treatment of Type 2 Diabetes Mellitus: A Clinical Practice Guideline from the American College of Physicians,&rdquo;",
"      <i>",
"       Ann Intern Med",
"      </i>",
"      , 2012, 156(3):218-31.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?26/37/27222/abstract-text/22312141/pubmed\" id=\"22312141\" target=\"_blank\">",
"        22312141",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 17143 Version 19.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-125.39.66.147-5A1610FE52-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f26_37_27222=[""].join("\n");
var outline_f26_37_27222=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F16339634\">",
"      Special Alerts",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13813081\">",
"      ALERT: U.S. Boxed Warning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13813137\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13759120\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13813120\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13813121\">",
"      Dosing: Geriatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13813123\">",
"      Dosing: Renal Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13813122\">",
"      Dosing: Hepatic Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13766180\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13813083\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13813126\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13759122\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13813082\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13813100\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13813089\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13813090\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13853583\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13853581\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13813103\">",
"      Ethanol/Nutrition/Herb Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13813085\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13813086\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13813087\">",
"      Lactation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13813088\">",
"      Breast-Feeding Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13813125\">",
"      Dietary Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F16322931\">",
"      Pricing: U.S. (Medi-Span&reg;)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13813128\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13813107\">",
"      Reference Range",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13813106\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13813108\">",
"      Pharmacodynamics/Kinetics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/17143\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/17143|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?35/22/36197?source=related_link\">",
"      Linagliptin and Metformin: Patient drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f26_37_27223="Gemcitabine: Pediatric drug information";
var content_f26_37_27223=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Gemcitabine: Pediatric drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_general\" href=\"UTD.htm?31/1/31769?source=see_link\">",
"    see \"Gemcitabine: Drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?0/42/677?source=see_link\">",
"    see \"Gemcitabine: Patient drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F175343\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Gemzar&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F175344\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Gemcitabine For Injection, USP;",
"     </li>",
"     <li>",
"      Gemzar&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list_set htclist drugH1Div drugBrandNames\" id=\"F1016262\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Therapeutic Category",
"    </span>",
"    <ul>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Antineoplastic Agent, Antimetabolite (Pyrimidine Antagonist)",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block dos drugH1Div\" id=\"F1016297\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Usual",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_general\" href=\"UTD.htm?31/1/31769?source=see_link\">",
"      see \"Gemcitabine: Drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Details concerning dosing in combination regimens should also be consulted.",
"     <b>",
"      Note:",
"     </b>",
"     Prolongation of the infusion time &gt;60 minutes and administration more frequently than once weekly have been shown to increase toxicity. Refer to individual protocols: I.V.:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Children and Adolescents:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <b>",
"      Hodgkin&rsquo;s lymphoma, refractory or relapsed:",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Children &ge;10 years and Adolescents: 1000 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     /dose over 100 minutes on days 1 and 8 (in combination with vinorelbine); repeat cycle every 21 days (Cole, 2009)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Adolescents &ge;17 years: 1000 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     /dose over 60 minutes on days 1, 8, and 15 (in combination with vinorelbine); repeat cycle every 28 days (Suyani, 2011)",
"     <b>",
"      or",
"     </b>",
"     800 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     /dose on days 1 and 4 (in combination with ifosfamide and vinorelbine); repeat cycle every 21 days (Santoro, 2007)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <b>",
"      Sarcomas, refractory or relapsed (including Ewing&rsquo;s sarcoma, osteosarcoma):",
"     </b>",
"     Children &ge;3 years and Adolescents: 675",
"     <b>",
"      or",
"     </b>",
"     1000 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     /dose over 90 minutes on days 1 and 8 (in combination with docetaxel); repeat cycle every 21 days (Mora, 2009; Navid, 2008)",
"     <b>",
"      or",
"     </b>",
"     1000 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     /dose over 30 minutes on days 1 and 8 (in combination with oxaliplatin and irinotecan); repeat cycle every 28 days (Hartmann, 2011)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <b>",
"      Solid tumors, refractory or relapsed:",
"     </b>",
"     Children &ge;1 year and Adolescents: 1000 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     /dose over 30 minutes on days 1 and 8 (in combination with oxaliplatin and irinotecan); repeat cycle every 28 days (Hartmann, 2011)",
"     <b>",
"      or",
"     </b>",
"     1000 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     /dose over 100 minutes on day 1 (in combination with oxaliplatin); repeat cycle every 14 days (Geoerger, 2011)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     <b>",
"      Note:",
"     </b>",
"     Dosage reductions for toxicity (Geoerger, 2011): 800 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     /dose over 80 minutes if grade 3/4 nonhematological toxicity, grade 4 neutropenia with documented infection or lasting &gt;7 days, grade 3/4 thrombocytopenia lasting &gt;7 days or requiring platelets during &gt;7 days, or delay of next cycle &ge;14 days; if necessary dose could be reduced a second time to 600 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     /dose",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <b>",
"      Germ cell tumor, refractory:",
"     </b>",
"     Adolescents &ge;16 years: 1200 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     /dose over 30 minutes on days 1, 8, and 15; repeat cycle every 28 days for up to 6 cycles (Einhorn, 1999)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Adults:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <b>",
"      Breast cancer, metastatic (AGC should be &ge;1500/mm",
"      <sup>",
"       3",
"      </sup>",
"      and platelets &ge;100,000/mm",
"      <sup>",
"       3",
"      </sup>",
"      prior to each cycle):",
"     </b>",
"     1250 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     over 30 minutes on days 1 and 8; repeat cycle every 21 days (in combination with paclitaxel)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <b>",
"      Nonsmall cell lung cancer, locally advanced or metastatic (in combination with cisplatin):",
"     </b>",
"     1000 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     over 30 minutes on days 1, 8, and 15; repeat cycle every 28 days",
"     <b>",
"      or",
"     </b>",
"     1250 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     over 30 minutes on days 1 and 8; repeat cycle every 21 days",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <b>",
"      Ovarian cancer, advanced (AGC should be &ge;1500/mm",
"      <sup>",
"       3",
"      </sup>",
"      and platelets &ge;100,000/mm",
"      <sup>",
"       3",
"      </sup>",
"      prior to each cycle):",
"     </b>",
"     1000 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     over 30 minutes days 1 and 8; repeat cycle every 21 days (in combination with carboplatin)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <b>",
"      Pancreatic cancer, locally advanced or metastatic:",
"     </b>",
"     Initial: 1000 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     over 30 minutes once weekly for up to 7 weeks followed by 1 week of rest; then 1000 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     once weekly for 3 weeks out of every 4 weeks",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Dose escalation: Patients who complete an entire cycle of therapy may have the dose in subsequent cycles increased by 25% as long as the absolute granulocyte count (AGC) nadir is &gt;1500/mm",
"     <sup>",
"      3",
"     </sup>",
"     , platelet nadir is &gt;100,000/mm",
"     <sup>",
"      3",
"     </sup>",
"     , and nonhematologic toxicity is less than WHO Grade 1. If the increased dose is tolerated (with the same parameters) the dose in subsequent cycles may again be increased by 20%.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Dosing adjustment for renal impairment:",
"     </b>",
"     Adults: The manufacturer&rsquo;s labeling does not contain dosing adjustment guidelines; use with caution in patients with pre-existing renal dysfunction. Discontinue if severe renal toxicity or hemolytic uremic syndrome (HUS) occur during gemcitabine treatment.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     The following adjustments have been made by some clinicians (Janus, 2010; Li, 2007):",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Mild to severe renal impairment: No adjustment required",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     ESRD withhemodialysis: Hemodialysis should begin 6-12 hours after gemcitabine infusion",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Dosing adjustment for hepatic impairment:",
"     </b>",
"     Adults: The manufacturer&rsquo;s  labeling does not contain dosing adjustment guidelines; use with caution. Discontinue if severe hepatotoxicity occurs during treatment with gemcitabine. The following guidelines have been used by some clinicians:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Transaminases elevated (with normal bilirubin): No adjustment required (Venook, 2000)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Serum bilirubin &gt;1.6 mg/dL: Use initial dose of 800 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     ; may escalate if tolerated (Ecklund, 2005; Floyd, 2006; Venook, 2000)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Dosing adjustment for hematologic toxicity:",
"     </b>",
"     Adults:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <b>",
"      Breast cancer:",
"     </b>",
"     Adjustments based on granulocyte and platelet counts on day 8:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     AGC &ge;1200/mm",
"     <sup>",
"      3",
"     </sup>",
"     <b>",
"      and",
"     </b>",
"     platelet count &gt;75,000/mm",
"     <sup>",
"      3",
"     </sup>",
"     : Administer 100% of full dose",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     AGC 1000-1199/mm",
"     <sup>",
"      3",
"     </sup>",
"     <b>",
"      or",
"     </b>",
"     platelet count 50,000-75,000/mm",
"     <sup>",
"      3",
"     </sup>",
"     : Administer 75% of full dose",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     AGC 700-999/mm",
"     <sup>",
"      3",
"     </sup>",
"     <b>",
"      and",
"     </b>",
"     platelet count &ge;50,000/mm",
"     <sup>",
"      3",
"     </sup>",
"     : Administer 50% of full dose",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     AGC &lt;700/mm",
"     <sup>",
"      3",
"     </sup>",
"     <b>",
"      or",
"     </b>",
"     platelet count &lt;50,000/mm",
"     <sup>",
"      3",
"     </sup>",
"     : Hold dose",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Severe (grades 3 or 4) nonhematologic toxicity (except alopecia, nausea, and vomiting): Hold or decrease dose by 50%. Paclitaxel dose may also need adjusted.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <b>",
"      Nonsmall cell lung cancer:",
"     </b>",
"     Refer to guidelines for pancreatic cancer. Cisplatin dosage may also need adjusted.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Severe (grades 3 or 4) nonhematologic toxicity (except alopecia, nausea, and vomiting): Hold or decrease dose by 50%",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <b>",
"      Ovarian cancer:",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Adjustments based on granulocyte and platelet counts on day 8:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">",
"     AGC &ge;1500/mm",
"     <sup>",
"      3",
"     </sup>",
"     <b>",
"      and",
"     </b>",
"     platelet count &ge;100,000/mm",
"     <sup>",
"      3",
"     </sup>",
"     : Administer 100% of full dose",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">",
"     AGC 1000-1499/mm",
"     <sup>",
"      3",
"     </sup>",
"     <b>",
"      and/or",
"     </b>",
"     platelet count 75,000-99,999/mm",
"     <sup>",
"      3",
"     </sup>",
"     : Administer 50% of full dose",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">",
"     AGC &lt;1000/mm",
"     <sup>",
"      3",
"     </sup>",
"     <b>",
"      and/or",
"     </b>",
"     platelet count &lt;75,000/mm",
"     <sup>",
"      3",
"     </sup>",
"     : Hold dose",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">",
"     Severe (grades 3 or 4) nonhematologic toxicity (except nausea and vomiting): Hold or decrease dose by 50%. Carboplatin dose may also need adjusted.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Dose adjustment for subsequent cycles:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">",
"     AGC &lt;500/mm",
"     <sup>",
"      3",
"     </sup>",
"     for &gt;5 days, AGC &lt;100/mm",
"     <sup>",
"      3",
"     </sup>",
"     for &gt;3 days, febrile neutropenia, platelet count &lt;25,000/mm",
"     <sup>",
"      3",
"     </sup>",
"     , cycle delay &gt;1 week due to toxicity: Reduce gemcitabine to 800 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     on days 1 and 8",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">",
"     For recurrence of any of the above toxicities after initial dose reduction: Administer gemcitabine 800 mg/m2 on day 1 only for the subsequent cycle",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <b>",
"      Pancreatic cancer:",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     AGC &ge;1000/mm",
"     <sup>",
"      3",
"     </sup>",
"     <b>",
"      and",
"     </b>",
"     platelet count &ge;100,000/mm",
"     <sup>",
"      3",
"     </sup>",
"     : Administer 100% of full dose",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     AGC 500-999/mm",
"     <sup>",
"      3",
"     </sup>",
"     <b>",
"      or",
"     </b>",
"     platelet count 50,000-99,999/mm",
"     <sup>",
"      3",
"     </sup>",
"     : Administer 75% of full dose",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     AGC &lt;500/mm",
"     <sup>",
"      3",
"     </sup>",
"     <b>",
"      or",
"     </b>",
"     platelet count &lt;50,000/mm",
"     <sup>",
"      3",
"     </sup>",
"     : Hold dose",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F175320\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Injection, powder for reconstitution: 200 mg, 1 g, 2 g",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Gemzar&reg;: 200 mg, 1 g",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Injection, solution: 38 mg/mL (5.26 mL, 26.3 mL, 52.6 mL)",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F175305\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Yes",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F1016304\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     I.V.: Hazardous agent; use appropriate precautions for handling and disposal",
"     <a href=\"file://www.cdc.gov/niosh/docs/2012-150/pdfs/2012-150.pdf\" target=\"_blank\">",
"      (NIOSH, 2012)",
"     </a>",
"     . Reconstitute lyophilized powder according to manufacturer&rsquo;s labeling to  a final concentration of 38 mg/mL (solution must be reconstituted to &le;40 mg/mL to completely dissolve). Maximum concentration for administration: 38 mg/mL; gemcitabine can be further diluted with 50-500 mL NS to concentrations as low as 0.1 mg/mL. Infuse over 30-90 minutes based on the protocol. Prolongation of the infusion time &gt;60 minutes has been shown to prolong gemcitabine&rsquo;s half-life and increase toxicity in adults; gemcitabine has been studied in adults utilizing a fixed-dose rate (FDR) of 10 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     /minute (Ko, 2006; Tempero, 2003); patients who receive gemcitabine FDR experience more grade 3/4 hematologic toxicity (Ko, 2006; Poplin, 2009). pH 2.7-3.3",
"    </p>",
"   </div>",
"   <div class=\"block scp drugH1Div\" id=\"F1016287\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Compatibility",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Stable in D",
"     <sub>",
"      5",
"     </sub>",
"     W, NS",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Y-site administration: Compatible:",
"     </b>",
"     Amifostine, amikacin, aminophylline, ampicillin, ampicillin/sulbactam, aztreonam, bleomycin, bumetanide, buprenorphine, butorphanol, calcium gluconate, carboplatin, carmustine, cefazolin, cefotetan, cefoxitin, ceftazidime, ceftizoxime, ceftriaxone, cefuroxime, chlorpromazine, cimetidine, ciprofloxacin, cisplatin, clindamycin, co-trimoxazole, cyclophosphamide, cytarabine, dactinomycin, daunorubicin, dexamethasone sodium phosphate, dexrazoxane, diphenhydramine, dobutamine, docetaxel, dopamine, doxorubicin, doxycycline, droperidol, enalaprilat, etoposide, etoposide phosphate, famotidine, floxuridine, fluconazole, fludarabine, fluorouracil, gatifloxacin, gentamicin, granisetron, haloperidol, heparin, hydrocortisone sodium phosphate, hydrocortisone sodium succinate, hydromorphone, hydroxyzine, idarubicin, ifosfamide, leucovorin, linezolid, lorazepam, mannitol, meperidine, mesna, metoclopramide, metronidazole, minocycline, mitoxantrone, morphine, nalbuphine, netilmicin, ofloxacin, ondansetron, paclitaxel, plicamycin, potassium chloride, promethazine, ranitidine, sodium bicarbonate, streptozocin, teniposide, thiotepa, ticarcillin, ticarcillin/clavulanate, tobramycin, topotecan, vancomycin, vinblastine, vincristine, vinorelbine, zidovudine.",
"     <b>",
"      Incompatible:",
"     </b>",
"     Acyclovir, amphotericin B, cefoperazone, cefotaxime, furosemide, ganciclovir, imipenem/cilastatin, irinotecan, methotrexate, methylprednisolone sodium succinate, mitomycin, piperacillin, piperacillin/tazobactam, prochlorperazine edisylate",
"    </p>",
"   </div>",
"   <div class=\"block sta drugH1Div\" id=\"F1016283\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Stability",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Lyophilized powder: Store intact vial at 20&ordm;C to 25&ordm;C (68&ordm;F to 77&ordm;F); reconstituted vials are stable up to 24 hours at room temperature; do not refrigerate as crystallization may occur",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Solution for injection: Store intact vials at 2&deg;C to 8&deg;C (36&deg;F to 46&deg;F); do not freeze. Solutions further diluted in NS are stable for 24 hours at room temperature. Do not refrigerate.",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F1016263\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Treatment of locally advanced, inoperable (stage IIIA or IIIB), or metastatic (stage IV) nonsmall cell lung cancer (NSCLC), metastatic breast cancer, and advanced relapsed ovarian cancer as part of combination therapy (FDA approved in adults); treatment of locally advanced or metastatic pancreatic cancer as a single agent (FDA approved in adults); has also been used in the treatment of refractory solid tumors (including brain tumors), refractory or relapsed Hodgkin&rsquo;s lymphoma, and refractory germ cell tumors",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F175393\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Sound-alike/look-alike issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       Gemcitabine may be confused with gemtuzumab",
"      </p>",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       Gemzar&reg; may be confused with Zinecard&reg;",
"      </p>",
"     </div>",
"    </div>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      High alert medication:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       This medication is in a class the Institute for Safe Medication Practices (ISMP) includes among its list of drug classes which have a heightened risk of causing significant patient harm when used in error.",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block arm drugH1Div\" id=\"F175389\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Cardiovascular: Edema, peripheral edema",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Central nervous system: Fever, somnolence",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Dermatologic: Alopecia, pruritus, rash",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Gastrointestinal: Diarrhea, nausea/vomiting, stomatitis",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Hematologic: Anemia, hemorrhage, leukopenia, neutropenia, thrombocytopenia; myelosuppression is the dose-limiting toxicity",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Hepatic: Alkaline phosphatase increased, ALT increased, AST increased, bilirubin increased",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Local: Injection site reactions",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Neuromuscular &amp; skeletal: Paresthesia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Renal: BUN increased, creatinine increased, hematuria, proteinuria",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Respiratory: Bronchospasm, dyspnea",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Miscellaneous: Flu-like syndrome, infection",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Rare but important or life-threatening (reported with single-agent use or with combination therapy): Acute/adult respiratory distress syndrome, anaphylactoid reaction, arrhythmias, bullous skin eruptions, cellulitis, cerebrovascular accident, CHF, desquamation, fulminant hepatic failure, gangrene, GGT increased, hemolytic uremic syndrome (HUS), hepatic sinusoidal obstruction syndrome (SOS; veno-occlusive liver disease), hepatotoxicity (rare), hyper-/hypotension, interstitial pneumonitis, liver failure, MI, neuropathy, peripheral vasculitis, petechiae, pulmonary edema, pulmonary fibrosis, radiation recall, renal failure, respiratory failure, reversible posterior leukoencephalopathy syndrome (RPLS), sepsis, supraventricular arrhythmia, thrombotic thrombocytopenic purpura",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F1016269\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to gemcitabine or any component",
"    </p>",
"   </div>",
"   <div class=\"block pre drugH1Div\" id=\"F2886956\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Precautions",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Use with caution in patients with renal or hepatic impairment. Use with caution in patients receiving concurrent radiation therapy; radiation toxicity, including tissue injury, severe mucositis, esophagitis, or pneumonitis has been reported with concurrent and nonconcurrent administration. Gemcitabine and radiation therapy have radiosensitizing activity when given &le;7 days apart; lower gemcitabine doses with concurrent radiation therapy may produce less severe toxicity; however, an optimum regimen for combination therapy has not been determined for all tumor types; radiation recall may occur when gemcitabine and radiation therapy are given &gt;7 days apart.",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F1016270\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hazardous agent; use appropriate precautions for handling and disposal",
"     <a href=\"file://www.cdc.gov/niosh/docs/2012-150/pdfs/2012-150.pdf\" target=\"_blank\">",
"      (NIOSH, 2012)",
"     </a>",
"     . Prolongation of the infusion time &gt;60 minutes as well as more frequent than once weekly dosing have been shown to increase toxicity. Longer infusion times allow increased accumulation of the active metabolite, gemcitabine triphosphate, optimizing the pharmacokinetics. Myelosuppression is usually the dose-limiting toxicity; monitor CBC with differential and platelet count prior to each dose; reduce or withhold dose depending on the degree of hematologic toxicity. Gemcitabine has been reported to cause hemolytic uremic syndrome and/or renal failure requiring dialysis or leading to death; monitor renal function prior to initial dose and then periodically. Hepatotoxicity, including liver failure and death, has been reported with gemcitabine use; monitor hepatic function prior to initial dose and then periodically. Pulmonary toxicity has also been reported with use. Discontinue gemcitabine if severe lung, renal, or hepatotoxicity occurs. Gemcitabine may cause fever in the absence of clinical infection.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F13299393\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     None known.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F175314\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     BCG: Immunosuppressants may diminish the therapeutic effect of BCG.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Bleomycin: Gemcitabine may enhance the adverse/toxic effect of Bleomycin. The risk of pulmonary toxicity may be increased.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CloZAPine: Myelosuppressive Agents may enhance the adverse/toxic effect of CloZAPine. Specifically, the risk for agranulocytosis may be increased.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Coccidioidin Skin Test: Immunosuppressants may diminish the diagnostic effect of Coccidioidin Skin Test.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Denosumab: May enhance the adverse/toxic effect of Immunosuppressants. Specifically, the risk for serious infections may be increased.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Echinacea: May diminish the therapeutic effect of Immunosuppressants.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Fluorouracil (Systemic): Gemcitabine may increase the serum concentration of Fluorouracil (Systemic).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Fluorouracil (Topical): Gemcitabine may increase the serum concentration of Fluorouracil (Topical).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Leflunomide: Immunosuppressants may enhance the adverse/toxic effect of Leflunomide. Specifically, the risk for hematologic toxicity such as pancytopenia, agranulocytosis, and/or thrombocytopenia may be increased.  Management: Consider not using a leflunomide loading dose in patients receiving other immunosuppressants.  Patients receiving both leflunomide and another immunosuppressant should be monitored for bone marrow suppression at least monthly.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Natalizumab: Immunosuppressants may enhance the adverse/toxic effect of Natalizumab. Specifically, the risk of concurrent infection may be increased.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pimecrolimus: May enhance the adverse/toxic effect of Immunosuppressants.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Roflumilast: May enhance the immunosuppressive effect of Immunosuppressants.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Sipuleucel-T: Immunosuppressants may diminish the therapeutic effect of Sipuleucel-T.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tacrolimus (Topical): May enhance the adverse/toxic effect of Immunosuppressants.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tofacitinib: Immunosuppressants may enhance the immunosuppressive effect of Tofacitinib.  Management: Concurrent use with antirheumatic doses of methotrexate or other non-disease modifying antirheumatic drugs (non-DMARDs) is permitted, and this warning seems to particularly focused on more potent immunosuppressants.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Trastuzumab: May enhance the neutropenic effect of Immunosuppressants.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Vaccines (Inactivated): Immunosuppressants may diminish the therapeutic effect of Vaccines (Inactivated).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Vaccines (Live): Immunosuppressants may enhance the adverse/toxic effect of Vaccines (Live). Vaccinial infections may develop. Immunosuppressants may diminish the therapeutic effect of Vaccines (Live).  Management: Avoid use of live organism vaccines with immunosuppressants; live-attenuated vaccines should not be given for at least 3 months after immunosuppressants.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Vitamin K Antagonists (eg, warfarin): Antineoplastic Agents may enhance the anticoagulant effect of Vitamin K Antagonists. Antineoplastic Agents may diminish the anticoagulant effect of Vitamin K Antagonists.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F175316\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     D (",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F175329\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Embryotoxicity and fetal malformations (cleft palate, incomplete ossification, fused pulmonary artery, absence of gallbladder) have been reported in animal studies. There are no adequate and well-controlled studies in pregnant women. If patient becomes pregnant, she should be informed of risks. May cause fetal harm if administered during pregnancy; adverse effects in reproduction are anticipated based on the mechanism of action.",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F1016306\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     CBC with differential and platelet count prior to each dose; monitor renal and hepatic function prior to initial dose and then periodically, bilirubin, LDH, and reticulocyte count; monitor serum electrolytes, including potassium, magnesium, and calcium (when in combination therapy with cisplatin)",
"    </p>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F1016288\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Gemcitabine undergoes intracellular phosphorylation to its corresponding diphosphate and triphosphate nucleosides which inhibit DNA polymerase and ribonucleotide reductase; results in inhibition of DNA synthesis; specific for the S-phase of the cell cycle.",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F1016290\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacokinetics (Adult data unless noted)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Distribution: Widely distributed into tissues; present in ascitic fluid",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     V",
"     <sub>",
"      d",
"     </sub>",
"     :",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     I.V. infusion &lt;70 minutes: 50 L/m",
"     <sup>",
"      2",
"     </sup>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     I.V. infusion 70-285 minutes: 370 L/m",
"     <sup>",
"      2",
"     </sup>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Protein binding: Negligible",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Metabolism: Intracellularly by nucleoside kinases to active di- and triphosphate metabolites; metabolized by cytidine deaminase to an inactive metabolite",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Half-life:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     I.V. infusion &lt;70 minutes: 0.7-1.6 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     I.V. infusion 70-285 minutes: 4.1-10.6 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Elimination: 92% to 98% excreted in the urine as gemcitabine (&lt;10%) and inactive uracil metabolite, difluorodeoxyuridine (dFdU)",
"    </p>",
"   </div>",
"   <div class=\"block pai drugH1Div\" id=\"F1016310\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Patient Information",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?0/42/677?source=see_link\">",
"      see \"Gemcitabine: Patient drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Notify physician if extreme fatigue, severe GI upset or diarrhea, bleeding or bruising, fever, chills, sore throat, vaginal discharge, signs of fluid retention, yellowing of the skin or eyes, change in color of urine or stool, muscle or skeletal pain/weakness occur. Advise women of childbearing potential to avoid becoming pregnant while receiving gemcitabine.",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      Cole PD, Schwartz CL, Drachtman RA, et al, \"Phase II Study of Weekly Gemcitabine and Vinorelbine for Children With Recurrent or Refractory Hodgkin's Disease: A Children's Oncology Group Report,\"",
"      <i>",
"       J Clin Oncol",
"      </i>",
"      , 2009, 27(9):1456-61.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?26/37/27223/abstract-text/19224841/pubmed\" id=\"19224841\" target=\"_blank\">",
"        19224841",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Eklund JW, Trifilio S, and Mulcahy MF, \"Chemotherapy Dosing in the Setting of Liver Dysfunction,\"",
"      <i>",
"       Oncology (Williston Park)",
"      </i>",
"      , 2005, 19(8):1057-63.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?26/37/27223/abstract-text/16131047/pubmed\" id=\"16131047\" target=\"_blank\">",
"        16131047",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Einhorn LH, Stender MJ, and Williams SD, \"Phase II Trial of Gemcitabine in Refractory Germ Cell Tumors,\"",
"      <i>",
"       J Clin Oncol",
"      </i>",
"      , 1999, 17(2):509-11.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?26/37/27223/abstract-text/10080592/pubmed\" id=\"10080592\" target=\"_blank\">",
"        10080592",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Floyd J, Mirza I, Sachs B, et al, \"Hepatotoxicity of Chemotherapy,\"",
"      <i>",
"       Semin Oncol",
"      </i>",
"      , 2006, 33(1):50-67.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?26/37/27223/abstract-text/16473644/pubmed\" id=\"16473644\" target=\"_blank\">",
"        16473644",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Geoerger B, Chisholm J, Le Deley MC, et al, \"Phase II Study of Gemcitabine Combined With Oxaliplatin in Relapsed or Refractory Paediatric Solid Malignancies: An Innovative Therapy for Children With Cancer European Consortium Study,\"",
"      <i>",
"       Eur J Cancer",
"      </i>",
"      , 2011, 47(2):230-8.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?26/37/27223/abstract-text/20943374/pubmed\" id=\"20943374\" target=\"_blank\">",
"        20943374",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Hartmann C, Weinel P, Schmid H, et al, \"Oxaliplatin, Irinotecan, and Gemcitabine: A Novel Combination in the Therapy of Progressed, Relapsed, or Refractory Tumors in Children,\"",
"      <i>",
"       J Pediatr Hematol Oncol",
"      </i>",
"      ,  2011, 33(5):344-9.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?26/37/27223/abstract-text/21572345/pubmed\" id=\"21572345\" target=\"_blank\">",
"        21572345",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Janus N, Thariat J, Boulanger H, et al, \"Proposal for Dosage Adjustment and Timing of Chemotherapy in Hemodialyzed Patients,\"",
"      <i>",
"       Ann Oncol",
"      </i>",
"      , 2010, 21(7):1395-403.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?26/37/27223/abstract-text/20118214/pubmed\" id=\"20118214\" target=\"_blank\">",
"        20118214",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Ko AH, Dito E, Schillinger B, et al, \"Phase II Study of Fixed Dose Rate Gemcitabine With Cisplatin for Metastatic Adenocarcinoma of the Pancreas,\"",
"      <i>",
"       J Clin Oncol",
"      </i>",
"      , 2006, 24(3):379-85.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?26/37/27223/abstract-text/16344320/pubmed\" id=\"16344320\" target=\"_blank\">",
"        16344320",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Li YF, Fu S, Hu W, et al, \"Systemic Anticancer Therapy in Gynecological Cancer Patients With Renal Dysfunction,\"",
"      <i>",
"       Int J Gynecol Cancer",
"      </i>",
"      , 2007, 17(4):739-63.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?26/37/27223/abstract-text/17309673/pubmed\" id=\"17309673\" target=\"_blank\">",
"        17309673",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Mora J, Cruz CO, Parareda A, et al, \"Treatment of Relapsed/Refractory Pediatric Sarcomas With Gemcitabine and Docetaxel,\"",
"      <i>",
"       J Pediatr Hematol Oncol",
"      </i>",
"      , 2009, 31(10):723-9.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?26/37/27223/abstract-text/19727011/pubmed\" id=\"19727011\" target=\"_blank\">",
"        19727011",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      National Institute for Occupational Safety and Health (NIOSH), \"NIOSH List of Antineoplastic and Other Hazardous Drugs in Healthcare Settings 2012.\" Available at",
"      <a href=\"file://www.cdc.gov/niosh/docs/2012-150/pdfs/2012-150.pdf\" target=\"_blank\">",
"       file://www.cdc.gov/niosh/docs/2012-150/pdfs/2012-150.pdf",
"      </a>",
"      . Accessed January 21, 2013.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Navid F, Willert JR, McCarville MB, et al, \"Combination of Gemcitabine and Docetaxel in the Treatment of Children and Young Adults With Refractory Bone Sarcoma,\"",
"      <i>",
"       Cancer",
"      </i>",
"      , 2008, 113(2):419-25.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?26/37/27223/abstract-text/18484657/pubmed\" id=\"18484657\" target=\"_blank\">",
"        18484657",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Ozkaynak MF and Jayabose S, \"Gemcitabine and Vinorelbine as a Salvage Regimen for Relapse in Hodgkin Lymphoma After Autologous Hematopoietic Stem Cell Transplantation,\"",
"      <i>",
"       Pediatr Hematol Oncol",
"      </i>",
"      , 2004, 21(2):107-13.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?26/37/27223/abstract-text/15160509/pubmed\" id=\"15160509\" target=\"_blank\">",
"        15160509",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Poplin E, Feng Y, Berlin J, et al, \"Phase III, Randomized Study of Gemcitabine and Oxaliplatin Versus Gemcitabine (Fixed-Dose Rate Infusion) Compared With Gemcitabine (30-Minute Infusion) in Patients With Pancreatic Carcinoma E6201: A Trial of the Eastern Cooperative Oncology Group,\"",
"      <i>",
"       J Clin Oncol",
"      </i>",
"      , 2009, 27(23):3778-85.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?26/37/27223/abstract-text/19581537/pubmed\" id=\"19581537\" target=\"_blank\">",
"        19581537",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Reid JM, Qu W, Safgren SL, et al, \"Phase I Trial and Pharmacokinetics of Gemcitabine in Children With Advanced Solid Tumors,\"",
"      <i>",
"       J Clin Oncol",
"      </i>",
"      , 2004, 22(12):2445-51.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?26/37/27223/abstract-text/15197207/pubmed\" id=\"15197207\" target=\"_blank\">",
"        15197207",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Santoro A, Magagnoli M, Spina M, et al, \"Ifosfamide, Gemcitabine, and Vinorelbine: A New Induction Regimen for Refractory and Relapsed Hodgkin's Lymphoma,\"",
"      <i>",
"       Haematologica",
"      </i>",
"      , 2007, 92(1):35-41.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?26/37/27223/abstract-text/17229633/pubmed\" id=\"17229633\" target=\"_blank\">",
"        17229633",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Suyan E, Sucak GT, Ak Z, et al, \"Gemcitabine and Vinorelbine Combination Is Effective in Both as a Salvage and Mobilization Regimen in Relapsed or Refractory Hodgkin Lymphoma Prior to ASCT,\"",
"      <i>",
"       Ann Hematol",
"      </i>",
"      , 2011, 90(6):685-91.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?26/37/27223/abstract-text/21072518/pubmed\" id=\"21072518\" target=\"_blank\">",
"        21072518",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Tempero M, Plunkett W, Ruiz Van Haperen V, et al, \"Randomized Phase II Comparison of Dose-Intense Gemcitabine: Thirty-Minute Infusion and Fixed Dose Rate Infusion in Patients With Pancreatic Adenocarcinoma,\"",
"      <i>",
"       J Clin Oncol",
"      </i>",
"      , 2003, 21(18):3402-8.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?26/37/27223/abstract-text/12885837/pubmed\" id=\"12885837\" target=\"_blank\">",
"        12885837",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Venook AP, Egorin MJ, Rosner GL, et al, \"Phase I and Pharmacokinetic Trial of Gemcitabine in Patients With Hepatic or Renal Dysfunction: Cancer and Leukemia Group B 9565,\"",
"      <i>",
"       J Clin Oncol",
"      </i>",
"      , 2000, 18(14):2780-7.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?26/37/27223/abstract-text/10894879/pubmed\" id=\"10894879\" target=\"_blank\">",
"        10894879",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 13154 Version 40.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-61.234.146.186-FBD0C7583D-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f26_37_27223=[""].join("\n");
var outline_f26_37_27223=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F175343\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F175344\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1016262\">",
"      Therapeutic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1016297\">",
"      Dosing: Usual",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F175320\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F175305\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1016304\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1016287\">",
"      Compatibility",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1016283\">",
"      Stability",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1016263\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F175393\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F175389\">",
"      Adverse Reactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1016269\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2886956\">",
"      Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1016270\">",
"      Warnings",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13299393\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F175314\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F175316\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F175329\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1016306\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1016288\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1016290\">",
"      Pharmacokinetics (Adult data unless noted)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1016310\">",
"      Patient Information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_PED/13154\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_PED/13154|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?31/1/31769?source=related_link\">",
"      Gemcitabine: Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?0/42/677?source=related_link\">",
"      Gemcitabine: Patient drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f26_37_27224="Symptomatic relief of sore throat in children and adolescents";
var content_f26_37_27224=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Symptomatic relief of sore throat in children and adolescents",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?26/37/27224/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?26/37/27224/contributors\">",
"     Jan E Drutz, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?26/37/27224/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?26/37/27224/contributors\">",
"     Teresa K Duryea, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?26/37/27224/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?26/37/27224/contributors\">",
"     Mary M Torchia, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?26/37/27224/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jul 6, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Symptomatic relief of sore throat in children and adolescents will be reviewed here. The evaluation of sore throat and the approach to acute pharyngitis are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/31/39415?source=see_link\">",
"     \"Evaluation of sore throat in children\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/28/41417?source=see_link\">",
"     \"Approach to diagnosis of acute infectious pharyngitis in children and adolescents\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     OVERVIEW",
"    </span>",
"    &nbsp;&mdash;&nbsp;Sore throat, due to pharyngitis",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    tonsillitis, is a common complaint among children and adolescents. In the ambulatory pediatric setting, acute pharyngitis is the second-most common diagnosis [",
"    <a class=\"abstract\" href=\"UTD.htm?26/37/27224/abstract/1\">",
"     1",
"    </a>",
"    ]. Throat pain may be caused by an infectious process, traumatic injury, allergic reaction, irritant inhalant, or dryness (",
"    <a class=\"graphic graphic_table graphicRef60174 \" href=\"UTD.htm?2/1/2077\">",
"     table 1",
"    </a>",
"    ). Traumatic causes of throat pain include foreign body injury, hot liquids, caustic agents, various chemicals, and inhaled toxic gases, any of which may cause an inflammatory reaction. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/31/39415?source=see_link&amp;anchor=H2#H2\">",
"     \"Evaluation of sore throat in children\", section on 'Causes'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Sore throat caused by infections usually lasts a few days. The untreated symptoms resolve by three and seven days in approximately 50 and 90 percent of people, respectively [",
"    <a class=\"abstract\" href=\"UTD.htm?26/37/27224/abstract/2\">",
"     2",
"    </a>",
"    ]. The natural history is similar in patients who have positive tests for group A beta-hemolytic streptococcal (GABHS) infections, negative tests for GABHS, and those who are untested.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Treatment of underlying etiology",
"    </span>",
"    &nbsp;&mdash;&nbsp;The treatment of pharyngitis and tonsillitis depends to some extent upon the etiology. Bacterial infections, traumatic injuries, and allergies should be treated as indicated (eg, with antimicrobial therapy, foreign body removal, antihistamines); exposure to irritant inhalants should be minimized.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Viruses &mdash; Viral agents are the most common infectious cause of pharyngitis in children. Adenoviruses, enteroviruses, rhinoviruses, coronaviruses, influenza viruses A and B, and parainfluenza viruses 1, 2, and 3 are the most frequently encountered in the immunocompetent host [",
"      <a class=\"abstract\" href=\"UTD.htm?26/37/27224/abstract/3\">",
"       3",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?36/40/37513?source=see_link&amp;anchor=H16#H16\">",
"       \"Diagnosis and treatment of adenovirus infection\", section on 'Treatment'",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?26/7/26746?source=see_link&amp;anchor=H20#H20\">",
"       \"Antiviral drugs for the prevention and treatment of seasonal influenza in children\", section on 'Antiviral therapy'",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?12/53/13146?source=see_link&amp;anchor=H199065563#H199065563\">",
"       \"The common cold in children: Treatment and prevention\", section on 'Treatment'",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?35/60/36808?source=see_link&amp;anchor=H12#H12\">",
"       \"Parainfluenza viruses in children\", section on 'Treatment'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Bacteria &mdash; Bacterial pharyngitis usually requires specific antimicrobial therapy. Among bacterial organisms causing acute",
"      <span class=\"nowrap\">",
"       pharyngitis/tonsillitis,",
"      </span>",
"      Streptococcus pyogenes (group A beta-hemolytic streptococcus, GABHS) is the most common [",
"      <a class=\"abstract\" href=\"UTD.htm?26/37/27224/abstract/3\">",
"       3",
"      </a>",
"      ]. The peak incidence for GABHS pharyngitis occurs at 5 to 15 years of age [",
"      <a class=\"abstract\" href=\"UTD.htm?26/37/27224/abstract/3\">",
"       3",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?2/38/2666?source=see_link\">",
"       \"Treatment and prevention of streptococcal tonsillopharyngitis\"",
"      </a>",
"      .)",
"      <br/>",
"      <br/>",
"      Beta-hemolytic streptococci of Lancefield groups C and G cause epidemics of acute pharyngitis, often associated with contaminated foods. Group G infections occasionally occur on college campuses. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?26/28/27080?source=see_link\">",
"       \"Group C and group G streptococcal infection\"",
"      </a>",
"      .)",
"      <br/>",
"      <br/>",
"      Causes of bacterial pharyngitis that are more common in adolescents and young adults include Mycoplasma pneumoniae and Arcanobacterium hemolyticum. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?6/35/6713?source=see_link\">",
"       \"Mycoplasma pneumoniae infection in children\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?40/28/41417?source=see_link&amp;anchor=H7#H7\">",
"       \"Approach to diagnosis of acute infectious pharyngitis in children and adolescents\", section on 'Other bacteria'",
"      </a>",
"      .)",
"      <br/>",
"      <br/>",
"      Other bacteria that cause acute pharyngitis include Neisseria gonorrhoeae, Corynebacterium diphtheriae, Treponema pallidum (secondary syphilis), and oral anaerobes (Vincent's angina). Less common bacterial causes of acute pharyngitis include Yersinia enterocolitica, Y. pestis, and Francisella tularensis. (See appropriate topic reviews.)",
"      <br/>",
"      <br/>",
"      Bacteria that may be recovered on throat culture but do not cause acute pharyngitis and therefore do not require antimicrobial therapy include: S. aureus, S. pneumoniae, and gram-negative bacilli (eg, H. influenza, Moraxella catarrhalis, E. coli, Klebsiella pneumoniae) [",
"      <a class=\"abstract\" href=\"UTD.htm?26/37/27224/abstract/4\">",
"       4",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Allergy &mdash; The treatment of allergic rhinitis is discussed separately. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?36/60/37834?source=see_link\">",
"       \"Pharmacotherapy of allergic rhinitis\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Symptomatic treatment",
"    </span>",
"    &nbsp;&mdash;&nbsp;Once treatment of the underlying etiology is addressed, management is focused on providing symptomatic relief. For infectious pharyngitis, rest, adequate fluid intake, and antipyretics generally are recommended [",
"    <a class=\"abstract\" href=\"UTD.htm?26/37/27224/abstract/5\">",
"     5",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Symptomatic relief of throat pain may be achieved with various systemic and topical agents. The therapies described as \"standard\" therapies have been approved by the United States Food and Drug Administration (US FDA) for the treatment of sore throat or other inflammatory conditions or are long-standing therapies with little perceived risk. Approval by the US FDA indicates that the therapies have undergone study for safety and efficacy (albeit not necessarily for relief of throat pain and not necessarily in children or young children). In addition to the standard therapies, health food stores, vitamin outlets, and Internet Web sites frequently recommend alternative preparations. The remainder of this topic review will focus on symptomatic treatment of throat pain.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h1\">",
"     STANDARD THERAPIES",
"    </span>",
"    &nbsp;&mdash;&nbsp;A variety of systemic and topical therapies are commonly used for the symptomatic relief of pharyngitis and tonsillitis.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Systemic therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Systemic therapy may include antimicrobial agents, analgesics,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    antiinflammatory agents.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h3\">",
"     Antimicrobials",
"    </span>",
"    &nbsp;&mdash;&nbsp;Antimicrobial therapy should be provided for patients with bacterial",
"    <span class=\"nowrap\">",
"     pharyngitis/tonsillitis.",
"    </span>",
"    Antibiotic therapy helps to prevent complications and the spread of infection [",
"    <a class=\"abstract\" href=\"UTD.htm?26/37/27224/abstract/2,6\">",
"     2,6",
"    </a>",
"    ]. For patients with GABHS, early initiation of antibiotic therapy also appears to modestly reduce the duration of symptoms; however, the magnitude of this effect is small compared with other interventions (eg, analgesics) [",
"    <a class=\"abstract\" href=\"UTD.htm?26/37/27224/abstract/6,7\">",
"     6,7",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?2/38/2666?source=see_link\">",
"     \"Treatment and prevention of streptococcal tonsillopharyngitis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h3\">",
"     Analgesics",
"    </span>",
"    &nbsp;&mdash;&nbsp;We suggest systemic analgesics for the treatment of moderate to severe throat pain due to pharyngitis",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    tonsillitis. Systemic",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?19/15/19705?source=see_link\">",
"     acetaminophen",
"    </a>",
"    and nonsteroidal antiinflammatory drugs (NSAIDs) such as",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?7/48/7946?source=see_link\">",
"     ibuprofen",
"    </a>",
"    have been shown to alleviate sore throat pain in randomized controlled trials and systematic reviews [",
"    <a class=\"abstract\" href=\"UTD.htm?26/37/27224/abstract/6,8-12\">",
"     6,8-12",
"    </a>",
"    ]. In addition, they may alleviate fever and inflammation.",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?19/10/19624?source=see_link\">",
"     Aspirin",
"    </a>",
"    should be avoided in children because of the risk of Reye syndrome. For the rare patient with severe discomfort unresponsive to over-the-counter analgesics, combination",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?5/12/5319?source=see_link\">",
"     acetaminophen-codeine",
"    </a>",
"    may be warranted [",
"    <a class=\"abstract\" href=\"UTD.htm?26/37/27224/abstract/13\">",
"     13",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h3\">",
"     Glucocorticoids",
"    </span>",
"    &nbsp;&mdash;&nbsp;The use of oral or intramuscular glucocorticoids in the treatment of acute pharyngitis has been evaluated in several studies with variable results [",
"    <a class=\"abstract\" href=\"UTD.htm?26/37/27224/abstract/14-20\">",
"     14-20",
"    </a>",
"    ]. Systematic reviews concluded that a single dose of glucocorticoid may reduce the pain from sore throat in patients of any age [",
"    <a class=\"abstract\" href=\"UTD.htm?26/37/27224/abstract/20,21\">",
"     20,21",
"    </a>",
"    ]. The addition of glucocorticoids to antibiotics may be beneficial for adults with streptococcal pharyngitis, although the magnitude and duration of benefit are inconsistent [",
"    <a class=\"abstract\" href=\"UTD.htm?26/37/27224/abstract/20,21\">",
"     20,21",
"    </a>",
"    ]. In randomized controlled trials in children with streptococcal pharyngitis, adding a single dose of glucocorticoid therapy to antimicrobial therapy did not significantly affect the time to complete resolution of throat pain [",
"    <a class=\"abstract\" href=\"UTD.htm?26/37/27224/abstract/14,16\">",
"     14,16",
"    </a>",
"    ]. A systematic review found no evidence of significant benefit in children [",
"    <a class=\"abstract\" href=\"UTD.htm?26/37/27224/abstract/21\">",
"     21",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    There is little information regarding the adverse effects of glucocorticoids administered to children or adolescents with sore throat. Adverse effects of long-term glucocorticoid use are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/47/27386?source=see_link\">",
"     \"Major side effects of systemic glucocorticoids\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    There are no studies directly comparing analgesics and glucocorticoids for the relief of throat pain in children and adolescents. Given the potential adverse effects associated with the administration of glucocorticoids and the availability of safe and effective alternative agents for pain relief (ie,",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?19/15/19705?source=see_link\">",
"     acetaminophen",
"    </a>",
"    , NSAIDs), we suggest not using glucocorticoids for the symptomatic relief of throat pain in children and adolescents. However, for patients experiencing significant throat discomfort as a complication of infectious mononucleosis, a short-term course of glucocorticoids can be beneficial; such therapy is controversial.",
"   </p>",
"   <p>",
"    Glucocorticoid administration to relieve upper-airway obstruction in Epstein-Barr infection is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?13/55/14202?source=see_link&amp;anchor=H26#H26\">",
"     \"Clinical manifestations and treatment of Epstein-Barr virus infection\", section on 'Treatment and prevention'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Topical therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Topical therapies include oral rinses (gargles), sprays, and lozenges. In an observational study using",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?19/61/20438?source=see_link\">",
"     methylene blue",
"    </a>",
"    dye, oral rinses were more effective at coating the oral cavity and base of the tongue, and sprays were more effective at coating the posterior pharynx [",
"    <a class=\"abstract\" href=\"UTD.htm?26/37/27224/abstract/22\">",
"     22",
"    </a>",
"    ]. This finding suggests that oral rinses may be more helpful for conditions affecting the oral cavity and tongue, and oral sprays for conditions affecting the posterior pharynx. However, sprays may have no significant benefit when compared with sucking on a piece of candy. (See",
"    <a class=\"local\" href=\"#H12\">",
"     'Sprays'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h3\">",
"     Oral rinses",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Saltwater gargles are an old stand-by for relief of throat pain [",
"      <a class=\"abstract\" href=\"UTD.htm?26/37/27224/abstract/5\">",
"       5",
"      </a>",
"      ]. Although the benefit of gargling with saltwater has not been proven in clinical trials, this treatment is unlikely to be harmful. Most recipes suggest",
"      <span class=\"nowrap\">",
"       1/4",
"      </span>",
"      to",
"      <span class=\"nowrap\">",
"       1/2",
"      </span>",
"      teaspoon of salt per cup (8 ounces) of warm water. Children younger than six to eight years of age generally are incapable of gargling properly.",
"     </li>",
"     <li>",
"      An oral rinse composed of equal parts of",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?36/57/37776?source=see_link\">",
"       lidocaine",
"      </a>",
"      ,",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?33/29/34256?source=see_link\">",
"       diphenhydramine",
"      </a>",
"      , and Maalox (",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?28/59/29622?source=see_link\">",
"       magnesium hydroxide",
"      </a>",
"      ,",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?20/36/21062?source=see_link\">",
"       aluminum hydroxide",
"      </a>",
"      , and",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?27/9/27795?source=see_link\">",
"       simethicone",
"      </a>",
"      ) may be helpful [",
"      <a class=\"abstract\" href=\"UTD.htm?26/37/27224/abstract/4\">",
"       4",
"      </a>",
"      ]. This combination is most often suggested to treat patients with stomatitis, gingivitis, and mouth ulcers resulting from viral infections (eg, Coxsackie A or B or herpes simplex). When using this oral rinse, care must be taken to avoid overdosing the lidocaine component [",
"      <a class=\"abstract\" href=\"UTD.htm?26/37/27224/abstract/23,24\">",
"       23,24",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Oral rinses containing",
"      <a class=\"drug drug_general\" href=\"UTD.htm?6/45/6867?source=see_link\">",
"       benzydamine",
"      </a>",
"      hydrochloride (a topical NSAID with antiinflammatory, analgesic, and anesthetic activity) have been shown to be effective for throat pain in randomized trials in children, adolescents, and adults [",
"      <a class=\"abstract\" href=\"UTD.htm?26/37/27224/abstract/25-27\">",
"       25-27",
"      </a>",
"      ], but are used more frequently to prevent or treat radiation mucositis [",
"      <a class=\"abstract\" href=\"UTD.htm?26/37/27224/abstract/28,29\">",
"       28,29",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?22/1/22554?source=see_link&amp;anchor=H722454567#H722454567\">",
"       \"Management and prevention of complications of head and neck cancer during initial treatment\", section on 'Benzydamine'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h3\">",
"     Sprays",
"    </span>",
"    &nbsp;&mdash;&nbsp;Sprays containing topical anesthetics (eg,",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?11/19/11574?source=see_link\">",
"     benzocaine",
"    </a>",
"    , phenol) are available to treat sore throat. However, such sprays are no more effective than sucking on hard candy [",
"    <a class=\"abstract\" href=\"UTD.htm?26/37/27224/abstract/30\">",
"     30",
"    </a>",
"    ]. In addition, they may contain ingredients that can cause an allergic reaction, and topical benzocaine has been associated with methemoglobinemia and should not be used in children younger than two years [",
"    <a class=\"abstract\" href=\"UTD.htm?26/37/27224/abstract/31\">",
"     31",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?8/33/8729?source=see_link&amp;anchor=H6#H6\">",
"     \"Clinical features, diagnosis, and treatment of methemoglobinemia\", section on 'Acquired causes'",
"    </a>",
"    .) We suggest not using such sprays for symptomatic relief of throat pain in children.",
"   </p>",
"   <p>",
"    An investigational mouth spray contains",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?43/9/44180?source=see_link\">",
"     chlorhexidine",
"    </a>",
"    (a topical antimicrobial) and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?6/45/6867?source=see_link\">",
"     benzydamine",
"    </a>",
"    (a topical NSAID with antiinflammatory, analgesic, and anesthetic activity). In separate randomized trials,",
"    <span class=\"nowrap\">",
"     chlorhexidine/benzydamine",
"    </span>",
"    spray was effective in reducing self-reported symptoms of acute viral pharyngitis and group A streptococcal pharyngitis in patients &ge;16 years [",
"    <a class=\"abstract\" href=\"UTD.htm?26/37/27224/abstract/32,33\">",
"     32,33",
"    </a>",
"    ]. Additional studies are necessary before this spray can be recommended for the symptomatic relief of sore throat in children and adolescents.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h3\">",
"     Lozenges",
"    </span>",
"    &nbsp;&mdash;&nbsp;A variety of lozenges (cough drops, troches, or pastilles) are available for symptomatic relief of throat pain. Some are designed to relieve dryness, others to relieve pain. Menthol (a cooling agent), antiseptics (",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/63/38897?source=see_link\">",
"     hexylresorcinol",
"    </a>",
"    ), anesthetics (eg, phenol,",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?11/19/11574?source=see_link\">",
"     benzocaine",
"    </a>",
"    , hexylresorcinol,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?6/45/6867?source=see_link\">",
"     benzydamine",
"    </a>",
"    ),",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    antiinflammatory agents are commonly contained in such products.",
"   </p>",
"   <p>",
"    Medicated throat lozenges can provide symptomatic relief [",
"    <a class=\"abstract\" href=\"UTD.htm?26/37/27224/abstract/4,5,34\">",
"     4,5,34",
"    </a>",
"    ], but it is not clear that they work any better than other forms of hard candy [",
"    <a class=\"abstract\" href=\"UTD.htm?26/37/27224/abstract/30,35\">",
"     30,35",
"    </a>",
"    ]. Similar to throat sprays, medicated throat lozenges have the potential to cause an allergic reaction, and those that contain",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?11/19/11574?source=see_link\">",
"     benzocaine",
"    </a>",
"    may cause methemoglobinemia. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?8/33/8729?source=see_link&amp;anchor=H13#H13\">",
"     \"Clinical features, diagnosis, and treatment of methemoglobinemia\", section on 'Acquired methemoglobinemia'",
"    </a>",
"    .) We suggest not using medicated throat lozenges for symptomatic relief of throat pain in children.",
"   </p>",
"   <p>",
"    Lozenges are a choking hazard for young children and should not be offered to those who are younger than three to four years of age.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Other interventions",
"    </span>",
"    &nbsp;&mdash;&nbsp;Other interventions include sipping warm beverages (eg, honey or lemon tea, chicken soup) or cold beverages, or eating cold or frozen desserts (eg, ice cream, popsicles) [",
"    <a class=\"abstract\" href=\"UTD.htm?26/37/27224/abstract/36,37\">",
"     36,37",
"    </a>",
"    ]. Honey should be avoided in children younger than one year of age because of the possible contamination of the honey with Clostridium botulinum spores, potentially leading to infantile botulism. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/36/37448?source=see_link&amp;anchor=H9#H9\">",
"     \"Botulism\", section on 'Infant botulism'",
"    </a>",
"    .) For children with enlarged tonsils and difficulty swallowing solid foods, a soft diet may be more palatable [",
"    <a class=\"abstract\" href=\"UTD.htm?26/37/27224/abstract/30\">",
"     30",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h1\">",
"     ALTERNATIVE THERAPIES",
"    </span>",
"    &nbsp;&mdash;&nbsp;In addition to the standard therapies for symptomatic relief, health food stores, vitamin outlets, and Internet Web sites frequently recommend alternative preparations. We suggest that alternative products not be used in the treatment of children with",
"    <span class=\"nowrap\">",
"     pharyngitis/tonsillitis.",
"    </span>",
"    Alternative therapeutic preparations generally are inadequately labeled regarding actual content. They may contain ingredients that could prove harmful to a child, particularly one taking other prescription or nonprescription medications.",
"   </p>",
"   <p>",
"    There are no specific US FDA controls regarding the safety, purity, or potency of herbal products contained in the preparations discussed below. Manufacturers of alternative products can claim efficacy and safety without having to provide evidence based on the rigorous testing that is required by the US FDA for prescription and nonprescription medications. Nonetheless, some of these agents have been studied in randomized controlled trials [",
"    <a class=\"abstract\" href=\"UTD.htm?26/37/27224/abstract/38-43\">",
"     38-43",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Some alternative products may be contaminated with other herbs, pesticides, herbicides during growth, harvesting, preparation,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    storage. Active chemical constituents may not be standardized, resulting in different potencies from lot to lot or from capsule to capsule. Families considering the use of herbs and dietary supplements should proceed with caution and seek products only from reputable manufacturers [",
"    <a class=\"abstract\" href=\"UTD.htm?26/37/27224/abstract/44\">",
"     44",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Single agents",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h3\">",
"     Slippery elm",
"    </span>",
"    &nbsp;&mdash;&nbsp;Slippery elm (Ulmus rubra, also known as Indian elm, moose elm, and sweet elm) has been used for the treatment of a number of maladies and infections, as well as for pain relief. Because of its demulcent properties, it is used in some oral lozenges to sooth throat pain and is considered to be possibly effective [",
"    <a class=\"abstract\" href=\"UTD.htm?26/37/27224/abstract/45\">",
"     45",
"    </a>",
"    ]. We suggest not using slippery elm for the symptomatic relief of sore throat in children and adolescents.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h3\">",
"     Serrapeptase",
"    </span>",
"    &nbsp;&mdash;&nbsp;Serrapeptase (Serratia peptidase, serratiopeptidase) is a proteolytic enzyme isolated from silk worms. It is thought to have anti-inflammatory properties and to be able to decrease pain by inhibiting the release of bradykinin and other factors from inflamed or damaged tissue.",
"   </p>",
"   <p>",
"    There is some evidence suggesting that patients with laryngitis or pharyngitis taking 10 mg of serrapeptase three times per day experience significantly reduced pain, swallowing difficulty, and fever [",
"    <a class=\"abstract\" href=\"UTD.htm?26/37/27224/abstract/46\">",
"     46",
"    </a>",
"    ]. In adult clinical trials lasting up to four weeks, serrapeptase appears to be safe [",
"    <a class=\"abstract\" href=\"UTD.htm?26/37/27224/abstract/39,46\">",
"     39,46",
"    </a>",
"    ]. Little information exists as to its effectiveness and safety in children [",
"    <a class=\"abstract\" href=\"UTD.htm?26/37/27224/abstract/46\">",
"     46",
"    </a>",
"    ]. We suggest not using serrapeptase for the symptomatic relief of sore throat in children and adolescents.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h3\">",
"     Papain",
"    </span>",
"    &nbsp;&mdash;&nbsp;Papain (Carica papaya, also known as papainum curdum, protease concentrate, vegetable pepsin) is a proteolytic enzyme that is used commercially as a meat tenderizer. It is used to treat a number of problems, including inflammation following trauma and surgery and for reducing the inflammation of pharyngitis. When used orally in amounts commonly found in foods, it is considered safe, but in large amounts it can lead to esophageal perforation [",
"    <a class=\"abstract\" href=\"UTD.htm?26/37/27224/abstract/47\">",
"     47",
"    </a>",
"    ]. We suggest not using papain for the symptomatic relief of sore throat in children and adolescents.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h3\">",
"     Andrographis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Andrographis (Andrographis paniculata, also known as Justicia paniculata) has been used to treat an array of health conditions, including cardiovascular, gastrointestinal, hepatic, pharyngitis, and other upper respiratory tract problems. When used orally and in an appropriate dose for a limited number of days (four to seven), it is considered to be possibly safe for the treatment of children [",
"    <a class=\"abstract\" href=\"UTD.htm?26/37/27224/abstract/48\">",
"     48",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Some evidence exists that several days of treatment with high doses of andrographis are comparable to",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?19/15/19705?source=see_link\">",
"     acetaminophen",
"    </a>",
"    in the treatment of fever and sore throat associated with tonsillopharyngitis [",
"    <a class=\"abstract\" href=\"UTD.htm?26/37/27224/abstract/40\">",
"     40",
"    </a>",
"    ]. One report indicates that in combination with Siberian ginseng (Eleutherococcus senticosus), andrographis relieves cold symptoms in children better than Echinacea or placebo [",
"    <a class=\"abstract\" href=\"UTD.htm?26/37/27224/abstract/41\">",
"     41",
"    </a>",
"    ]. In adults, andrographis has been used to treat the common cold in a dose of 400 mg three times per day [",
"    <a class=\"abstract\" href=\"UTD.htm?26/37/27224/abstract/42\">",
"     42",
"    </a>",
"    ]. To treat adult tonsillopharyngitis, the recommended dose is 3 to 6 grams daily [",
"    <a class=\"abstract\" href=\"UTD.htm?26/37/27224/abstract/48\">",
"     48",
"    </a>",
"    ]. We suggest not using andrographis for the symptomatic relief of sore throat in children and adolescents.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h2\">",
"     Combination products",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Honey-B-Anise Sore Throat Syrup &mdash; Honey-B-Anise Sore Throat Syrup is a combination product consisting of vegetable",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?26/10/26787?source=see_link\">",
"       glycerin",
"      </a>",
"      , honey, purified water, propylene glycol, anise oil, and bee propolis. None of these components individually or in combination has been proven to provide significant relief from sore throat discomfort. Propolis may have some anti-inflammatory effect; propolis mouth rinse has been reported to improve healing and to reduce pain and inflammation for patients undergoing oral surgery (sulcoplasty) [",
"      <a class=\"abstract\" href=\"UTD.htm?26/37/27224/abstract/49\">",
"       49",
"      </a>",
"      ]. Anise, propolis, and honey have the potential to cause an allergic reaction.",
"      <br/>",
"      <br/>",
"      We suggest that Honey-B-Anise Sore Throat Syrup not be used for the relief of throat pain in children and adolescents. It certainly should be avoided in infants because of the possible contamination of the honey with Clostridium botulinum spores. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?36/36/37448?source=see_link&amp;anchor=H9#H9\">",
"       \"Botulism\", section on 'Infant botulism'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      NatraBio Sore Throat Relief&nbsp;tablets &mdash; NatraBio Sore Throat Relief tablets are a homeopathic preparation consisting of cayenne (Capsicum annuum), horse chestnut (Aesculus hippocastanum), pokeweed (Phytolacca decandra), yellow dock (Rumex crispus), sponge (Spongia tosta), viper venom (lachesis), and several chemical combinations including potassium dichromate, iron phosphate, and cyanide of mercury. Other inactive ingredients are also contained.",
"      <br/>",
"      <br/>",
"      Minimal to no information exists as to whether any of these ingredients, with the possible exception of capsicum, provides effective pain relief. The majority of the active ingredients are considered unsafe for oral consumption by children; several can account for adverse gastrointestinal reactions. We suggest not using NatraBio Sore Throat Relief tablets for the symptomatic relief of sore throat in children and adolescents.",
"     </li>",
"     <li>",
"      NatraBio Sore Throat Relief&nbsp;liquid &mdash; NatraBio Sore Throat Relief liquid also contains horse chestnut and pokeweed as well as iron phosphate and potassium dichromate. Other active ingredients include belladonna and mercuric oxide. There is little information regarding the safety of the majority of these components in children. We suggest not using NatraBio Sore Throat Relief liquid for the symptomatic relief of sore throat in children and adolescents.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topics (see",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?27/26/28066?source=see_link\">",
"       \"Patient information: Sore throat in children (The Basics)\"",
"      </a>",
"      and",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?8/34/8738?source=see_link\">",
"       \"Patient information: Strep throat in children (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Beyond the Basics topics (see",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?3/22/3427?source=see_link\">",
"       \"Patient information: Sore throat in children (Beyond the Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Throat pain may be caused by an infectious process, traumatic injury, allergic reaction, irritant inhalant, or dryness (",
"      <a class=\"graphic graphic_table graphicRef60174 \" href=\"UTD.htm?2/1/2077\">",
"       table 1",
"      </a>",
"      ). Bacterial infections, traumatic injuries, and allergies should be treated as indicated. Once treatment of the underlying etiology is addressed, management is focused on providing symptomatic relief. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Overview'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      We suggest systemic analgesics for the treatment of moderate to severe throat pain due to pharyngitis",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      tonsillitis (",
"      <a class=\"grade\" href=\"._grade_4?title=Grade 2A\">",
"       Grade 2A",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H8\">",
"       'Analgesics'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      We suggest not using glucocorticoids for the symptomatic relief of throat pain in children and adolescents (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ). However, a short-term course of glucocorticoids may be beneficial for older children and adolescents experiencing significant throat discomfort as a complication of infectious mononucleosis; such therapy is controversial. (See",
"      <a class=\"local\" href=\"#H9\">",
"       'Glucocorticoids'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?13/55/14202?source=see_link&amp;anchor=H26#H26\">",
"       \"Clinical manifestations and treatment of Epstein-Barr virus infection\", section on 'Treatment and prevention'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      We suggest not using medicated throat sprays or medicated lozenges for the treatment of sore throat in children and adolescents (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). Gargling with saltwater (for children older than six to eight years of age) or sucking on hard candy (for children older than three to four years of age) may provide some relief. (See",
"      <a class=\"local\" href=\"#H10\">",
"       'Topical therapy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      We suggest not using alternative products in the treatment of children with",
"      <span class=\"nowrap\">",
"       pharyngitis/tonsillitis",
"      </span>",
"      (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H15\">",
"       'Alternative therapies'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/37/27224/abstract/1\">",
"      Chi H, Chiu NC, Li WC, Huang FY. Etiology of acute pharyngitis in children: is antibiotic therapy needed? J Microbiol Immunol Infect 2003; 36:26.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/37/27224/abstract/2\">",
"      Del Mar CB, Glasziou PP, Spinks AB. Antibiotics for sore throat. Cochrane Database Syst Rev 2006; :CD000023.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/37/27224/abstract/3\">",
"      Bisno AL. Acute pharyngitis: etiology and diagnosis. Pediatrics 1996; 97:949.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/37/27224/abstract/4\">",
"      Feder, HM. Acute pharyngitis: fitting the drug to the bug. Contemp Pediatr 2001; 18:41.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/37/27224/abstract/5\">",
"      Bisno AL. Acute pharyngitis. N Engl J Med 2001; 344:205.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/37/27224/abstract/6\">",
"      Thomas M, Del Mar C, Glasziou P. How effective are treatments other than antibiotics for acute sore throat? Br J Gen Pract 2000; 50:817.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/37/27224/abstract/7\">",
"      Bradley CP. Taking another look at the acute sore throat. Br J Gen Pract 2000; 50:780.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/37/27224/abstract/8\">",
"      Gehanno P, Dreiser RL, Ionescu E, et al. Lowest effective single dose of diclofenac for antipyretic and analgesic effects in acute febrile sore throat. Clin Drug Investig 2003; 23:263.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/37/27224/abstract/9\">",
"      Schachtel BP, Thoden WR. A placebo-controlled model for assaying systemic analgesics in children. Clin Pharmacol Ther 1993; 53:593.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/37/27224/abstract/10\">",
"      Bertin L, Pons G, d'Athis P, et al. Randomized, double-blind, multicenter, controlled trial of ibuprofen versus acetaminophen (paracetamol) and placebo for treatment of symptoms of tonsillitis and pharyngitis in children. J Pediatr 1991; 119:811.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/37/27224/abstract/11\">",
"      Benarrosh C. [Multicenter double blind study of tiaprofenic acid versus placebo in tonsillitis and pharyngitis in children]. Arch Fr Pediatr 1989; 46:541.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/37/27224/abstract/12\">",
"      Eccles R, Loose I, Jawad M, Nyman L. Effects of acetylsalicylic acid on sore throat pain and other pain symptoms associated with acute upper respiratory tract infection. Pain Med 2003; 4:118.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/37/27224/abstract/13\">",
"      King, BR. An evidence-based approach to the evaluation and treatment of pharyngitis in children. Pediatric Emerg Med Practice 2007; 4:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/37/27224/abstract/14\">",
"      Olympia RP, Khine H, Avner JR. Effectiveness of oral dexamethasone in the treatment of moderate to severe pharyngitis in children. Arch Pediatr Adolesc Med 2005; 159:278.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/37/27224/abstract/15\">",
"      O'Brien JF, Meade JL, Falk JL. Dexamethasone as adjuvant therapy for severe acute pharyngitis. Ann Emerg Med 1993; 22:212.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/37/27224/abstract/16\">",
"      Bulloch B, Kabani A, Tenenbein M. Oral dexamethasone for the treatment of pain in children with acute pharyngitis: a randomized, double-blind, placebo-controlled trial. Ann Emerg Med 2003; 41:601.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/37/27224/abstract/17\">",
"      Marvez-Valls EG, Stuckey A, Ernst AA. A randomized clinical trial of oral versus intramuscular delivery of steroids in acute exudative pharyngitis. Acad Emerg Med 2002; 9:9.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/37/27224/abstract/18\">",
"      Roy M, Bailey B, Amre DK, et al. Dexamethasone for the treatment of sore throat in children with suspected infectious mononucleosis: a randomized, double-blind, placebo-controlled, clinical trial. Arch Pediatr Adolesc Med 2004; 158:250.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/37/27224/abstract/19\">",
"      Niland ML, Bonsu BK, Nuss KE, Goodman DG. A pilot study of 1 versus 3 days of dexamethasone as add-on therapy in children with streptococcal pharyngitis. Pediatr Infect Dis J 2006; 25:477.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/37/27224/abstract/20\">",
"      Wing A, Villa-Roel C, Yeh B, et al. Effectiveness of corticosteroid treatment in acute pharyngitis: a systematic review of the literature. Acad Emerg Med 2010; 17:476.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/37/27224/abstract/21\">",
"      Hayward G, Thompson M, Heneghan C, et al. Corticosteroids for pain relief in sore throat: systematic review and meta-analysis. BMJ 2009; 339:b2976.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/37/27224/abstract/22\">",
"      Patel SK, Ghufoor K, Jayaraj SM, et al. Pictorial assessment of the delivery of oropharyngeal rinse versus oropharyngeal spray. J Laryngol Otol 1999; 113:1092.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/37/27224/abstract/23\">",
"      Hess GP, Walson PD. Seizures secondary to oral viscous lidocaine. Ann Emerg Med 1988; 17:725.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/37/27224/abstract/24\">",
"      Gonzalez del Rey J, Wason S, Druckenbrod RW. Lidocaine overdose: another preventable case? Pediatr Emerg Care 1994; 10:344.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/37/27224/abstract/25\">",
"      Turnbull RS. Benzydamine Hydrochloride (Tantum) in the management of oral inflammatory conditions. J Can Dent Assoc 1995; 61:127.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/37/27224/abstract/26\">",
"      Pass&agrave;li D, Volont&eacute; M, Pass&agrave;li GC, et al. Efficacy and safety of ketoprofen lysine salt mouthwash versus benzydamine hydrochloride mouthwash in acute pharyngeal inflammation: a randomized, single-blind study. Clin Ther 2001; 23:1508.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/37/27224/abstract/27\">",
"      Wethington JF. Double-blind study of benzydamine hydrochloride, a new treatment for sore throat. Clin Ther 1985; 7:641.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/37/27224/abstract/28\">",
"      Epstein JB, Silverman S Jr, Paggiarino DA, et al. Benzydamine HCl for prophylaxis of radiation-induced oral mucositis: results from a multicenter, randomized, double-blind, placebo-controlled clinical trial. Cancer 2001; 92:875.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/37/27224/abstract/29\">",
"      Kim JH, Chu FC, Lakshmi V, Houde R. Benzydamine HCl, a new agent for the treatment of radiation mucositis of the oropharynx. Am J Clin Oncol 1986; 9:132.",
"     </a>",
"    </li>",
"    <li>",
"     Schmitt, BD. Sore throat (pharyngitis). In: Instructions for Pediatric Patients, WB Saunders, Philadelphia 1999. p.91.",
"    </li>",
"    <li>",
"     Questions &amp; Answers: Reports of a rare, but serious and potentially fatal adverse effect with the use of over-the-counter (OTC) benzocaine gels and liquids applied to the gums or mouth www.fda.gov/Drugs/DrugSafety/ucm250029.htm (Accessed on August 03, 2012).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/37/27224/abstract/32\">",
"      Cingi C, Songu M, Ural A, et al. Effect of chlorhexidine gluconate and benzydamine hydrochloride mouth spray on clinical signs and quality of life of patients with streptococcal tonsillopharyngitis: multicentre, prospective, randomised, double-blinded, placebo-controlled study. J Laryngol Otol 2011; 125:620.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/37/27224/abstract/33\">",
"      Cingi C, Songu M, Ural A, et al. Effects of chlorhexidine/benzydamine mouth spray on pain and quality of life in acute viral pharyngitis: a prospective, randomized, double-blind, placebo-controlled, multicenter study. Ear Nose Throat J 2010; 89:546.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/37/27224/abstract/34\">",
"      Watson N, Nimmo WS, Christian J, et al. Relief of sore throat with the anti-inflammatory throat lozenge flurbiprofen 8.75 mg: a randomised, double-blind, placebo-controlled study of efficacy and safety. Int J Clin Pract 2000; 54:490.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/37/27224/abstract/35\">",
"      Flurbiprofen: new indication. Lozenges: NSAIDs are not to be taken like sweets! Prescrire Int 2007; 16:13.",
"     </a>",
"    </li>",
"    <li>",
"     American Academy of Family Physicians. Sore throat: Easing the pain of a sore throat. Available at: familydoctor.org/online/famdocen/home/common/infections/cold-flu/163.html. (Accessed on October 29, 2007).",
"    </li>",
"    <li>",
"     Medline Plus. Sore throat. Available at: www.nlm.nih.gov/medlineplus/ency/article/003053.htm. (Accessed on October 29, 2007).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/37/27224/abstract/38\">",
"      Bereznoy VV, Riley DS, Wassmer G, Heger M. Efficacy of extract of Pelargonium sidoides in children with acute non-group A beta-hemolytic streptococcus tonsillopharyngitis: a randomized, double-blind, placebo-controlled trial. Altern Ther Health Med 2003; 9:68.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/37/27224/abstract/39\">",
"      Mazzone A, Catalani M, Costanzo M, et al. Evaluation of Serratia peptidase in acute or chronic inflammation of otorhinolaryngology pathology: a multicentre, double-blind, randomized trial versus placebo. J Int Med Res 1990; 18:379.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/37/27224/abstract/40\">",
"      Thamlikitkul V, Dechatiwongse T, Theerapong S, et al. Efficacy of Andrographis paniculata, Nees for pharyngotonsillitis in adults. J Med Assoc Thai 1991; 74:437.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/37/27224/abstract/41\">",
"      Spasov AA, Ostrovskij OV, Chernikov MV, Wikman G. Comparative controlled study of Andrographis paniculata fixed combination, Kan Jang and an Echinacea preparation as adjuvant, in the treatment of uncomplicated respiratory disease in children. Phytother Res 2004; 18:47.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/37/27224/abstract/42\">",
"      C&aacute;ceres DD, Hancke JL, Burgos RA, et al. Use of visual analogue scale measurements (VAS) to asses the effectiveness of standardized Andrographis paniculata extract SHA-10 in reducing the symptoms of common cold. A randomized double blind-placebo study. Phytomedicine 1999; 6:217.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/37/27224/abstract/43\">",
"      Brinckmann J, Sigwart H, van Houten Taylor L. Safety and efficacy of a traditional herbal medicine (Throat Coat) in symptomatic temporary relief of pain in patients with acute pharyngitis: a multicenter, prospective, randomized, double-blinded, placebo-controlled study. J Altern Complement Med 2003; 9:285.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/37/27224/abstract/44\">",
"      Chan, E, Gardiner, P, Kemper, KJ. \"At least it's natural....\" Herbs and dietary supplements in ADHD. Contemp Pediatr 2000; 17:116.",
"     </a>",
"    </li>",
"    <li>",
"     Jellin, JM, Gregory, PJ, et al. Pharmacist's Letter/Prescriber's Letter. Natural Medicines Database, 9th ed, Therapeutic Research Faculty, Stockton, CA 2007. p.1162.",
"    </li>",
"    <li>",
"     Jellin, JM, Gregory, PJ, et al. Pharmacist's Letter/Prescriber's Letter. Natural Medicines Database, 9th ed, Therapeutic Research Faculty, Stockton, CA 2007. p.1149.",
"    </li>",
"    <li>",
"     Jellin, JM, Gregory, PJ, et al. Pharmacist's Letter/Prescriber's Letter. Natural Medicines Database, 9th ed, Therapeutic Research Faculty, Stockton, CA 2007. p.977.",
"    </li>",
"    <li>",
"     Jellin, JM, Gregory, PJ, et al. Pharmacist's Letter/Prescriber's Letter. Natural Medicines Database, 9th ed, Therapeutic Research Faculty, Stockton, CA 2007. p.56.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/37/27224/abstract/49\">",
"      Magro-Filho O, de Carvalho AC. Topical effect of propolis in the repair of sulcoplasties by the modified Kazanjian technique. Cytological and clinical evaluation. J Nihon Univ Sch Dent 1994; 36:102.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 2875 Version 12.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0604-41.78.124.10-00EF7A87C0-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f26_37_27224=[""].join("\n");
var outline_f26_37_27224=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H23\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      OVERVIEW",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Treatment of underlying etiology",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Symptomatic treatment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      STANDARD THERAPIES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Systemic therapy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      - Antimicrobials",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      - Analgesics",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      - Glucocorticoids",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Topical therapy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      - Oral rinses",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      - Sprays",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      - Lozenges",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Other interventions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      ALTERNATIVE THERAPIES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Single agents",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      - Slippery elm",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      - Serrapeptase",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      - Papain",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      - Andrographis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      Combination products",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PEDS/2875\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PEDS/2875|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?2/1/2077\" title=\"table 1\">",
"      Etiology sore throat",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/7/26746?source=related_link\">",
"      Antiviral drugs for the prevention and treatment of seasonal influenza in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?40/28/41417?source=related_link\">",
"      Approach to diagnosis of acute infectious pharyngitis in children and adolescents",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?36/36/37448?source=related_link\">",
"      Botulism",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?8/33/8729?source=related_link\">",
"      Clinical features, diagnosis, and treatment of methemoglobinemia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?13/55/14202?source=related_link\">",
"      Clinical manifestations and treatment of Epstein-Barr virus infection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?36/40/37513?source=related_link\">",
"      Diagnosis and treatment of adenovirus infection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?38/31/39415?source=related_link\">",
"      Evaluation of sore throat in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/28/27080?source=related_link\">",
"      Group C and group G streptococcal infection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/47/27386?source=related_link\">",
"      Major side effects of systemic glucocorticoids",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/1/22554?source=related_link\">",
"      Management and prevention of complications of head and neck cancer during initial treatment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?6/35/6713?source=related_link\">",
"      Mycoplasma pneumoniae infection in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?35/60/36808?source=related_link\">",
"      Parainfluenza viruses in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?3/22/3427?source=related_link\">",
"      Patient information: Sore throat in children (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?27/26/28066?source=related_link\">",
"      Patient information: Sore throat in children (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?8/34/8738?source=related_link\">",
"      Patient information: Strep throat in children (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?36/60/37834?source=related_link\">",
"      Pharmacotherapy of allergic rhinitis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?12/53/13146?source=related_link\">",
"      The common cold in children: Treatment and prevention",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?2/38/2666?source=related_link\">",
"      Treatment and prevention of streptococcal tonsillopharyngitis",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f26_37_27225="Persistent pulmonary hypertension of the newborn";
var content_f26_37_27225=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"5\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Persistent pulmonary hypertension of the newborn",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?26/37/27225/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?26/37/27225/contributors\">",
"     James M Adams, Jr, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?26/37/27225/contributors\">",
"     Ann R Stark, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?26/37/27225/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?26/37/27225/contributors\">",
"     Joseph A Garcia-Prats, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?26/37/27225/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?26/37/27225/contributors\">",
"     Melanie S Kim, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?26/37/27225/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Nov 20, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Persistent pulmonary hypertension of the newborn (PPHN) occurs when pulmonary vascular resistance (PVR) remains elevated after birth, resulting in right-to-left shunting of blood through fetal circulatory pathways. This in turn leads to severe hypoxemia that may not respond to conventional respiratory support. The prevalence of PPHN has been estimated at 1.9 per 1000 live births [",
"    <a class=\"abstract\" href=\"UTD.htm?26/37/27225/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     PHYSIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;The fetal circulation operates in parallel. Both the right and left ventricles eject blood into the aorta with subsequent perfusion of the placenta, the fetal organ of respiration (",
"    <a class=\"graphic graphic_figure graphicRef55037 \" href=\"UTD.htm?33/3/33848\">",
"     figure 1",
"    </a>",
"    ). The right ventricle is dominant, and blood is shunted right-to-left through the foramen ovale and ductus arteriosus, mostly bypassing the lung, which is not participating in gas exchange. In contrast, the postnatal (adult) circulation operates in series. All venous return passes through the right side of the heart and into the lung, where gas exchange occurs. The oxygenated blood returns to the left side of the heart and is pumped into the systemic circulation for oxygen delivery to the tissues. No mixing occurs between the two sides of the adult circulation.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Transitional circulation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Major circulatory adjustments occur at birth as the organ of gas exchange changes from the placenta to the lung. Under normal circumstances, a progressive fall in pulmonary vascular resistance (PVR) accompanies the immediate rise in systemic vascular resistance (SVR) that occurs after birth. For a short period, a transitional circulatory pattern exists that combines features of both the fetal and adult circulatory patterns. The decline in the",
"    <span class=\"nowrap\">",
"     PVR/SVR",
"    </span>",
"    ratio results in a steady increase in pulmonary blood flow and oxygen uptake in the lung.",
"   </p>",
"   <p>",
"    The process of transition depends upon several factors. Factors that contribute to the postnatal increase in SVR include removal of the placenta, the catecholamine surge associated with birth, and the cold extrauterine environment. Factors that promote the postnatal decrease in PVR include expansion of the lung to normal resting volume, establishment of adequate alveolar ventilation and oxygenation, and successful clearance of fetal lung fluid. Conditions that interfere with the normal postnatal decline in the",
"    <span class=\"nowrap\">",
"     PVR/SVR",
"    </span>",
"    ratio cause the transitional circulation to persist and result in PPHN.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     PATHOPHYSIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Persistent pulmonary hypertension of the newborn (PPHN) occurs primarily in term or late preterm infants &ge;34 weeks gestation. Three types of abnormalities of the pulmonary vasculature underlie the disorder: underdevelopment, maldevelopment, and maladaptation [",
"    <a class=\"abstract\" href=\"UTD.htm?26/37/27225/abstract/2-5\">",
"     2-5",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Underdevelopment",
"    </span>",
"    &nbsp;&mdash;&nbsp;In abnormalities of underdevelopment, the cross sectional area of the pulmonary vasculature is reduced, resulting in a relatively fixed elevation of pulmonary vascular resistance (PVR). Underdevelopment occurs with pulmonary hypoplasia associated with a variety of conditions. They include congenital diaphragmatic hernia (CDH), cystic adenomatoid malformation of the lung, renal agenesis, oligohydramnios accompanying obstructive uropathy, and intrauterine growth restriction. Although some degree of postnatal pulmonary vasodilatation can occur, this adaptive mechanism is limited. As a result, mortality risk is greatest in this category of patients.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Maldevelopment",
"    </span>",
"    &nbsp;&mdash;&nbsp;Maldevelopment occurs in the setting of normal development of the lung, including branching and alveolar differentiation, and the normal number of pulmonary vessels. However, the muscle layer of the pulmonary arterioles is abnormally thick and extends into small vessels that normally have thin walls and no muscle cells [",
"    <a class=\"abstract\" href=\"UTD.htm?26/37/27225/abstract/4\">",
"     4",
"    </a>",
"    ]. The extracellular matrix that surrounds the pulmonary vessels also is excessive. In this disorder, remodeling of the pulmonary vascular bed is thought to occur during the first 7 to 14 days after birth, with an accompanying fall in PVR.",
"   </p>",
"   <p>",
"    The mechanisms that stimulate maldevelopment of the pulmonary vasculature are uncertain, but vascular mediators appear to play a role. In one report, for example, infants with severe PPHN had, compared to healthy controls, higher plasma concentrations of the vasoconstrictor endothelin-1 and lower concentrations of cyclic guanosine monophosphate (representing stimulation of guanylate cyclase by nitric oxide [NO], a vasodilator that cannot be readily measured) [",
"    <a class=\"abstract\" href=\"UTD.htm?26/37/27225/abstract/6\">",
"     6",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Genetic predisposition may influence the availability of precursors for NO synthesis and affect cardiopulmonary adaptation at birth. This was illustrated in a report in which infants with pulmonary hypertension had lower plasma concentrations of arginine, a precursor of NO and a urea cycle intermediate, and NO metabolites than control infants with respiratory distress [",
"    <a class=\"abstract\" href=\"UTD.htm?26/37/27225/abstract/7\">",
"     7",
"    </a>",
"    ]. A functional polymorphism of the gene encoding carbamoyl-phosphate synthetase, which controls the rate-limiting step in the urea cycle, occurred more frequently in all of the infants with respiratory distress, with or without pulmonary hypertension, than in the general population.",
"   </p>",
"   <p>",
"    Conditions associated with PPHN caused by vascular maldevelopment include post-term delivery, meconium staining, and meconium aspiration syndrome. In these disorders, the pulmonary vasculature responds poorly to stimuli that normally result in a decrease in PVR, such as increased oxygen levels and the establishment of ventilation. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/16/21768?source=see_link\">",
"     \"Clinical features and diagnosis of meconium aspiration syndrome\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Disorders producing excessive perfusion of the fetal lung also may predispose to vascular maldevelopment. They include premature closure of the ductus arteriosus (eg, caused by nonsteroidal antiinflammatory drugs) or foramen ovale, high placental vascular resistance, and total anomalous pulmonary venous drainage. Use of nonsteroidal antiinflammatory drugs (NSAIDs) in pregnancy is associated with PPHN, probably caused by ductal constriction in the fetus. In a case-control study, PPHN was significantly associated with the presence in meconium of",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?19/10/19624?source=see_link\">",
"     aspirin",
"    </a>",
"    (odds ratio [OR] 8.1, 95% CI 3.3-20.1),",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?7/48/7946?source=see_link\">",
"     ibuprofen",
"    </a>",
"    (OR 12.9, 95% CI 3.9-42.3),",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?26/61/27608?source=see_link\">",
"     naproxen",
"    </a>",
"    (OR 3.3, 95% CI 1.2-9.3), or at least one nonsteroidal antiinflammatory drug (NSAID) (aspirin, ibuprofen, naproxen,",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?17/27/17848?source=see_link\">",
"     indomethacin",
"    </a>",
"    ) (OR 21.5, 95% CI 7.1-64.7) [",
"    <a class=\"abstract\" href=\"UTD.htm?26/37/27225/abstract/8\">",
"     8",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Maladaptation",
"    </span>",
"    &nbsp;&mdash;&nbsp;In maladaptation, the pulmonary vascular bed is normally developed. However, adverse perinatal conditions cause active vasoconstriction and interfere with the normal postnatal fall in PVR. These conditions include perinatal depression, pulmonary parenchymal diseases, and bacterial infections, especially those caused by group B streptococcus (GBS). The mechanism of increased PVR with GBS infection is activation of vasoactive mediators by bacterial phospholipid components. In a study in newborn lambs, pulmonary hypertension was induced by infusion of cardiolipin and phosphatidylglycerol, phospholipids located primarily in the cell wall of GBS [",
"    <a class=\"abstract\" href=\"UTD.htm?26/37/27225/abstract/9\">",
"     9",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/16/18698?source=see_link&amp;anchor=H14#H14\">",
"     \"Group B streptococcal infection in neonates and young infants\", section on 'Pneumonia'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h1\">",
"     CLINICAL FEATURES",
"    </span>",
"    &nbsp;&mdash;&nbsp;The clinical features of persistent pulmonary hypertension of the newborn (PPHN) were described in a study of 385 infants (mean gestational age 39 weeks) with the disorder admitted to the neonatal intensive care units of the participating centers in the National Institute of Child Health and Human Development Neonatal Research Network [",
"    <a class=\"abstract\" href=\"UTD.htm?26/37/27225/abstract/1\">",
"     1",
"    </a>",
"    ]. The diagnosis of PPHN was documented by echocardiogram or a difference between the preductal and postductal arterial oxygen tension. Infants included in the study received &ge;50 percent inspired oxygen concentration",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    mechanical ventilation.",
"   </p>",
"   <p>",
"    Many of the newborns were considered to be at high risk for an abnormal initial course [",
"    <a class=\"abstract\" href=\"UTD.htm?26/37/27225/abstract/1\">",
"     1",
"    </a>",
"    ]. Amniotic fluid was meconium-stained in 50 percent of cases, and fetal heart rate abnormalities occurred in 49 percent of those who had antenatal monitoring. Delivery was by cesarean delivery in 51 percent and without labor in approximately one-third. Infants often were depressed at birth. Apgar scores were &le;5 at one and five minutes in 54 and 21 percent, respectively.",
"   </p>",
"   <p>",
"    The majority of infants had respiratory diagnoses associated with PPHN, although the condition was considered idiopathic in 17 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?26/37/27225/abstract/1\">",
"     1",
"    </a>",
"    ]. The primary respiratory diagnoses were:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Meconium aspiration syndrome (41 percent) (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?21/16/21768?source=see_link\">",
"       \"Clinical features and diagnosis of meconium aspiration syndrome\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Pneumonia (14 percent) (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?21/0/21512?source=see_link\">",
"       \"Neonatal pneumonia\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Respiratory distress syndrome (RDS, 13 percent) (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?19/12/19656?source=see_link\">",
"       \"Pathophysiology and clinical manifestations of respiratory distress syndrome in the newborn\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Pneumonia",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      RDS, when they could not be distinguished (14 percent)",
"     </li>",
"     <li>",
"      Congenital diaphragmatic hernia (CDH, 10 percent) (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?27/23/28026?source=see_link\">",
"       \"Congenital diaphragmatic hernia in the neonate\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Pulmonary hypoplasia (4 percent)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In utero exposure of selective serotonin receptor inhibitors (SSRIs) during the second half of pregnancy has been associated with a six-fold increased risk of PPHN compared to nonexposed infants. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?11/29/11736?source=see_link&amp;anchor=H8#H8\">",
"     \"Infants with antenatal exposure to serotonin reuptake inhibitors\", section on 'Persistent pulmonary hypertension'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15569970\">",
"    <span class=\"h2\">",
"     Preterm infants",
"    </span>",
"    &nbsp;&mdash;&nbsp;Persistent pulmonary hypertension is a relatively infrequent finding in premature infants. This was illustrated in a prospective study of 765 infants (gestational age &le;32 weeks) in which only 2.2 percent (n = 17) developed hypoxic respiratory failure with pulmonary hypertension documented by echocardiography [",
"    <a class=\"abstract\" href=\"UTD.htm?26/37/27225/abstract/10\">",
"     10",
"    </a>",
"    ]. In all 17 cases, there was prolonged premature rupture of membranes, and all patients responded to inhaled nitric oxide (iNO). Although routine use of iNO in preterm infants to prevent bronchopulmonary dysplasia is not recommended (see",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/14/27880?source=see_link\">",
"     \"Prevention of bronchopulmonary dysplasia\"",
"    </a>",
"    ), these results and those of previous studies of preterm infants with PPROM and severe respiratory failure support the need of a therapeutic trial of iNO for this specific clinical setting (see",
"    <a class=\"local\" href=\"#H23\">",
"     'Inhaled nitric oxide'",
"    </a>",
"    below) [",
"    <a class=\"abstract\" href=\"UTD.htm?26/37/27225/abstract/11-13\">",
"     11-13",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h1\">",
"     DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The diagnosis of persistent pulmonary hypertension of the newborn (PPHN) should be considered in any infant with severe cyanosis. In affected patients, arterial oxygenation typically improves little or not at all in response to 100 percent inspired oxygen concentration, increased mean airway pressure with continuous positive airway pressure, or high inspiratory pressures with positive pressure ventilation. The definitive diagnosis of PPHN is made by echocardiography.",
"   </p>",
"   <p>",
"    Other diagnoses that must be considered include uncomplicated pulmonary parenchymal disease, infection, structural heart disease, and myocardial dysfunction.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Physical examination",
"    </span>",
"    &nbsp;&mdash;&nbsp;The physical examination usually is not helpful in establishing the diagnosis, although it may show signs of associated conditions, such as respiratory disorders or meconium staining of skin and nails. Infants with PPHN may have a prominent precordial impulse and a narrowly split and accentuated second heart sound. A harsh systolic murmur consistent with tricuspid insufficiency sometimes is heard at the lower left sternal border.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Chest radiograph",
"    </span>",
"    &nbsp;&mdash;&nbsp;As with the physical examination, the chest radiograph is more helpful in identifying associated pulmonary disorders, such as parenchymal disease, air leak, or congenital diaphragmatic hernia (CDH). The heart size typically is normal or slightly enlarged. Pulmonary blood flow may appear normal or reduced.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Electrocardiogram",
"    </span>",
"    &nbsp;&mdash;&nbsp;The electrocardiogram may be normal for age, with right ventricular predominance. Signs of myocardial ischemia, such as ST segment elevation, may be present in infants with perinatal depression.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Arterial blood gas",
"    </span>",
"    &nbsp;&mdash;&nbsp;An arterial blood gas sample typically will show low partial pressure of oxygen (PaO2 below 100 mmHg in 100 percent inspired oxygen concentration). However, in contrast to infants with cyanotic lesions, many infants with PPHN have at least one measurement of PaO2 &gt;100 mmHg early in the course of their illness. The arterial PCO2 is normal in infants without accompanying lung disease.",
"   </p>",
"   <p>",
"    A right-to-left shunt through the ductus arteriosus can be documented by a difference in oxygen tension between preductal and postductal arterial blood gas samples. These samples usually are obtained from the right radial artery and the umbilical artery, after placement of an umbilical artery catheter. Alternatively, a transcutaneous oxygen monitor can be used. A difference between preductal and postductal (right thumb and either great toe) oxygen saturation also supports the diagnosis. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/61/29656?source=see_link\">",
"     \"Oxygen monitoring and therapy in the newborn\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    It is important to recognize that the absence of a preductal and postductal gradient in oxygenation does",
"    <strong>",
"     not",
"    </strong>",
"    exclude the diagnosis of PPHN, since right-to-left shunting can occur predominantly through the foramen ovale rather than the ductus arteriosus.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Echocardiography",
"    </span>",
"    &nbsp;&mdash;&nbsp;The definitive diagnosis of PPHN is made by echocardiography. Echocardiography is essential in any infant with severe and unremitting hypoxemia to exclude the diagnosis of structural heart disease and detect myocardial dysfunction, if present.",
"   </p>",
"   <p>",
"    In PPHN, echocardiography demonstrates normal structural anatomy with evidence of pulmonary hypertension, such as a flattened or displaced ventricular septum. Doppler studies show right-to-left shunting through the ductus arteriosus",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    foramen ovale. Continuous-wave Doppler sampling of the velocity of a jet of tricuspid insufficiency, if present, can be used to estimate pulmonary artery pressure.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h1\">",
"     MANAGEMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;The management of persistent pulmonary hypertension of the newborn (PPHN) is largely supportive. It is directed toward promoting a progressive decline in the ratio of pulmonary vascular resistance (PVR) to systemic vascular resistance (SVR) and to maintaining adequate tissue oxygenation until PVR falls. Specific treatment is provided for any associated parenchymal lung disease.",
"   </p>",
"   <p>",
"    The general approach to care is similar for all infants and begins with identification of risk factors and anticipation of potential illness. Infants depressed at birth should be resuscitated promptly and monitored closely to ensure adequate oxygenation and ventilation. All ill newborns should be cared for in a neutral thermal environment to minimize oxygen consumption. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/49/31511?source=see_link\">",
"     \"Overview of neonatal respiratory distress: Disorders of transition\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Oxygen",
"    </span>",
"    &nbsp;&mdash;&nbsp;Oxygen is a pulmonary vasodilator and initially should be administered in a concentration of 100 percent to infants with PPHN in an attempt to reverse pulmonary vasoconstriction. However, even short term use of high oxygen concentrations has undesirable effects on lung function, and there is no advantage to maintaining an elevated PaO2. The targeted PaO2 goal is between 50 and 90 mmHg (oxygen saturation &gt;90 percent). Although uncommon in PPHN, persistent hyperoxemia should be avoided.",
"   </p>",
"   <p>",
"    If the oxygen saturation cannot be maintained above 90 percent, other interventions to preserve adequate tissue oxygenation include maintenance of a hemoglobin concentration between 15 and 16",
"    <span class=\"nowrap\">",
"     g/dL",
"    </span>",
"    and optimizing circulatory function. (See",
"    <a class=\"local\" href=\"#H21\">",
"     'Circulatory support'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     Assisted ventilation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Because hypercarbia and acidosis increase PVR, we initially attempt to establish and maintain normal ventilation (PaCO2 35 to 40 mmHg). In the above study of practice and outcomes in PPHN prior to the availability of inhaled nitric oxide (iNO), hyperventilation was used in two-thirds of patients, although this intervention has not been tested in a controlled trial [",
"    <a class=\"abstract\" href=\"UTD.htm?26/37/27225/abstract/1\">",
"     1",
"    </a>",
"    ]. As the infant's ventilatory status becomes more stable, we maintain PaCO2 in the range of 40 to 50 mmHg to minimize lung injury associated with high tidal volumes.",
"   </p>",
"   <p>",
"    The strategy of ventilator support depends upon the presence or absence of pulmonary parenchymal disease and the infant's response to treatment.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In infants with no associated lung disease, hypoxemia is caused by right-to-left shunting rather than ventilation&ndash;perfusion imbalance. As a result, hypoxemia may not respond to conventional ventilator maneuvers. In this circumstance, strategies that elevate mean airway pressure may impede cardiac output and increase PVR. Thus, we minimize mean airway pressure by using low inspiratory pressures and short inspiratory times.",
"     </li>",
"     <li>",
"      When PPHN is associated with lung disease, atelectasis and the resulting maldistribution of ventilation may exacerbate high PVR. Assisted ventilation is used to recruit atelectatic segments, maintain adequate resting lung volume, and ensure appropriate oxygenation and ventilation. When lung disease is severe, we usually use high-frequency oscillatory ventilation (HFOV). In a randomized trial of HFOV and iNO in severe PPHN, 23 percent of patients initially assigned to HFOV recovered without crossover to iNO with conventional mechanical ventilation or to iNO with HFOV [",
"      <a class=\"abstract\" href=\"UTD.htm?26/37/27225/abstract/14\">",
"       14",
"      </a>",
"      ]. (See below).",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1270145414\">",
"    <span class=\"h3\">",
"     Sedation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Infants with PPHN may breathe out of synchrony with the ventilator and become agitated. Agitation may cause catecholamine release, resulting in increased PVR. Thus, in ventilated infants we use an opioid analgesic such as",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?31/30/32233?source=see_link\">",
"     morphine sulfate",
"    </a>",
"    (loading dose of 100 to 150",
"    <span class=\"nowrap\">",
"     mcg/kg",
"    </span>",
"    over one hour, then 10 to 20",
"    <span class=\"nowrap\">",
"     mcg/kg",
"    </span>",
"    per hour, IV) or",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?34/45/35546?source=see_link\">",
"     fentanyl",
"    </a>",
"    (1 to 5",
"    <span class=\"nowrap\">",
"     mcg/kg",
"    </span>",
"    per hour).",
"   </p>",
"   <p>",
"    If dyssynchronous breathing and severe hypoxemia persist and a specific cause cannot be identified (eg, airway obstruction or air leak), we may use neuromuscular blockade. However, we limit this intervention as much as possible because of potential adverse effects. In the survey of practice variation and outcome, neuromuscular blockade appeared to be associated with increased risk of death (odds ratio 2.8, 95% CI 1.1-7.2) that exceeded the mortality risk associated with either HFOV or extracorporeal membrane oxygenation (ECMO); however, the difference did not remain significant when infants with congenital diaphragmatic hernia (CDH) were removed from the analysis [",
"    <a class=\"abstract\" href=\"UTD.htm?26/37/27225/abstract/1\">",
"     1",
"    </a>",
"    ]. Prolonged skeletal muscle paralysis may also reduce functional residual capacity and pulmonary compliance [",
"    <a class=\"abstract\" href=\"UTD.htm?26/37/27225/abstract/15\">",
"     15",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h2\">",
"     Surfactant",
"    </span>",
"    &nbsp;&mdash;&nbsp;Surfactant should be administered to infants with respiratory distress syndrome (RDS). It also should be considered for improvement of alveolar recruitment in infants with other pulmonary conditions (eg, sepsis, pneumonia, or meconium aspiration syndrome) in which surfactant function may be impaired [",
"    <a class=\"abstract\" href=\"UTD.htm?26/37/27225/abstract/16,17\">",
"     16,17",
"    </a>",
"    ]. In a randomized trial in term infants with severe respiratory failure, surfactant administration significantly reduced the need for ECMO therapy (29 versus 40 percent with placebo), without increasing the risk of complications [",
"    <a class=\"abstract\" href=\"UTD.htm?26/37/27225/abstract/17\">",
"     17",
"    </a>",
"    ]. However, there seemed to be no effect when PPHN was the primary diagnosis (30 versus 32 percent).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h2\">",
"     Circulatory support",
"    </span>",
"    &nbsp;&mdash;&nbsp;Because PVR is elevated in PPHN, decreased SVR or poor cardiac output that result in decreased mean systemic blood pressure can increase right-to-left shunting. Thus, circulatory support usually is needed in severely affected patients. An adequate vascular volume should be maintained with intravenous fluids. Transfusion of packed red blood cells usually is required to replace blood lost from sampling and to optimize tissue oxygen delivery, especially in patients with marginal oxygenation. In general, we maintain hemoglobin concentration above 15 g (hematocrit above 40 to 45 percent).",
"   </p>",
"   <p>",
"    Vasopressor support usually is needed in patients with PPHN [",
"    <a class=\"abstract\" href=\"UTD.htm?26/37/27225/abstract/18\">",
"     18",
"    </a>",
"    ]. Dopamine has been the most commonly used medication use in neonates requiring pharmacologic inotropic support. We begin with dopamine (2.5 to 10",
"    <span class=\"nowrap\">",
"     mcg/kg",
"    </span>",
"    per min IV) and titrate the infusion rate to maintain the mean arterial blood pressure at a level that minimizes right-to-left shunting (typically &gt;50 mmHg). Alternative agents include",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?24/48/25348?source=see_link\">",
"     dobutamine",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?26/37/27225/abstract/19\">",
"     19",
"    </a>",
"    ] and norepinephrine [",
"    <a class=\"abstract\" href=\"UTD.htm?26/37/27225/abstract/20\">",
"     20",
"    </a>",
"    ]. However, effects of these agents are variable and nonspecific. Even if blood pressure is maintained, higher doses of these drugs may result in decreased cardiac output, increased pulmonary artery pressure, and an unfavorable rise in",
"    <span class=\"nowrap\">",
"     PVR/SVR",
"    </span>",
"    ratio.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h2\">",
"     Correction of acidosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Acidosis increases PVR and should be corrected. However, alkali infusion to maintain alkalosis is",
"    <strong>",
"     not",
"    </strong>",
"    recommended. In the study of practice and outcomes, alkali infusion was used in 74 percent of patients [",
"    <a class=\"abstract\" href=\"UTD.htm?26/37/27225/abstract/1\">",
"     1",
"    </a>",
"    ]. However, infants treated with alkali infusion compared to those treated with hyperventilation appeared to be more likely to need ECMO and require oxygen supplementation at 28 days. It is unclear if these observations reflect an adverse effect of alkali therapy or increased severity of disease in those who received alkali therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?26/37/27225/abstract/21-31\">",
"     21-31",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1270145468\">",
"    <span class=\"h2\">",
"     Oxygenation index",
"    </span>",
"    &nbsp;&mdash;&nbsp;The oxygenation index (OI) is used to assess the severity of hypoxemia in PPHN and to guide the timing of interventions such as iNO administration or ECMO support. The OI is calculated as follows:",
"   </p>",
"   <p>",
"    &nbsp;OI = [mean airway pressure x FiO2 &divide; PaO2] x 100",
"   </p>",
"   <p>",
"    In most cases when the OI is used, the infant is receiving an inspired oxygen concentration (FiO2) of 1.0. Thus, the OI can be calculated easily from the mean airway pressure displayed on the ventilator and the PaO2. A high OI indicates severe hypoxemic respiratory failure. A term or late preterm infant with an OI &ge;25 should receive care in a center where HFOV, iNO, and ECMO are readily available [",
"    <a class=\"abstract\" href=\"UTD.htm?26/37/27225/abstract/32\">",
"     32",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h2\">",
"     Inhaled nitric oxide",
"    </span>",
"    &nbsp;&mdash;&nbsp;Endogenous NO regulates vascular tone by causing relaxation of vascular smooth muscle. When inhaled, NO is a selective pulmonary vasodilator.",
"   </p>",
"   <p>",
"    Administration of inhaled NO (iNO) decreases the pulmonary artery pressure and pulmonary-to-systemic arterial pressure ratio [",
"    <a class=\"abstract\" href=\"UTD.htm?26/37/27225/abstract/21\">",
"     21",
"    </a>",
"    ]. Oxygenation improves as vessels are dilated in well-ventilated parts of the lung, thereby redistributing blood flow from regions with decreased ventilation and reducing intrapulmonary shunting. In the circulation, NO combines with hemoglobin and is rapidly converted to methemoglobin and nitrate. As a result, there is little effect on SVR and systemic blood pressure.",
"   </p>",
"   <p>",
"    Inhaled NO improves oxygenation and reduces the need for ECMO in term and late preterm infants with severe PPHN and does not appear to have toxicity [",
"    <a class=\"abstract\" href=\"UTD.htm?26/37/27225/abstract/14,22-26\">",
"     14,22-26",
"    </a>",
"    ]. A large and well-designed multicenter trial was conducted by the Neonatal Research Network in 235 infants with gestational age &ge;34 weeks who had severe hypoxic respiratory failure (OI &ge;25) and did not have CDH [",
"    <a class=\"abstract\" href=\"UTD.htm?26/37/27225/abstract/22\">",
"     22",
"    </a>",
"    ]. Echocardiography was performed in most infants before randomization and demonstrated pulmonary hypertension in 78 percent. Infants were randomly assigned to iNO (initial dose 20 ppm) or control (100 percent oxygen). Fewer infants treated with iNO died within 120 days or received ECMO therapy, (46 versus 64 percent; relative risk 0.72, 95% CI 0.57-0.91) compared to control. This difference was entirely due to decreased requirement for ECMO (39 versus 54 percent); there was no difference between groups in mortality.",
"   </p>",
"   <p>",
"    Similar findings (less requirement for ECMO and no difference in mortality) were noted in another large randomized trial [",
"    <a class=\"abstract\" href=\"UTD.htm?26/37/27225/abstract/24\">",
"     24",
"    </a>",
"    ] and in a systematic review by the Cochrane database of 12 randomized controlled trials [",
"    <a class=\"abstract\" href=\"UTD.htm?26/37/27225/abstract/26\">",
"     26",
"    </a>",
"    ]. In the Cochrane review, iNO improved oxygenation in approximately one-half of infants who received the drug [",
"    <a class=\"abstract\" href=\"UTD.htm?26/37/27225/abstract/26\">",
"     26",
"    </a>",
"    ]. Within 30 to 60 minutes of beginning therapy, PaO2 increased by a mean of 53 mmHg and OI decreased by a mean of 15.1. Outcome did not appear to be affected by whether infants had echocardiographic evidence of PPHN, but no benefit was noted in those with congenital diaphragmatic hernia. (See",
"    <a class=\"local\" href=\"#H24\">",
"     'Congenital diaphragmatic hernia'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Potential toxicity of iNO includes methemoglobinemia secondary to excess iNO concentrations or impaired metabolism, pulmonary injury related to increased levels of nitrogen dioxide during administration, and contamination of ambient air. However, iNO appears to be relatively safe if high iNO doses are avoided and appropriately monitored [",
"    <a class=\"abstract\" href=\"UTD.htm?26/37/27225/abstract/26,33\">",
"     26,33",
"    </a>",
"    ]. Bleeding times are prolonged in newborns treated with iNO because of inhibition of platelet function, although clinically significant bleeding has not been observed in term or late preterm infants [",
"    <a class=\"abstract\" href=\"UTD.htm?26/37/27225/abstract/27\">",
"     27",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In a randomized trial, early initiation of iNO in infants with mild to moderate respiratory impairment with OI between 15 and 25 compared to routine initiation at OI &gt; 25 did not reduce the incidence of mortality or the need for ECMO therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?26/37/27225/abstract/28\">",
"     28",
"    </a>",
"    ]. It also did not affect the outcomes of neurodevelopment and hearing of surviving infants evaluated at 18 to 24 months of age [",
"    <a class=\"abstract\" href=\"UTD.htm?26/37/27225/abstract/29\">",
"     29",
"    </a>",
"    ]. As a result, iNO is not recommended for infants with moderate respiratory distress and should be reserved for infants with severe respiratory failure with an OI &gt;25.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h3\">",
"     Congenital diaphragmatic hernia",
"    </span>",
"    &nbsp;&mdash;&nbsp;Inhaled NO does",
"    <strong>",
"     not",
"    </strong>",
"    appear to be of long-term benefit in infants with CDH [",
"    <a class=\"abstract\" href=\"UTD.htm?26/37/27225/abstract/26,30\">",
"     26,30",
"    </a>",
"    ]. In the one trial that specifically addressed this issue, 53 infants with CDH and hypoxemic respiratory failure (OI &ge;25) and &ge;34 weeks gestational age were randomly assigned to receive iNO (20 ppm) or control (100 percent oxygen). Death before 120 days or need for ECMO was not significantly different in iNO or control groups (96 versus 82 percent, respectively). ECMO use occurred significantly more in the iNO group (80 versus 54 percent, respectively), although the proportion of infants who died was not different (48 versus 43 percent, respectively). No significant changes in PaO2 or OI were detected 30 minutes after starting iNO. However, a transitory improvement occurred in approximately one-half of the infants treated with iNO, suggesting that this intervention might be helpful in stabilizing some patients for transport and initiation of ECMO. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/23/28026?source=see_link&amp;anchor=H5#H5\">",
"     \"Congenital diaphragmatic hernia in the neonate\", section on 'Management'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h3\">",
"     Recommendations",
"    </span>",
"    &nbsp;&mdash;&nbsp;Recommendations for the use of iNO in infants with severe hypoxemic respiratory failure have been published by the American Academy of Pediatrics [",
"    <a class=\"abstract\" href=\"UTD.htm?26/37/27225/abstract/32\">",
"     32",
"    </a>",
"    ]. They include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Care of patients in centers with personnel experienced with multiple modes of respiratory support, rescue therapies, and use of iNO",
"     </li>",
"     <li>",
"      Availability of ECMO at the center, or an established mechanism for timely transfer of infants to an ECMO center",
"     </li>",
"     <li>",
"      Performance of an echocardiogram to exclude the diagnosis of congenital heart disease.",
"     </li>",
"     <li>",
"      Use of iNO according to the indications, dosing, administration, and monitoring guidelines on the product label.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    We begin iNO therapy in term or late preterm infants (gestational age &ge;34 weeks) with severe hypoxemic respiratory failure, defined as an OI &ge;25 with maximum respiratory support using conventional mechanical ventilation or HFOV. Prior to initiating treatment, we perform echocardiography to confirm the diagnosis of PPHN and exclude congenital heart disease.",
"   </p>",
"   <p>",
"    The initial dose of iNO is 20 ppm. In infants who respond, an improvement of approximately 20 percent in PaO2 or SaO2 typically occurs within 15 to 20 minutes. The iNO concentration is decreased slowly as oxygenation improves [",
"    <a class=\"abstract\" href=\"UTD.htm?26/37/27225/abstract/31\">",
"     31",
"    </a>",
"    ]. Patients who respond to iNO typically require treatment for three to four days, although some require longer courses. We monitor for potential toxic effects by measuring the serum methemoglobin concentration, levels of nitrogen dioxide at the airway opening, and ambient air contamination.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26\">",
"    <span class=\"h2\">",
"     Extracorporeal membrane oxygenation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Approximately 40 percent of infants with severe PPHN remain hypoxemic on maximal ventilatory support with iNO and require ECMO [",
"    <a class=\"abstract\" href=\"UTD.htm?26/37/27225/abstract/22\">",
"     22",
"    </a>",
"    ]. The goal of this treatment is to maintain adequate tissue oxygen delivery and avoid irreversible lung injury while PVR decreases and pulmonary hypertension resolves.",
"   </p>",
"   <p>",
"    Criteria for institution of ECMO include an elevated OI. In most cases, ECMO is started when the OI is consistently &ge;40. However, because mean airway pressures are higher on HFOV than conventional ventilation, some clinicians wait until OI is &ge;60 when HFOV is used.",
"   </p>",
"   <p>",
"    Most patients with PPHN are weaned from ECMO within five to seven days. However, two or more weeks occasionally may be necessary for adequate remodeling of the pulmonary circulation in severe cases. Patients who fail to improve may have an irreversible condition, such as alveolar capillary dysplasia [",
"    <a class=\"abstract\" href=\"UTD.htm?26/37/27225/abstract/34\">",
"     34",
"    </a>",
"    ] or severe pulmonary hypoplasia.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27\">",
"    <span class=\"h2\">",
"     Potential agents",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although iNO and ECMO have improved outcome for many infants with PPHN, there still remain those who do not respond to these interventions. In addition, these modalities are expensive and unavailable in many regions of the world.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21603149\">",
"    <span class=\"h3\">",
"     Sildenafil",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?37/9/38041?source=see_link\">",
"     Sildenafil",
"    </a>",
"    , a phosphodiesterase inhibitor type 5, is an agent that has been shown to selectively reduce pulmonary vascular resistance in both animal models and adult humans. It has also been reported (to be successful in the treatment of infants with PPHN) [",
"    <a class=\"abstract\" href=\"UTD.htm?26/37/27225/abstract/35-39\">",
"     35-39",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In a systematic review of three small trials that included 77 infants, there was a significant reduction in mortality in the group of patients treated with enteral",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?37/9/38041?source=see_link\">",
"     sildenafil",
"    </a>",
"    compared with controls (relative risk 0.20, 95% CI 0.07-0.57) [",
"    <a class=\"abstract\" href=\"UTD.htm?26/37/27225/abstract/40\">",
"     40",
"    </a>",
"    ]. These three studies were performed in resource-limited settings, in which inhaled nitric oxide and high frequency ventilation were not available.",
"   </p>",
"   <p>",
"    An open-label dose-escalation trial of a continuous intravenous infusion of",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?37/9/38041?source=see_link\">",
"     sildenafil",
"    </a>",
"    was conducted in 36 neonates between 48 hours and 7 days of age with PPHN and an OI &gt;15 [",
"    <a class=\"abstract\" href=\"UTD.htm?26/37/27225/abstract/41\">",
"     41",
"    </a>",
"    ]. In patients who received higher doses of sildenafil, OI improved from 28.7 to 19.3 after four hours of continuous infusion. There was one death (which was not considered related to sildenafil), and one patient required ECMO. Six of seven infants given sildenafil prior to treatment with iNO survived to discharge with no need for iNO or ECMO. Six treatment-related adverse events were reported in five patients including five hypotensive episodes (three of which required discontinuation of therapy) and the development of patent ductus arteriosus with left to right shunting in one patient.",
"   </p>",
"   <p>",
"    In 2012, the US Food and Drug Administration issued a warning that",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?37/9/38041?source=see_link\">",
"     sildenafil",
"    </a>",
"    not be prescribed to children with pulmonary arterial hypertension (PAH) because of reports of associated mortality with administration of high doses of sildenafil in children between 1 and 17 years of age with sildenafil, and that low doses of this drug were not effective in improving the exercise ability in these children [",
"    <a class=\"abstract\" href=\"UTD.htm?26/37/27225/abstract/42\">",
"     42",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    As a result, although the results of the above studies are promising, the use of",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?37/9/38041?source=see_link\">",
"     sildenafil",
"    </a>",
"    cannot be recommended in settings where iNO is available unless larger randomized controlled studies have shown that a limited course of sildenafil is effective and safe in the treatment of PPHN. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/24/35210?source=see_link\">",
"     \"Treatment of pulmonary hypertension in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21603164\">",
"    <span class=\"h3\">",
"     Other agents",
"    </span>",
"    &nbsp;&mdash;&nbsp;Other agents include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Inhaled or intravenous prostacyclin is a potential intervention in patients who fail NO therapy, but is no longer commonly used [",
"      <a class=\"abstract\" href=\"UTD.htm?26/37/27225/abstract/43,44\">",
"       43,44",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?24/60/25542?source=see_link\">",
"       Milrinone",
"      </a>",
"      , a phosphodiesterase III inhibitor milrinone, has improved oxygenation in infants refractory to iNO [",
"      <a class=\"abstract\" href=\"UTD.htm?26/37/27225/abstract/45\">",
"       45",
"      </a>",
"      ]. However, randomized trials are needed to demonstrate efficacy and safety [",
"      <a class=\"abstract\" href=\"UTD.htm?26/37/27225/abstract/46\">",
"       46",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?21/8/21641?source=see_link\">",
"       Bosentan",
"      </a>",
"      , an endothelin-1 receptor antagonist, was reported to be effective and safe in treating patients with PPHN. This was illustrated in a single trial of 47 neonates with PPHN in a setting where iNO and ECMO are unavailable that showed bosentan (1",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      given through orogastric tube twice a day) was more effective than placebo in improving OI and oxygen saturation and decreasing the time of mechanical ventilation [",
"      <a class=\"abstract\" href=\"UTD.htm?26/37/27225/abstract/47\">",
"       47",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H28\">",
"    <span class=\"h1\">",
"     OUTCOME",
"    </span>",
"    &nbsp;&mdash;&nbsp;Survivors of severe persistent pulmonary hypertension of the newborn (PPHN)",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    extracorporeal membrane oxygenation (ECMO) treatment are at increased risk of developmental delay, motor disability, and hearing deficits [",
"    <a class=\"abstract\" href=\"UTD.htm?26/37/27225/abstract/48-54\">",
"     48-54",
"    </a>",
"    ]. In one study, survivors of PPHN compared to a matched control group were more likely to have sensorineural hearing loss based upon audiologic evaluation and chronic health problems (eg, cerebral palsy, developmental delay, the use of bronchodilator therapy, and remedial education) by parental report at 5 to 11 years of age [",
"    <a class=\"abstract\" href=\"UTD.htm?26/37/27225/abstract/54\">",
"     54",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    iNO does not appear to increase the risk of adverse outcomes.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In one report, 87 percent of surviving infants enrolled in the Neonatal Research Network trial of inhaled nitric oxide (iNO) were evaluated at 18 to 24 months of age [",
"      <a class=\"abstract\" href=\"UTD.htm?26/37/27225/abstract/48\">",
"       48",
"      </a>",
"      ]. Approximately one-third of the infants had at least one disability. Abnormal outcomes included sensorineural hearing loss (14 percent) and moderate to severe cerebral palsy (7.5 percent), but were not different between groups. Mental and psychomotor developmental scores also were not different.",
"     </li>",
"     <li>",
"      In a report from a single tertiary center, 109 of 187 children who were term infants treated for PPHN were evaluated at school age (mean age 7.1 years) [",
"      <a class=\"abstract\" href=\"UTD.htm?26/37/27225/abstract/55\">",
"       55",
"      </a>",
"      ]. Overall, 9 percent of the cohort had an IQ score less than 70, and 7 percent had an IQ score between 70 and 84. There was no difference in the medical and neurodevelopmental outcome between the 77 children who had received iNO, of whom 12 were also treated by ECMO, and those who did not receive iNO.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Treatment with iNO does not appear to alter lung function in later infancy, as illustrated in a study in which 22 infants who had severe PPHN (15 treated with iNO) and 18 healthy controls were evaluated 4 to 12 months after discharge from the neonatal intensive care unit [",
"    <a class=\"abstract\" href=\"UTD.htm?26/37/27225/abstract/56\">",
"     56",
"    </a>",
"    ]. No differences between groups were detected in functional residual capacity or respiratory system compliance.",
"   </p>",
"   <p>",
"    All infants with severe PPHN who have been treated with INO",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    ECMO should have neurodevelopmental follow-up [",
"    <a class=\"abstract\" href=\"UTD.htm?26/37/27225/abstract/32\">",
"     32",
"    </a>",
"    ]. Assessment should be performed through infancy at 6- to 12-month intervals, and longer if abnormalities are present. Hearing should be tested prior to hospital discharge and at 18 to 24 months corrected age.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topics (see",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?22/44/23233?source=see_link\">",
"       \"Patient information: Persistent pulmonary hypertension in a newborn (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1270145189\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Persistent pulmonary hypertension of the newborn (PPHN) occurs when pulmonary vascular resistance (PVR) remains elevated after birth, resulting in right-to-left shunting of blood through fetal circulatory pathways (",
"    <a class=\"graphic graphic_figure graphicRef55037 \" href=\"UTD.htm?33/3/33848\">",
"     figure 1",
"    </a>",
"    ) that leads to hypoxemia, which in some cases may be severe and not responsive to conventional respiratory support.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      PPHN occurs primarily in term or late preterm infants &ge;34 weeks gestation. It is caused by abnormalities of the pulmonary vasculature that includes underdevelopment, maldevelopment (ie, abnormally thick pulmonary arteriolar musculature), and maladaption (abnormal vasoconstriction that interferes with the normal postnatal fall in PVR). (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Pathophysiology'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      PPHN is associated with a variety of primary respiratory disorders, such as meconium aspiration syndrome, pneumonia, respiratory distress syndrome, congenital diaphragmatic syndrome, and pulmonary hypoplasia. (See",
"      <a class=\"local\" href=\"#H8\">",
"       'Clinical features'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The diagnosis of PPHN should be considered in any infant with severe cyanosis and the diagnosis is made by echocardiography. (See",
"      <a class=\"local\" href=\"#H9\">",
"       'Diagnosis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The management of PPHN is largely supportive. It is directed toward promoting a progressive decline in the ratio of PVR to SVR, and to maintaining adequate tissue oxygenation until PVR falls. Specific treatment is provided for any associated parenchymal lung disease.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Our approach to treating infants with PPHN includes the following:",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Supplemental oxygen &ndash; Oxygen is a pulmonary vasodilator and initially should be administered in a concentration of 100 percent to infants with PPHN in an attempt to reverse pulmonary vasoconstriction. PaO2 should be maintained subsequently in the range of 50 to 90 mmHg (oxygen saturation &gt;90 percent). (See",
"      <a class=\"local\" href=\"#H16\">",
"       'Oxygen'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Mechanical ventilation to initially maintain PaCO2 between 35 to 40 mmHg, as hypercarbia and acidosis increase PVR. (See",
"      <a class=\"local\" href=\"#H17\">",
"       'Assisted ventilation'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Maintenance of adequate circulatory function by providing sufficient vascular volume and the use of inotropic agents. (See",
"      <a class=\"local\" href=\"#H21\">",
"       'Circulatory support'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Use of oxygenation index (OI) to assess the severity of hypoxia. (See",
"      <a class=\"local\" href=\"#H1270145468\">",
"       'Oxygenation index'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      We use inhaled nitric oxide (iNO) to initially treat term or late preterm infants when there is significant hypoxemia on substantial ventilatory support indicated by an OI &ge;25. (See",
"      <a class=\"local\" href=\"#H23\">",
"       'Inhaled nitric oxide'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      We use extracorporeal membrane oxygenation in patients who have an OI &ge;40 despite the use of iNO and maximum ventilatory support. (See",
"      <a class=\"local\" href=\"#H26\">",
"       'Extracorporeal membrane oxygenation'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Survivors of severe PPHN",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      ECMO treatment are at increased risk of developmental delay, motor disability, and hearing deficits. (See",
"      <a class=\"local\" href=\"#H28\">",
"       'Outcome'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/37/27225/abstract/1\">",
"      Walsh-Sukys MC, Tyson JE, Wright LL, et al. Persistent pulmonary hypertension of the newborn in the era before nitric oxide: practice variation and outcomes. Pediatrics 2000; 105:14.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/37/27225/abstract/2\">",
"      Levin DL. Morphologic analysis of the pulmonary vascular bed in congenital left-sided diaphragmatic hernia. J Pediatr 1978; 92:805.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/37/27225/abstract/3\">",
"      Geggel RL, Murphy JD, Langleben D, et al. Congenital diaphragmatic hernia: arterial structural changes and persistent pulmonary hypertension after surgical repair. J Pediatr 1985; 107:457.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/37/27225/abstract/4\">",
"      Murphy JD, Rabinovitch M, Goldstein JD, Reid LM. The structural basis of persistent pulmonary hypertension of the newborn infant. J Pediatr 1981; 98:962.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/37/27225/abstract/5\">",
"      Dhillon R. The management of neonatal pulmonary hypertension. Arch Dis Child Fetal Neonatal Ed 2012; 97:F223.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/37/27225/abstract/6\">",
"      Christou H, Adatia I, Van Marter LJ, et al. Effect of inhaled nitric oxide on endothelin-1 and cyclic guanosine 5'-monophosphate plasma concentrations in newborn infants with persistent pulmonary hypertension. J Pediatr 1997; 130:603.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/37/27225/abstract/7\">",
"      Pearson DL, Dawling S, Walsh WF, et al. Neonatal pulmonary hypertension--urea-cycle intermediates, nitric oxide production, and carbamoyl-phosphate synthetase function. N Engl J Med 2001; 344:1832.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/37/27225/abstract/8\">",
"      Alano MA, Ngougmna E, Ostrea EM Jr, Konduri GG. Analysis of nonsteroidal antiinflammatory drugs in meconium and its relation to persistent pulmonary hypertension of the newborn. Pediatrics 2001; 107:519.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/37/27225/abstract/9\">",
"      Curtis J, Kim G, Wehr NB, Levine RL. Group B streptococcal phospholipid causes pulmonary hypertension. Proc Natl Acad Sci U S A 2003; 100:5087.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/37/27225/abstract/10\">",
"      Aikio O, Metsola J, Vuolteenaho R, et al. Transient defect in nitric oxide generation after rupture of fetal membranes and responsiveness to inhaled nitric oxide in very preterm infants with hypoxic respiratory failure. J Pediatr 2012; 161:397.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/37/27225/abstract/11\">",
"      Ball MK, Steinhorn RH. Inhaled nitric oxide for preterm infants: a Marksman's approach. J Pediatr 2012; 161:379.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/37/27225/abstract/12\">",
"      Peliowski A, Finer NN, Etches PC, et al. Inhaled nitric oxide for premature infants after prolonged rupture of the membranes. J Pediatr 1995; 126:450.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/37/27225/abstract/13\">",
"      Chock VY, Van Meurs KP, Hintz SR, et al. Inhaled nitric oxide for preterm premature rupture of membranes, oligohydramnios, and pulmonary hypoplasia. Am J Perinatol 2009; 26:317.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/37/27225/abstract/14\">",
"      Kinsella JP, Truog WE, Walsh WF, et al. Randomized, multicenter trial of inhaled nitric oxide and high-frequency oscillatory ventilation in severe, persistent pulmonary hypertension of the newborn. J Pediatr 1997; 131:55.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/37/27225/abstract/15\">",
"      Bhutani VK, Abbasi S, Sivieri EM. Continuous skeletal muscle paralysis: effect on neonatal pulmonary mechanics. Pediatrics 1988; 81:419.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/37/27225/abstract/16\">",
"      Findlay RD, Taeusch HW, Walther FJ. Surfactant replacement therapy for meconium aspiration syndrome. Pediatrics 1996; 97:48.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/37/27225/abstract/17\">",
"      Lotze A, Mitchell BR, Bulas DI, et al. Multicenter study of surfactant (beractant) use in the treatment of term infants with severe respiratory failure. Survanta in Term Infants Study Group. J Pediatr 1998; 132:40.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/37/27225/abstract/18\">",
"      Seri I. Circulatory support of the sick preterm infant. Semin Neonatol 2001; 6:85.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/37/27225/abstract/19\">",
"      Roz&eacute; JC, Tohier C, Maingueneau C, et al. Response to dobutamine and dopamine in the hypotensive very preterm infant. Arch Dis Child 1993; 69:59.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/37/27225/abstract/20\">",
"      Tourneux P, Rakza T, Bouissou A, et al. Pulmonary circulatory effects of norepinephrine in newborn infants with persistent pulmonary hypertension. J Pediatr 2008; 153:345.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/37/27225/abstract/21\">",
"      Tworetzky W, Bristow J, Moore P, et al. Inhaled nitric oxide in neonates with persistent pulmonary hypertension. Lancet 2001; 357:118.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/37/27225/abstract/22\">",
"      Inhaled nitric oxide in full-term and nearly full-term infants with hypoxic respiratory failure. The Neonatal Inhaled Nitric Oxide Study Group. N Engl J Med 1997; 336:597.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/37/27225/abstract/23\">",
"      Davidson D, Barefield ES, Kattwinkel J, et al. Inhaled nitric oxide for the early treatment of persistent pulmonary hypertension of the term newborn: a randomized, double-masked, placebo-controlled, dose-response, multicenter study. The I-NO/PPHN Study Group. Pediatrics 1998; 101:325.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/37/27225/abstract/24\">",
"      Clark RH, Kueser TJ, Walker MW, et al. Low-dose nitric oxide therapy for persistent pulmonary hypertension of the newborn. Clinical Inhaled Nitric Oxide Research Group. N Engl J Med 2000; 342:469.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/37/27225/abstract/25\">",
"      Roberts JD Jr, Fineman JR, Morin FC 3rd, et al. Inhaled nitric oxide and persistent pulmonary hypertension of the newborn. The Inhaled Nitric Oxide Study Group. N Engl J Med 1997; 336:605.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/37/27225/abstract/26\">",
"      Finer NN, Barrington KJ. Nitric oxide for respiratory failure in infants born at or near term. Cochrane Database Syst Rev 2001; :CD000399.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/37/27225/abstract/27\">",
"      George TN, Johnson KJ, Bates JN, Segar JL. The effect of inhaled nitric oxide therapy on bleeding time and platelet aggregation in neonates. J Pediatr 1998; 132:731.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/37/27225/abstract/28\">",
"      Konduri GG, Solimano A, Sokol GM, et al. A randomized trial of early versus standard inhaled nitric oxide therapy in term and near-term newborn infants with hypoxic respiratory failure. Pediatrics 2004; 113:559.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/37/27225/abstract/29\">",
"      Konduri GG, Vohr B, Robertson C, et al. Early inhaled nitric oxide therapy for term and near-term newborn infants with hypoxic respiratory failure: neurodevelopmental follow-up. J Pediatr 2007; 150:235.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/37/27225/abstract/30\">",
"      Inhaled nitric oxide and hypoxic respiratory failure in infants with congenital diaphragmatic hernia. The Neonatal Inhaled Nitric Oxide Study Group (NINOS). Pediatrics 1997; 99:838.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/37/27225/abstract/31\">",
"      Davidson D, Barefield ES, Kattwinkel J, et al. Safety of withdrawing inhaled nitric oxide therapy in persistent pulmonary hypertension of the newborn. Pediatrics 1999; 104:231.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/37/27225/abstract/32\">",
"      American Academy of Pediatrics. Committee on Fetus and Newborn. Use of inhaled nitric oxide. Pediatrics 2000; 106:344.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/37/27225/abstract/33\">",
"      Hamon I, Gauthier-Moulinier H, Grelet-Dessioux E, et al. Methaemoglobinaemia risk factors with inhaled nitric oxide therapy in newborn infants. Acta Paediatr 2010; 99:1467.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/37/27225/abstract/34\">",
"      Somaschini M, Bellan C, Chinaglia D, et al. Congenital misalignment of pulmonary vessels and alveolar capillary dysplasia: how to manage a neonatal irreversible lung disease? J Perinatol 2000; 20:189.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/37/27225/abstract/35\">",
"      Garc&iacute;a Mart&iacute;nez E, Ibarra de la Rosa I, P&eacute;rez Navero JL, et al. [Sildenafil in the treatment of pulmonary hypertension]. An Pediatr (Barc) 2003; 59:110.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/37/27225/abstract/36\">",
"      Karatza AA, Narang I, Rosenthal M, et al. Treatment of primary pulmonary hypertension with oral sildenafil. Respiration 2004; 71:192.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/37/27225/abstract/37\">",
"      Keller RL, Hamrick SE, Kitterman JA, et al. Treatment of rebound and chronic pulmonary hypertension with oral sildenafil in an infant with congenital diaphragmatic hernia. Pediatr Crit Care Med 2004; 5:184.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/37/27225/abstract/38\">",
"      Baquero H, Soliz A, Neira F, et al. Oral sildenafil in infants with persistent pulmonary hypertension of the newborn: a pilot randomized blinded study. Pediatrics 2006; 117:1077.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/37/27225/abstract/39\">",
"      Ahsman MJ, Witjes BC, Wildschut ED, et al. Sildenafil exposure in neonates with pulmonary hypertension after administration via a nasogastric tube. Arch Dis Child Fetal Neonatal Ed 2010; 95:F109.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/37/27225/abstract/40\">",
"      Shah PS, Ohlsson A. Sildenafil for pulmonary hypertension in neonates. Cochrane Database Syst Rev 2011; :CD005494.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/37/27225/abstract/41\">",
"      Steinhorn RH, Kinsella JP, Pierce C, et al. Intravenous sildenafil in the treatment of neonates with persistent pulmonary hypertension. J Pediatr 2009; 155:841.",
"     </a>",
"    </li>",
"    <li>",
"     FDA Drug Safety Communication: FDA recommends against use of Revatio in children with pulmonary hypertension file://www.fda.gov/Drugs/DrugSafety/ucm317123.htm (Accessed on August 31, 2012).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/37/27225/abstract/43\">",
"      Kelly LK, Porta NF, Goodman DM, et al. Inhaled prostacyclin for term infants with persistent pulmonary hypertension refractory to inhaled nitric oxide. J Pediatr 2002; 141:830.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/37/27225/abstract/44\">",
"      Golzand E, Bar-Oz B, Arad I. Intravenous prostacyclin in the treatment of persistent pulmonary hypertension of the newborn refractory to inhaled nitric oxide. Isr Med Assoc J 2005; 7:408.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/37/27225/abstract/45\">",
"      Bassler D, Choong K, McNamara P, Kirpalani H. Neonatal persistent pulmonary hypertension treated with milrinone: four case reports. Biol Neonate 2006; 89:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/37/27225/abstract/46\">",
"      Bassler D, Kreutzer K, McNamara P, Kirpalani H. Milrinone for persistent pulmonary hypertension of the newborn. Cochrane Database Syst Rev 2010; :CD007802.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/37/27225/abstract/47\">",
"      Mohamed WA, Ismail M. A randomized, double-blind, placebo-controlled, prospective study of bosentan for the treatment of persistent pulmonary hypertension of the newborn. J Perinatol 2012; 32:608.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/37/27225/abstract/48\">",
"      Inhaled nitric oxide in term and near-term infants: neurodevelopmental follow-up of the neonatal inhaled nitric oxide study group (NINOS). J Pediatr 2000; 136:611.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/37/27225/abstract/49\">",
"      Ellington M Jr, O'Reilly D, Allred EN, et al. Child health status, neurodevelopmental outcome, and parental satisfaction in a randomized, controlled trial of nitric oxide for persistent pulmonary hypertension of the newborn. Pediatrics 2001; 107:1351.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/37/27225/abstract/50\">",
"      Rosenberg AA, Kennaugh JM, Moreland SG, et al. Longitudinal follow-up of a cohort of newborn infants treated with inhaled nitric oxide for persistent pulmonary hypertension. J Pediatr 1997; 131:70.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/37/27225/abstract/51\">",
"      Robertson CM, Finer NN, Sauve RS, et al. Neurodevelopmental outcome after neonatal extracorporeal membrane oxygenation. CMAJ 1995; 152:1981.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/37/27225/abstract/52\">",
"      Cohen DA, Nsuami M, Etame RB, et al. A school-based Chlamydia control program using DNA amplification technology. Pediatrics 1998; 101:E1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/37/27225/abstract/53\">",
"      Fligor BJ, Neault MW, Mullen CH, et al. Factors associated with sensorineural hearing loss among survivors of extracorporeal membrane oxygenation therapy. Pediatrics 2005; 115:1519.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/37/27225/abstract/54\">",
"      Eriksen V, Nielsen LH, Klokker M, Greisen G. Follow-up of 5- to 11-year-old children treated for persistent pulmonary hypertension of the newborn. Acta Paediatr 2009; 98:304.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/37/27225/abstract/55\">",
"      Rosenberg AA, Lee NR, Vaver KN, et al. School-age outcomes of newborns treated for persistent pulmonary hypertension. J Perinatol 2010; 30:127.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/37/27225/abstract/56\">",
"      Dobyns EL, Griebel J, Kinsella JP, et al. Infant lung function after inhaled nitric oxide therapy for persistent pulmonary hypertension of the newborn. Pediatr Pulmonol 1999; 28:24.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 5045 Version 14.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0503-190.111.122.2-74CF0474CE-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f26_37_27225=[""].join("\n");
var outline_f26_37_27225=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H1270145189\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      PHYSIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Transitional circulation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      PATHOPHYSIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Underdevelopment",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Maldevelopment",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Maladaptation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      CLINICAL FEATURES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15569970\">",
"      Preterm infants",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Physical examination",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Chest radiograph",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Electrocardiogram",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Arterial blood gas",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Echocardiography",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      MANAGEMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Oxygen",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      Assisted ventilation",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H1270145414\">",
"      - Sedation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      Surfactant",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      Circulatory support",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      Correction of acidosis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1270145468\">",
"      Oxygenation index",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      Inhaled nitric oxide",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      - Congenital diaphragmatic hernia",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      - Recommendations",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H26\">",
"      Extracorporeal membrane oxygenation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H27\">",
"      Potential agents",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H21603149\">",
"      - Sildenafil",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H21603164\">",
"      - Other agents",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H28\">",
"      OUTCOME",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1270145189\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PEDS/5045\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PEDS/5045|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?33/3/33848\" title=\"figure 1\">",
"      Fetal circulation",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?21/16/21768?source=related_link\">",
"      Clinical features and diagnosis of meconium aspiration syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/23/28026?source=related_link\">",
"      Congenital diaphragmatic hernia in the neonate",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?18/16/18698?source=related_link\">",
"      Group B streptococcal infection in neonates and young infants",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?11/29/11736?source=related_link\">",
"      Infants with antenatal exposure to serotonin reuptake inhibitors",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?21/0/21512?source=related_link\">",
"      Neonatal pneumonia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/49/31511?source=related_link\">",
"      Overview of neonatal respiratory distress: Disorders of transition",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?28/61/29656?source=related_link\">",
"      Oxygen monitoring and therapy in the newborn",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?19/12/19656?source=related_link\">",
"      Pathophysiology and clinical manifestations of respiratory distress syndrome in the newborn",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?22/44/23233?source=related_link\">",
"      Patient information: Persistent pulmonary hypertension in a newborn (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/14/27880?source=related_link\">",
"      Prevention of bronchopulmonary dysplasia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?34/24/35210?source=related_link\">",
"      Treatment of pulmonary hypertension in adults",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f26_37_27226="Prevalence of and risk factors for coronary heart disease in diabetes mellitus";
var content_f26_37_27226=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"4\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Prevalence of and risk factors for coronary heart disease in diabetes mellitus",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?26/37/27226/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?26/37/27226/contributors\">",
"     Richard W Nesto, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?26/37/27226/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?26/37/27226/contributors\">",
"     Bernard J Gersh, MB, ChB, DPhil, FRCP, MACC",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?26/37/27226/contributors\">",
"     David M Nathan, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?26/37/27226/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?26/37/27226/contributors\">",
"     Brian C Downey, MD, FACC",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?26/37/27226/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Nov 9, 2011.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Heart disease, particularly coronary heart disease (CHD) is a major cause of morbidity and mortality among patients with diabetes mellitus [",
"    <a class=\"abstract\" href=\"UTD.htm?26/37/27226/abstract/1\">",
"     1",
"    </a>",
"    ]. The epidemiology of and risk factors for CHD and the frequency of silent myocardial ischemia in patients with diabetes will be reviewed here. Therapeutic issues are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/20/41289?source=see_link\">",
"     \"Treatment of acute myocardial infarction in diabetes mellitus\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?43/33/44567?source=see_link\">",
"     \"Glycemic control for acute myocardial infarction in patients with and without diabetes mellitus\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/15/30970?source=see_link\">",
"     \"Coronary artery revascularization in patients with diabetes mellitus and multivessel coronary artery disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     PREVALENCE",
"    </span>",
"    &nbsp;&mdash;&nbsp;Compared to individuals without diabetes, those with diabetes have a higher prevalence of CHD, a greater extent of coronary ischemia, and are more likely to have a myocardial infarction (MI), and silent myocardial ischemia.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Diabetes as a CHD equivalent",
"    </span>",
"    &nbsp;&mdash;&nbsp;The National Cholesterol Education Program report from the United States and guidelines from Europe consider type 2 diabetes to be a CHD equivalent, thereby elevating it to the highest risk category [",
"    <a class=\"abstract\" href=\"UTD.htm?26/37/27226/abstract/2,3\">",
"     2,3",
"    </a>",
"    ]. This classification was based in part upon the observation that patients with type 2 diabetes without a prior MI (mean age 58) were at the same risk for MI (20 and 19 percent, respectively) and coronary mortality (15 versus 16 percent) as patients without diabetes who had a prior MI (mean age 56) (",
"    <a class=\"graphic graphic_figure graphicRef80251 \" href=\"UTD.htm?34/1/34845\">",
"     figure 1",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?26/37/27226/abstract/4\">",
"     4",
"    </a>",
"    ]. Similar findings have been noted in other studies. (See",
"    <a class=\"local\" href=\"#H6\">",
"     'Myocardial infarction'",
"    </a>",
"    below and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/32/26122?source=see_link&amp;anchor=H2#H2\">",
"     \"Treatment of lipids (including hypercholesterolemia) in secondary prevention\", section on 'Identification of patients at risk'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The importance of the association between diabetes and CHD can be illustrated by findings from the Framingham Heart Study and the Multiple Risk Factor Intervention Trial (MRFIT). In the Framingham Heart Study, the presence of diabetes doubled the age-adjusted risk for cardiovascular disease in men and tripled it in women [",
"    <a class=\"abstract\" href=\"UTD.htm?26/37/27226/abstract/5\">",
"     5",
"    </a>",
"    ]. Diabetes remained a major independent cardiovascular risk factor even when adjusting for advancing age, hypertension, smoking, hypercholesterolemia, and left ventricular hypertrophy.",
"   </p>",
"   <p>",
"    Similar observations were noted in MRFIT [",
"    <a class=\"abstract\" href=\"UTD.htm?26/37/27226/abstract/6\">",
"     6",
"    </a>",
"    ]. Among 5163 men who reported taking medications for diabetes (mostly type 2), 9.7 percent died from cardiovascular disease over a 12 year period; the comparable cardiovascular death rate in the 342,815 men not taking medications for diabetes was 2.6 percent. This difference was independent of age, ethnic group, cholesterol level, systolic blood pressure, and tobacco use. However, among diabetic men, the increase in cardiovascular risk rose more steeply than in nondiabetics with the addition of each of these risk factors.",
"   </p>",
"   <p>",
"    The Emerging Risk Factors Collaboration group performed a meta-analysis of 102 studies that included 530,083 patients with no history of MI, angina, or stroke at the initial study visit [",
"    <a class=\"abstract\" href=\"UTD.htm?26/37/27226/abstract/7\">",
"     7",
"    </a>",
"    ]. After adjusting for other risk factors, patients with diabetes had an overall risk of CHD twice that of patients without diabetes (HR 2.0, 95%CI 1.8-2.2), with a similarly higher risk of cardiac death (HR 2.3, 95% CI 2.1-2.6) and non-fatal MI (HR 1.8, 95% CI 1.6-2.0).",
"   </p>",
"   <p>",
"    Although most patients in the above studies had type 2 diabetes, the relative risk for cardiovascular disease compared to nondiabetics of similar age is even greater in those with type 1 diabetes [",
"    <a class=\"abstract\" href=\"UTD.htm?26/37/27226/abstract/8,9\">",
"     8,9",
"    </a>",
"    ]. This was illustrated in a review of 292 patients with type 1 diabetes [",
"    <a class=\"abstract\" href=\"UTD.htm?26/37/27226/abstract/8\">",
"     8",
"    </a>",
"    ]. After age 30, CHD mortality increased rapidly, particularly in patients with renal disease. The cumulative CHD mortality was 35 percent by age 55, compared to 8 and 4 percent in nondiabetic men and women, respectively, in the Framingham Heart Study. Similar relationships were noted for nonfatal MI and angina.",
"   </p>",
"   <p>",
"    The age at which an individual transitions to a high risk for cardiovascular disease category is another way to demonstrate the powerful risk imparted by the presence of diabetes mellitus. This relationship was evaluated in a retrospective, population-based cohort of Canadians using a large provincial health claims database [",
"    <a class=\"abstract\" href=\"UTD.htm?26/37/27226/abstract/10\">",
"     10",
"    </a>",
"    ]. The transition to a high-risk category (10 year event rate risk of greater than 20 percent) occurred at a younger age for men and women with type 2 diabetes than for nondiabetic patients (mean difference 15 years). Using a broad definition of cardiovascular disease, the age of onset of high-risk was 41 and 48 years for men and women with diabetes, respectively.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h3\">",
"     Extent of coronary disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;Most [",
"    <a class=\"abstract\" href=\"UTD.htm?26/37/27226/abstract/11-18\">",
"     11-18",
"    </a>",
"    ] but not all [",
"    <a class=\"abstract\" href=\"UTD.htm?26/37/27226/abstract/19\">",
"     19",
"    </a>",
"    ] studies have found that the extent of the disease in the coronary arteries is greater among diabetic patients. As an example, the Thrombolysis and Angioplasty in Myocardial Infarction (TAMI) trial provided coronary angiographic data obtained during an acute myocardial infarction [",
"    <a class=\"abstract\" href=\"UTD.htm?26/37/27226/abstract/15\">",
"     15",
"    </a>",
"    ]. TAMI included 148 diabetic and 923 nondiabetic patients in whom cardiac catheterization was performed at 90 minutes and seven to ten days after thrombolytic therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?26/37/27226/abstract/15\">",
"     15",
"    </a>",
"    ]. Compared to the nondiabetics, the diabetic patients had a significantly higher incidence of multivessel disease (66 versus 46 percent) and a greater number of diseased vessels.",
"   </p>",
"   <p>",
"    Multivessel CHD is also common in asymptomatic patients with type 2 diabetes, particularly those with two or more coronary risk factors other than diabetes [",
"    <a class=\"abstract\" href=\"UTD.htm?26/37/27226/abstract/20\">",
"     20",
"    </a>",
"    ]. There also may be an association between the extent of coronary disease and the degree of glycemic control. (See",
"    <a class=\"local\" href=\"#H8\">",
"     'Silent ischemia and infarction'",
"    </a>",
"    below and",
"    <a class=\"local\" href=\"#H14\">",
"     'Hyperglycemia'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h3\">",
"     Temporal trends",
"    </span>",
"    &nbsp;&mdash;&nbsp;The incidence of cardiovascular disease has declined substantially in adults with and without diabetes over the last 50 years. The magnitude of this effect and the persistence of greater risk in diabetic patients were illustrated in a report from the Framingham Heart Study of participants seen between 1950 and 1966 and between 1977 and 1995 [",
"    <a class=\"abstract\" href=\"UTD.htm?26/37/27226/abstract/21\">",
"     21",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The age and sex-adjusted rate of cardiovascular events (MI, CHD death, or stroke) decline from 287 to 147 per 10,000 person years in participants with diabetes (a 49 percent decline) and from 85 to 54 cardiovascular events in those without diabetes (a 35 percent decline). Diabetes was still associated with a two-fold increase in risk (multivariable-adjusted hazard ratio 1.96, 95% CI 1.44-2.66). The reductions in risk were similar in men and women.",
"   </p>",
"   <p>",
"    However, different findings were noted in a report from the National Health and Nutrition Examination Survey (NHANES), which evaluated the time periods of 1971 to 1975 and 1982 to 1984 [",
"    <a class=\"abstract\" href=\"UTD.htm?26/37/27226/abstract/22\">",
"     22",
"    </a>",
"    ]. There was smaller decline in cardiovascular mortality over time in diabetic men (13 versus 36 percent in nondiabetic men), while the risk by 23 percent in diabetic women (compared to a 27 percent decline in risk in nondiabetic women). A possible explanation for the difference in findings is that the Framingham Heart Study compared outcomes over a much longer period, beginning in the 1950s and ending in the 1990s. In addition, the diagnosis of diabetes was confirmed in the Framingham report compared to a patient-reported physician diagnosis in NHANES.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Myocardial infarction",
"    </span>",
"    &nbsp;&mdash;&nbsp;Diabetes is associated with an increased risk of myocardial infarction. In the worldwide INTERHEART study of patients from 52 countries, diabetes accounted for 10 percent of the population-attributable risk of a first MI [",
"    <a class=\"abstract\" href=\"UTD.htm?26/37/27226/abstract/23\">",
"     23",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/59/39866?source=see_link&amp;anchor=H4873275#H4873275\">",
"     \"Overview of the risk equivalents and established risk factors for cardiovascular disease\", section on 'Diabetes mellitus'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The importance of diabetes as a risk factor for MI was demonstrated in a study that compared the seven year incidence of MI in 1373 nondiabetics and 1059 patients with type 2 diabetes in Finland [",
"    <a class=\"abstract\" href=\"UTD.htm?26/37/27226/abstract/4\">",
"     4",
"    </a>",
"    ]. Type 2 diabetics without a prior infarction were at the same risk for MI (20 and 19 percent, respectively) and coronary mortality (15 versus 16 percent) as nondiabetics with a prior MI (",
"    <a class=\"graphic graphic_figure graphicRef80251 \" href=\"UTD.htm?34/1/34845\">",
"     figure 1",
"    </a>",
"    ). The risk of infarction was greatest in diabetics with a prior MI and lowest in nondiabetics without a prior MI (45 and 4 percent, respectively). These findings were independent of other risk factors such as total cholesterol, hypertension, and smoking.",
"   </p>",
"   <p>",
"    Similar findings have been noted in other studies [",
"    <a class=\"abstract\" href=\"UTD.htm?26/37/27226/abstract/24,25\">",
"     24,25",
"    </a>",
"    ], including a much larger series of 13,790 patients in a population-based cohort from the Atherosclerosis Risk In Communities (ARIC) study in the United States [",
"    <a class=\"abstract\" href=\"UTD.htm?26/37/27226/abstract/24\">",
"     24",
"    </a>",
"    ]. At nine years of follow-up, there were 634 cardiac deaths or nonfatal MIs (4.6 percent). Event rates varied among patients with or without diabetes and with or without a history of MI as follows:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      No diabetes and no MI &mdash; 3.9 percent",
"     </li>",
"     <li>",
"      Diabetes and no MI &mdash; 10.8 percent",
"     </li>",
"     <li>",
"      No diabetes and prior MI &mdash; 18.9 percent",
"     </li>",
"     <li>",
"      Diabetes and prior MI &mdash; 32.2 percent",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    These relationships may vary with gender. In another report from Finland, prior MI was a greater risk factor for CHD mortality than diabetes without a prior MI in men (hazard ratio 1.78), but diabetes without a prior MI was a greater risk factor in women (hazard ratio 1.75) [",
"    <a class=\"abstract\" href=\"UTD.htm?26/37/27226/abstract/26\">",
"     26",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/57/28570?source=see_link\">",
"     \"Determinants and management of cardiovascular risk in women\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In addition to the increase in mortality, diabetic patients are also more likely to experience a complication associated with an MI, including postinfarction angina and heart failure. Possible contributory factors are that diabetic patients are more likely to have multivessel disease [",
"    <a class=\"abstract\" href=\"UTD.htm?26/37/27226/abstract/20\">",
"     20",
"    </a>",
"    ] and fewer coronary collateral vessels [",
"    <a class=\"abstract\" href=\"UTD.htm?26/37/27226/abstract/27\">",
"     27",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Asymptomatic CHD",
"    </span>",
"    &nbsp;&mdash;&nbsp;In addition to the increase in cardiovascular events, patients with type 2 diabetes also have a high rate of asymptomatic coronary disease as determined by the presence of coronary artery calcification (CAC) on electron beam CT scanning and by inducible silent ischemia on stress imaging [",
"    <a class=\"abstract\" href=\"UTD.htm?26/37/27226/abstract/28\">",
"     28",
"    </a>",
"    ]. These issues as well as possible screening for CHD in patients with diabetes are discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/20/18761?source=see_link\">",
"     \"Screening for coronary heart disease in patients with diabetes mellitus\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In addition to an increased rate of structural disease, patients with type 2 diabetes also have reduced myocardial flow reserve, a reflection of coronary vasodilator capacity [",
"    <a class=\"abstract\" href=\"UTD.htm?26/37/27226/abstract/29,30\">",
"     29,30",
"    </a>",
"    ]. This abnormality is inversely related to glycemic control [",
"    <a class=\"abstract\" href=\"UTD.htm?26/37/27226/abstract/29\">",
"     29",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h3\">",
"     Silent ischemia and infarction",
"    </span>",
"    &nbsp;&mdash;&nbsp;Some diabetic patients have a blunted appreciation of ischemic pain, which may result in atypical anginal symptoms, silent ischemia, or even silent infarction. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/33/28180?source=see_link\">",
"     \"Silent myocardial ischemia: Diagnosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Silent ischemia in diabetes is thought to be caused at least in part by autonomic denervation of the heart [",
"    <a class=\"abstract\" href=\"UTD.htm?26/37/27226/abstract/31-34\">",
"     31-34",
"    </a>",
"    ]. In support of this hypothesis is the observation that the uptake of metaiodobenzylguanidine (MIBG), a norepinephrine analog, is reduced in diabetic patients with silent ischemia [",
"    <a class=\"abstract\" href=\"UTD.htm?26/37/27226/abstract/33\">",
"     33",
"    </a>",
"    ]. This finding is suggestive of sympathetic denervation, which has also been seen with positron emission tomography [",
"    <a class=\"abstract\" href=\"UTD.htm?26/37/27226/abstract/30,35\">",
"     30,35",
"    </a>",
"    ]. Furthermore, regional heterogeneity in sympathetic innervation can predispose to myocardial electrical instability that may lead to life-threatening arrhythmias [",
"    <a class=\"abstract\" href=\"UTD.htm?26/37/27226/abstract/35\">",
"     35",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?8/46/8938?source=see_link\">",
"     \"Diabetic autonomic neuropathy\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Another component of decreased perception of myocardial ischemia is that diabetic patients have a prolongation of the anginal perceptual threshold during exercise testing, ie, the time from onset of ischemic changes on the electrocardiogram to the onset of angina [",
"    <a class=\"abstract\" href=\"UTD.htm?26/37/27226/abstract/36\">",
"     36",
"    </a>",
"    ]. The longer the threshold, the greater the exercise capacity and the more severe the ischemia.",
"   </p>",
"   <p>",
"    Diabetic patients also have an increased frequency of silent ST segment depression and coronary perfusion abnormalities during stress testing. Although the supportive data are presented separately, the potential magnitude of silent CHD can be illustrated by the results of the following study. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/20/18761?source=see_link&amp;anchor=H4#H4\">",
"     \"Screening for coronary heart disease in patients with diabetes mellitus\", section on 'Stress testing and coronary arteriography'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The rate of silent ischemia was evaluated in an observational study of 1899 asymptomatic patients with type 2 diabetes age &le;60 years (mean age 53) [",
"    <a class=\"abstract\" href=\"UTD.htm?26/37/27226/abstract/20\">",
"     20",
"    </a>",
"    ]. The patients underwent stress testing with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?40/25/41366?source=see_link\">",
"     dipyridamole",
"    </a>",
"    myocardial contrast echocardiography (MCE) and follow-up coronary angiography if the MCE were abnormal. The stress test was abnormal in 60 percent, 65 percent of whom had significant coronary disease on angiography.",
"   </p>",
"   <p>",
"    This report also evaluated the relationship between the number of risk factors and the presence of silent ischemia. Sixty percent of patients had &ge;2 CHD risk factors (dyslipidemia, hypertension, smoking, a positive family history of premature CHD, or the presence of microalbuminuria).",
"   </p>",
"   <p>",
"    The two risk groups (&ge;2 versus 0 or 1 risk factors) had equivalent rates of an abnormal stress test (60 percent) and of significant coronary disease on angiography (65 percent). However, the patients with &ge;2 risk factors had more severe coronary disease with significantly higher rates of three-vessel disease (33 versus 8 percent), diffuse disease (55 versus 18 percent), and vessel occlusion (31 versus 4 percent); they also had a lower rate of single vessel disease (29 versus 54 percent). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/15/30970?source=see_link\">",
"     \"Coronary artery revascularization in patients with diabetes mellitus and multivessel coronary artery disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Diabetes is associated with an increased frequency of unrecognized MI, as well as silent ischemia, at least in men [",
"    <a class=\"abstract\" href=\"UTD.htm?26/37/27226/abstract/31,37,38\">",
"     31,37,38",
"    </a>",
"    ]. In a report from the Framingham Heart Study, for example, the fraction of infarctions that were detected on routine electrocardiograms but unrecognized clinically was more than twice that in nondiabetic men (39 versus 18 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?26/37/27226/abstract/37\">",
"     37",
"    </a>",
"    ]. In comparison, diabetic women were less likely to have silent infarction, a finding also noted in a report from the HERS trial [",
"    <a class=\"abstract\" href=\"UTD.htm?26/37/27226/abstract/39\">",
"     39",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?43/20/44361?source=see_link&amp;anchor=H15#H15\">",
"     \"Epidemiology of coronary heart disease\", section on 'Silent myocardial ischemia and infarction'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     CHD before diabetes",
"    </span>",
"    &nbsp;&mdash;&nbsp;Impaired glucose tolerance or overt diabetes may first be diagnosed in the setting of acute MI. This could reflect blood testing being performed during the hospitalization in patients with previously unrecognized diabetes. A second mechanism is that the stress of MI unmasks or worsens the tendency toward hyperglycemia.",
"   </p>",
"   <p>",
"    The potential frequency with which this might occur was demonstrated in a prospective study of 181 patients with an acute MI and no previous diagnosis of diabetes in whom the fasting blood glucose and two-hour blood glucose after a standard load were serially measured [",
"    <a class=\"abstract\" href=\"UTD.htm?26/37/27226/abstract/40\">",
"     40",
"    </a>",
"    ]. Impaired glucose tolerance was present in 35 percent at hospital discharge and 40 percent three months later. The respective values for previously undiagnosed diabetes were 31 and 25 percent using oral glucose tolerance test criteria and 10 and 13 percent when only the fasting blood glucose was used.",
"   </p>",
"   <p>",
"    The hemoglobin A1C concentration on admission was an independent predictor for abnormal glucose tolerance at three months, indicating that the metabolic abnormality preceded the infarction and that the hyperglycemia could not be entirely attributed to stress.",
"   </p>",
"   <p>",
"    These findings strongly suggest that the fasting plasma glucose concentration and hemoglobin A1c should be measured during hospitalization in nondiabetic patients with an acute MI and that elevated values be repeated after discharge to identify those at increased risk. Whether an oral glucose test should be part of the standard evaluation remains uncertain.",
"   </p>",
"   <p>",
"    An increase in risk before the diagnosis of diabetes was also noted in a report from the Nurses' Health Study in which approximately 5 percent of over 115,000 initially nondiabetic women developed type 2 diabetes at 20 year follow-up [",
"    <a class=\"abstract\" href=\"UTD.htm?26/37/27226/abstract/41\">",
"     41",
"    </a>",
"    ]. These women had a multivariate adjusted relative risk for MI before the diagnosis of diabetes of 3.17 (95 percent CI 2.61 to 3.85).",
"   </p>",
"   <p>",
"    There appears to be a graded rise in cardiovascular risk with increasing degrees of glucose intolerance below the definition of overt diabetes [",
"    <a class=\"abstract\" href=\"UTD.htm?26/37/27226/abstract/42-48\">",
"     42-48",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In a meta-analysis of 20 studies that included almost 100,000 people, there was a curvilinear increase in the risk for a cardiovascular event with increasing glucose intolerance. As an example, when compared to patients with a fasting glucose of 75",
"      <span class=\"nowrap\">",
"       mg/dL",
"      </span>",
"      (4.2",
"      <span class=\"nowrap\">",
"       mmol/L),",
"      </span>",
"      the risk of an event was higher in patients with a fasting glucose of 110",
"      <span class=\"nowrap\">",
"       mg/dL",
"      </span>",
"      (6.1",
"      <span class=\"nowrap\">",
"       mmol/L)",
"      </span>",
"      or a two-hour glucose of 140",
"      <span class=\"nowrap\">",
"       mg/dL",
"      </span>",
"      (7.8",
"      <span class=\"nowrap\">",
"       mmol/)",
"      </span>",
"      (relative risk 1.33 and 1.58, respectively) [",
"      <a class=\"abstract\" href=\"UTD.htm?26/37/27226/abstract/42\">",
"       42",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Among survivors in the Framingham Heart Study, the HbA1c concentration was significantly related to prevalent cardiovascular disease in women but not men [",
"      <a class=\"abstract\" href=\"UTD.htm?26/37/27226/abstract/44\">",
"       44",
"      </a>",
"      ]. For each 1 percent increase in HbA1c (eg, from 5 to 6 percent), the relative odds of cardiovascular disease was 1.39 (95% CI 1.06-1.83).",
"     </li>",
"     <li>",
"      In a review of over 10,000 men and women, a 1 percentage point increase in HbA1c was associated with a relative risk for all-cause mortality of 1.24 (95% CI 1.14-1.34) in men and 1.28 (95% CI 1.06-1.32) in women [",
"      <a class=\"abstract\" href=\"UTD.htm?26/37/27226/abstract/47\">",
"       47",
"      </a>",
"      ]. The relative risk was not changed (1.26) when patients with known diabetes or cardiovascular disease or an HbA1c &ge;7 percent were excluded. The increase in risk was also independent of other major cardiovascular risk factors. The rates of cardiovascular disease and mortality were lowest at HbA1c values less than 5 percent, a finding that has also been noted in another study [",
"      <a class=\"abstract\" href=\"UTD.htm?26/37/27226/abstract/49\">",
"       49",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    It has been suggested that the two-hour glucose has greater predictive value than the fasting glucose [",
"    <a class=\"abstract\" href=\"UTD.htm?26/37/27226/abstract/40,45\">",
"     40,45",
"    </a>",
"    ]. Similar findings have been noted in other studies in which higher glucose levels two hours after an oral glucose tolerance test were also more closely associated than fasting glucose levels with cardiovascular risk factors [",
"    <a class=\"abstract\" href=\"UTD.htm?26/37/27226/abstract/50,51\">",
"     50,51",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Among patients with diabetes, the impact of glycemic control on cardiovascular risk is discussed below. (See",
"    <a class=\"local\" href=\"#H15\">",
"     'Effect of glycemic control'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h1\">",
"     RISK FACTORS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Diabetics have a greater burden of atherogenic risk factors than nondiabetics, including hypertension, obesity, lipid abnormalities, insulin, and elevated plasma fibrinogen (",
"    <a class=\"graphic graphic_table graphicRef63757 graphicRef72498 \" href=\"UTD.htm?33/14/34029\">",
"     table 1A-B",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?26/37/27226/abstract/1,52,53\">",
"     1,52,53",
"    </a>",
"    ]. Many of these risk factors are also present in the prediabetic state prior to conversion to overt type 2 diabetes [",
"    <a class=\"abstract\" href=\"UTD.htm?26/37/27226/abstract/54\">",
"     54",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Patients with the constellation of abdominal obesity, hypertension, diabetes, and dyslipidemia are considered to have the metabolic syndrome (also called the insulin resistance syndrome or syndrome X), which is associated with increased cardiovascular risk. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/11/32954?source=see_link\">",
"     \"The metabolic syndrome (insulin resistance syndrome or syndrome X)\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The CHD risk in diabetics varies widely with the intensity of these risk factors. The evidence is strongest for hypertension, elevated low density lipoprotein, smoking, the metabolic syndrome, hyperglycemia, and microalbuminuria. The following discussion is limited to the unique aspects of coronary risk factors in patients with diabetes.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Hypertension",
"    </span>",
"    &nbsp;&mdash;&nbsp;The general role of hypertension as a risk factor for cardiovascular disease and its importance in patients with diabetes are discussed in detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/51/37685?source=see_link\">",
"     \"Cardiovascular risks of hypertension\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/45/21210?source=see_link\">",
"     \"Treatment of hypertension in patients with diabetes mellitus\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Summarized briefly, hypertension is present at diagnosis in many patients with type 2 diabetes, but generally does not occur until after the onset of renal disease in patients with type 1 diabetes [",
"    <a class=\"abstract\" href=\"UTD.htm?26/37/27226/abstract/55\">",
"     55",
"    </a>",
"    ]. The most compelling evidence for the importance of hypertension in diabetes comes from the United Kingdom Prospective Diabetes Study (UKPDS) [",
"    <a class=\"abstract\" href=\"UTD.htm?26/37/27226/abstract/56\">",
"     56",
"    </a>",
"    ]. The following findings were noted at nine year follow-up:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Each 10 mmHg reduction in updated mean systolic pressure was associated with a 12 percent risk reduction in any complication related to diabetes (including cardiovascular disease); the lowest risk occurred at a systolic pressure below 120 mmHg (",
"      <a class=\"graphic graphic_figure graphicRef77963 \" href=\"UTD.htm?26/52/27469\">",
"       figure 2",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      A similar relationship was noted with fatal or nonfatal MI as the incidence fell from 33.1 per 1000 patient years at an updated mean systolic pressure &ge;160 mmHg to 18.4 per 1000 patient years at an updated mean systolic pressure below 120 mmHg.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Based upon these and other observations, antihypertensive therapy is warranted in all patients with diabetes (",
"    <a class=\"graphic graphic_table graphicRef72683 \" href=\"UTD.htm?34/41/35484\">",
"     table 2",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?26/37/27226/abstract/57\">",
"     57",
"    </a>",
"    ]. The optimal goal blood pressure and choice of antihypertensive drugs in such patients are discussed in detail separately. (See 'Treatment of hypertension in patients with diabetes mellitus-I\", section on 'Goal blood pressure' and section on 'Choice of antihypertensive drugs').",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Dyslipidemia",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are a number of differences in the lipid profile between diabetics and nondiabetics that may contribute to the increase in atherosclerosis [",
"    <a class=\"abstract\" href=\"UTD.htm?26/37/27226/abstract/58,59\">",
"     58,59",
"    </a>",
"    ]. The serum lipid abnormalities differ somewhat in patients with type 1 and type 2 diabetes [",
"    <a class=\"abstract\" href=\"UTD.htm?26/37/27226/abstract/59\">",
"     59",
"    </a>",
"    ]. These abnormalities are discussed in detail elsewhere but will be briefly reviewed here.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The lipid pattern in patients with type 1 diabetes is largely related to glycemic control. The Diabetes Control and Complications Trial (DCCT) found that patients with type 1 diabetes (mean HbA1c 8.8 percent) had similar serum lipid values as nondiabetic individuals in the Lipid Research Clinics (LRC) prevalence study except for young women, who had somewhat higher serum total cholesterol and lower high-density lipoprotein (HDL) cholesterol concentrations [",
"      <a class=\"abstract\" href=\"UTD.htm?26/37/27226/abstract/60\">",
"       60",
"      </a>",
"      ]. In comparison, worse glycemic control is characteristically associated with hypertriglyceridemia and low HDL-cholesterol concentrations [",
"      <a class=\"abstract\" href=\"UTD.htm?26/37/27226/abstract/58,61\">",
"       58,61",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Among patients with type 2 diabetes, insulin resistance, relative insulin deficiency, and obesity are associated with hypertriglyceridemia, low serum HDL cholesterol concentrations, and occasionally high serum LDL cholesterol and lipoprotein(a) values [",
"      <a class=\"abstract\" href=\"UTD.htm?26/37/27226/abstract/58,59\">",
"       58,59",
"      </a>",
"      ]. This pattern of lipid abnormalities can be detected before the onset of overt hyperglycemia and is thought to be due in part to hyperinsulinemia",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      insulin resistance [",
"      <a class=\"abstract\" href=\"UTD.htm?26/37/27226/abstract/62\">",
"       62",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    For any serum lipoprotein concentration, diabetic patients have more coronary disease than nondiabetic patients. This increase in risk may be due in part to qualitative differences in the lipoprotein fractions or to the presence of other proatherosclerotic metabolic changes. Among these changes are high serum concentrations of small dense LDL particles, enhanced oxidative modification of LDL, and elevations in serum lipoprotein(a) [",
"    <a class=\"abstract\" href=\"UTD.htm?26/37/27226/abstract/59\">",
"     59",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The association of elevated LDL cholesterol with cardiovascular risk in many epidemiologic studies has been reinforced by randomized clinical trials showing that statin therapy improves outcomes in diabetics, including those without clinical evidence of CHD and those with values below 116",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    (3",
"    <span class=\"nowrap\">",
"     mmol/L)",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?26/37/27226/abstract/63,64\">",
"     63,64",
"    </a>",
"    ]. The proposed modifications to the ATP III guidelines are summarized in the tables and discussed separately (",
"    <a class=\"graphic graphic_table graphicRef67460 \" href=\"UTD.htm?10/46/10989\">",
"     table 3",
"    </a>",
"    and",
"    <a class=\"graphic graphic_table graphicRef54585 \" href=\"UTD.htm?10/56/11147\">",
"     table 4",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?2/59/3002?source=see_link\">",
"     \"Intensity of lipid lowering therapy in secondary prevention of coronary heart disease\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/32/26122?source=see_link&amp;anchor=H1033672373#H1033672373\">",
"     \"Treatment of lipids (including hypercholesterolemia) in secondary prevention\", section on 'Diabetes mellitus as a CHD equivalent'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Non-HDL cholesterol (total cholesterol minus HDL cholesterol, which includes all cholesterol present in lipoprotein particles considered to be atherogenic; LDL, lipoprotein(a), intermediate-density lipoprotein, and very-low-density lipoprotein), appears to be a particularly strong predictor of CHD in both men and women with diabetes [",
"    <a class=\"abstract\" href=\"UTD.htm?26/37/27226/abstract/65\">",
"     65",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Smoking",
"    </span>",
"    &nbsp;&mdash;&nbsp;As in nondiabetics, smoking in diabetics increases cardiovascular morbidity and mortality, raises serum LDL cholesterol, and can impair glycemic control. This increase in risk is gradually reduced with smoking cessation. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?5/4/5189?source=see_link\">",
"     \"Smoking and cardiovascular risk in diabetes mellitus\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Hyperglycemia",
"    </span>",
"    &nbsp;&mdash;&nbsp;There is a graded rise in cardiovascular risk with increasing hyperglycemia in patients with overt diabetes. The magnitude of this effect was illustrated in a meta-analysis of 13 prospective cohort studies (10 in type 2 diabetes, including the UKPDS) [",
"    <a class=\"abstract\" href=\"UTD.htm?26/37/27226/abstract/66\">",
"     66",
"    </a>",
"    ]. For every one-percentage point increase in glycosylated hemoglobin (HbA1c), the relative risk for any cardiovascular event was 1.18 (95% CI 1.10-1.26).",
"   </p>",
"   <p>",
"    There may also be an association between HbA1c and the extent of coronary disease. This was suggested in a review of 315 patients with diabetes who underwent coronary angiography because of chest pain [",
"    <a class=\"abstract\" href=\"UTD.htm?26/37/27226/abstract/67\">",
"     67",
"    </a>",
"    ]. The mean HbA1c increased progressively in patients with 0, 1, 2, or 3-4 vessel disease (6.7, 8.0, 8.8, and 10.4, respectively, a trend that was highly significant). There was no significant difference among the four groups in the duration of diabetes or the prevalence of smoking, hypertension, or dyslipidemia.",
"   </p>",
"   <p>",
"    As noted above, there is also a graded rise in cardiovascular risk with increasing degrees of glucose intolerance below the definition of overt diabetes [",
"    <a class=\"abstract\" href=\"UTD.htm?26/37/27226/abstract/42-46\">",
"     42-46",
"    </a>",
"    ] (See",
"    <a class=\"local\" href=\"#H9\">",
"     'CHD before diabetes'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h3\">",
"     Effect of glycemic control",
"    </span>",
"    &nbsp;&mdash;&nbsp;Strict glycemic control is recommended in both type 1 and type 2 diabetes because of demonstrated benefits in terms of microvascular disease. Protection against macrovascular disease is established only in type 1 diabetes. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?11/34/11817?source=see_link&amp;anchor=H12#H12\">",
"     \"Glycemic control and vascular complications in type 1 diabetes mellitus\", section on 'Macrovascular disease'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Protection against macrovascular disease with strict glycemic control has not been established in type 2 diabetes. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?7/25/7578?source=see_link\">",
"     \"Glycemic control and vascular complications in type 2 diabetes mellitus\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Strict glycemic control appears to be important in patients with an acute MI. The data addressing this issue are presented separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?43/33/44567?source=see_link\">",
"     \"Glycemic control for acute myocardial infarction in patients with and without diabetes mellitus\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Sex",
"    </span>",
"    &nbsp;&mdash;&nbsp;The increase in CHD risk in patients with diabetes is greater in women than in men [",
"    <a class=\"abstract\" href=\"UTD.htm?26/37/27226/abstract/43,68\">",
"     43,68",
"    </a>",
"    ]. The magnitude of this effect was illustrated in a meta-analysis of 37 studies of almost 450,000 patients with type 2 diabetes: the summary relative risk for fatal CHD in patients with diabetes was 3.5 in women and 2.1 in men [",
"    <a class=\"abstract\" href=\"UTD.htm?26/37/27226/abstract/68\">",
"     68",
"    </a>",
"    ]. The excess risk is at least in part due to diabetes being more commonly accompanied by other cardiovascular risk factors in women. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/57/28570?source=see_link&amp;anchor=H6#H6\">",
"     \"Determinants and management of cardiovascular risk in women\", section on 'Diabetes mellitus'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     Microalbuminuria",
"    </span>",
"    &nbsp;&mdash;&nbsp;Microalbuminuria is the earliest clinical manifestation of diabetic nephropathy and is associated with an increased risk of cardiovascular disease in both diabetic and nondiabetic patients. These relationships are discussed in detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/49/42777?source=see_link\">",
"     \"Microalbuminuria in type 1 diabetes mellitus\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/33/39449?source=see_link\">",
"     \"Microalbuminuria in type 2 diabetes mellitus\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/16/20745?source=see_link\">",
"     \"High albuminuria (microalbuminuria) and cardiovascular disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The magnitude of the predictive value of microalbuminuria was illustrated in a review of over 9000 participants in the HOPE (Heart Outcomes Prevention Evaluation) trial [",
"    <a class=\"abstract\" href=\"UTD.htm?26/37/27226/abstract/69\">",
"     69",
"    </a>",
"    ]. The presence of microalbuminuria was associated with an increased relative risk of the primary aggregate end point (myocardial infarction, stroke, or cardiovascular death) in those with and without diabetes (1.97 and 1.61, respectively) [",
"    <a class=\"abstract\" href=\"UTD.htm?26/37/27226/abstract/69\">",
"     69",
"    </a>",
"    ]. The risk of an adverse cardiovascular event increased progressively with increased absolute levels of microalbuminuria.",
"   </p>",
"   <p>",
"    A similar impact of microalbuminuria was found among participants in the LIFE trial [",
"    <a class=\"abstract\" href=\"UTD.htm?26/37/27226/abstract/70\">",
"     70",
"    </a>",
"    ]. The urine albumin-to-creatinine ratio was measured in 7143 nondiabetic subjects (median value 1.16",
"    <span class=\"nowrap\">",
"     mg/mmol",
"    </span>",
"    [10.2",
"    <span class=\"nowrap\">",
"     mg/g])",
"    </span>",
"    and 1063 subjects with diabetes (median value 3.05",
"    <span class=\"nowrap\">",
"     mg/mmol",
"    </span>",
"    [26.9",
"    <span class=\"nowrap\">",
"     mg/g]).",
"    </span>",
"    For every 10-fold increase in the albumin-to-creatinine ratio, the risk of cardiovascular death, MI or stroke increased by 39 percent and the risk of cardiovascular death by 47 percent among diabetics. The respective increases in risk for nondiabetics were 57 and 98 percent.",
"   </p>",
"   <p>",
"    Annual cardiovascular death rates also increase with worsening diabetic nephropathy. This was illustrated in an analysis of 5097 subjects in the United Kingdom Prospective Diabetes Study [",
"    <a class=\"abstract\" href=\"UTD.htm?26/37/27226/abstract/71\">",
"     71",
"    </a>",
"    ]. Annual cardiovascular death rates for no nephropathy, microalbuminuria, macroalbuminuria, and elevated plasma creatinine concentration or renal replacement therapy were 0.7, 2.0, 3.5, and 12.1 percent, respectively [",
"    <a class=\"abstract\" href=\"UTD.htm?26/37/27226/abstract/71\">",
"     71",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    One observational study found that increased urinary albumin excretion and reduced estimated glomerular filtration rate are independent risk factors [",
"    <a class=\"abstract\" href=\"UTD.htm?26/37/27226/abstract/72\">",
"     72",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h2\">",
"     Exercise",
"    </span>",
"    &nbsp;&mdash;&nbsp;Regular exercise is associated with a lower risk of both CHD and cardiac death for both primary and secondary prevention. However, most of the evidence comes from long-term observational studies in which those who exercise regularly have significantly less CHD. Unfortunately, this type of evidence is subject to bias, since the decision to exercise is only one of the many choices made in adopting a healthy life style (eg, cessation of smoking). Thus, attribution of exercise as a prevention of CHD is confounded by other favorable reductions in risk characteristics. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?14/28/14793?source=see_link\">",
"     \"Exercise and fitness in the prevention of cardiovascular disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Similar observational studies have been performed in patients with diabetes:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In a prospective cohort study of 2896 diabetic adults, those who walked for at least two hours per week had lower cardiovascular mortality rates when compared with inactive individuals (HR 0.66; 95 percent CI 0.45 to 0.96; 1.4 versus 2.1 percent per year, respectively) [",
"      <a class=\"abstract\" href=\"UTD.htm?26/37/27226/abstract/73\">",
"       73",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In a similar study in 3316 Finnish patients with diabetes, both occupational and leisure time physical activity were associated with a significant reduction in cardiovascular mortality (hazard ratios 0.69 for both) and total mortality (hazard ratios 0.67 and 0.72, respectively) [",
"      <a class=\"abstract\" href=\"UTD.htm?26/37/27226/abstract/74\">",
"       74",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h2\">",
"     Lack of moderate alcohol intake",
"    </span>",
"    &nbsp;&mdash;&nbsp;The consumption of a moderate amount of alcohol may have health benefits, particularly with regard to coronary disease. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/33/31258?source=see_link\">",
"     \"Cardiovascular benefits and risks of moderate alcohol consumption\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The effect of light to moderate alcohol consumption in diabetic patients was evaluated in the Physicians' Health Study of 87,938 subjects who were free of myocardial infarction, cancer, or liver disease at baseline; 2790 had diabetes [",
"    <a class=\"abstract\" href=\"UTD.htm?26/37/27226/abstract/75\">",
"     75",
"    </a>",
"    ]. After a 5.5 year follow-up, diabetic patients who consumed alcohol on a weekly or daily basis had a significantly lower risk of death from CHD than those who rarely or never consumed alcohol (adjusted relative risk 0.67 and 0.42). The risk reduction was similar to that seen in nondiabetics.",
"   </p>",
"   <p>",
"    Similar benefits of moderate alcohol consumption were noted in diabetic women in the Nurses' Health Study, which evaluated 5103 women with a diagnosis of diabetes at &ge;30 years of age who were free of CHD, stroke, or cancer at baseline [",
"    <a class=\"abstract\" href=\"UTD.htm?26/37/27226/abstract/76\">",
"     76",
"    </a>",
"    ]. Compared to diabetic women reporting no alcohol intake, the adjusted relative risk for nonfatal or fatal coronary heart disease for diabetic women reporting a daily intake of 0.1 to 4.9 grams of alcohol (&lt;0.5 drinks) or &ge;5 grams (&ge;0.5 drinks) was 0.72 and 0.45, respectively.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h2\">",
"     Hyperhomocysteinemia",
"    </span>",
"    &nbsp;&mdash;&nbsp;An elevated serum concentration of homocysteine is a known risk factor for atherosclerosis and is associated with an increased risk of myocardial infarction and death. The risk appears to be greater in patients with diabetes as illustrated in a review of 2484 men and women aged 50 to 75 years [",
"    <a class=\"abstract\" href=\"UTD.htm?26/37/27226/abstract/77\">",
"     77",
"    </a>",
"    ]. After adjusting for major cardiovascular risk factors, the odds ratio for five year mortality for hyperhomocysteinemia was 2.51 for diabetics compared to 1.34 for nondiabetics. For each 5",
"    <span class=\"nowrap\">",
"     &micro;mol/L",
"    </span>",
"    increment in serum homocysteine concentrations, the odds ratio for diabetics and nondiabetics was 1.60 and 1.17, respectively. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/37/19034?source=see_link\">",
"     \"Overview of homocysteine\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h1\">",
"     MECHANISMS OF INCREASED RISK",
"    </span>",
"    &nbsp;&mdash;&nbsp;A variety of mechanisms may contribute to the increase in CHD risk in patients with diabetes in addition to the effects on blood pressure and lipid metabolism. A complete review is beyond the scope of this discussion [",
"    <a class=\"abstract\" href=\"UTD.htm?26/37/27226/abstract/78\">",
"     78",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h2\">",
"     Endothelial dysfunction",
"    </span>",
"    &nbsp;&mdash;&nbsp;Endothelial dysfunction has been documented in diabetic patients who have normal coronary arteries and no other risk factors for coronary disease [",
"    <a class=\"abstract\" href=\"UTD.htm?26/37/27226/abstract/78-83\">",
"     78-83",
"    </a>",
"    ]. The degree of impairment is related to the duration of diabetes, but a defect can occur acutely in patients who develop postprandial hyperglycemia despite having a normal fasting plasma glucose [",
"    <a class=\"abstract\" href=\"UTD.htm?26/37/27226/abstract/84\">",
"     84",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The presence of insulin resistance alone may be associated with coronary endothelial dysfunction [",
"    <a class=\"abstract\" href=\"UTD.htm?26/37/27226/abstract/85,86\">",
"     85,86",
"    </a>",
"    ]. In a study of 50 insulin-resistant and 22 insulin-sensitive Mexican-American subjects without glucose intolerance, CHD, hypertension, cigarette use, or dyslipidemia, endothelium-dependent coronary vasomotor function was abnormal (as assessed by myocardial blood flow response to a cold pressor test) in the insulin-resistant compared to the insulin-sensitive group [",
"    <a class=\"abstract\" href=\"UTD.htm?26/37/27226/abstract/85\">",
"     85",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    After three months of thiazolidinedione therapy, insulin sensitivity and coronary vasomotor function improved in the insulin-resistant subjects [",
"    <a class=\"abstract\" href=\"UTD.htm?26/37/27226/abstract/85\">",
"     85",
"    </a>",
"    ]. Endothelial function can also be improved by",
"    <a class=\"drug drug_general\" href=\"UTD.htm?7/48/7944?source=see_link\">",
"     metformin",
"    </a>",
"    in patients with type 2 diabetes and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/37/35417?source=see_link\">",
"     atorvastatin",
"    </a>",
"    and vitamin E in patients with type 1 diabetes [",
"    <a class=\"abstract\" href=\"UTD.htm?26/37/27226/abstract/87-89\">",
"     87-89",
"    </a>",
"    ]. Whether the improvement in endothelial function leads to better outcomes is not known.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h2\">",
"     Platelet activation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Diabetes has a number of effects on platelet function that may predispose to coronary thrombosis. These include increased primary and secondary platelet aggregation [",
"    <a class=\"abstract\" href=\"UTD.htm?26/37/27226/abstract/90-92\">",
"     90-92",
"    </a>",
"    ], increased platelet activation [",
"    <a class=\"abstract\" href=\"UTD.htm?26/37/27226/abstract/93\">",
"     93",
"    </a>",
"    ] with release of the contents of alpha-granules, including thromboglobulin and platelet factor 4 [",
"    <a class=\"abstract\" href=\"UTD.htm?26/37/27226/abstract/94\">",
"     94",
"    </a>",
"    ], enhanced binding of fibrinogen to the glycoprotein",
"    <span class=\"nowrap\">",
"     IIb/IIIa",
"    </span>",
"    complex, located on the platelet surface, an effect which may be due in part to an increase in the number of glycoprotein",
"    <span class=\"nowrap\">",
"     IIb/IIIa",
"    </span>",
"    receptors on the platelet surface.",
"   </p>",
"   <p>",
"    The altered platelet function in diabetics may be mediated in part by elevated blood glucose. In one study of 42 patients with stable coronary artery disease, the fasting blood glucose was an independent predictor of platelet-dependent thrombosis [",
"    <a class=\"abstract\" href=\"UTD.htm?26/37/27226/abstract/95\">",
"     95",
"    </a>",
"    ]. This relationship was continuous and graded and was even evident in a range of glucose levels considered to be normal. Plasma insulin levels were not associated with platelet-mediated thrombosis.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h2\">",
"     Coagulation abnormalities",
"    </span>",
"    &nbsp;&mdash;&nbsp;In addition to platelet activation, diabetes also predisposes individuals to abnormalities in various pathways involved in coagulation, hemostasis, and fibrinolysis [",
"    <a class=\"abstract\" href=\"UTD.htm?26/37/27226/abstract/96\">",
"     96",
"    </a>",
"    ]. The following are among the abnormalities that have been described.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Diabetes is associated with an increase in plasma fibrinogen, which is a cardiovascular risk factor [",
"      <a class=\"abstract\" href=\"UTD.htm?26/37/27226/abstract/97-99\">",
"       97-99",
"      </a>",
"      ]. Elevated plasma fibrinogen is also associated with other cardiovascular risk factors including older age, increased body mass, smoking, total cholesterol, and triglycerides [",
"      <a class=\"abstract\" href=\"UTD.htm?26/37/27226/abstract/99\">",
"       99",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Fibrinolytic activity is reduced [",
"      <a class=\"abstract\" href=\"UTD.htm?26/37/27226/abstract/100,101\">",
"       100,101",
"      </a>",
"      ]. Although circulating tissue-type plasminogen activator (tPA) levels are normal or increased in the plasma of diabetics, tPA activity is decreased because of increased plasma concentrations of and enhanced binding to its inhibitor, plasminogen activator inhibitor (PAI-1) [",
"      <a class=\"abstract\" href=\"UTD.htm?26/37/27226/abstract/102,103\">",
"       102,103",
"      </a>",
"      ]. Elevations in PAI-1, presumably due to increased synthesis, are also found in atheromata obtained from type 2 diabetic patients undergoing atherectomy, probably reflecting increased levels in the vessel wall [",
"      <a class=\"abstract\" href=\"UTD.htm?26/37/27226/abstract/104\">",
"       104",
"      </a>",
"      ].",
"      <br/>",
"      <br/>",
"      Hyperglycemia may contribute to impaired fibrinolysis via nonenzymatic glycosylation of certain proteins. LDL normally stimulates the production of PAI-1 and reduces the generation of tPA; these effects are enhanced by glycosylated LDL [",
"      <a class=\"abstract\" href=\"UTD.htm?26/37/27226/abstract/105\">",
"       105",
"      </a>",
"      ]. In addition, precursors of insulin such as proinsulin, the plasma concentrations of which are increased in patients with type 2 diabetes, also can contribute to the increase in PAI-1 synthesis [",
"      <a class=\"abstract\" href=\"UTD.htm?26/37/27226/abstract/106\">",
"       106",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Both tissue factor and blood thrombogenicity are increased in patients with poorly controlled diabetes and return toward normal with improved glycemic control [",
"      <a class=\"abstract\" href=\"UTD.htm?26/37/27226/abstract/107\">",
"       107",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h2\">",
"     Plaque composition",
"    </span>",
"    &nbsp;&mdash;&nbsp;Plaque composition may differ in diabetics and affect coronary risk. In a histologic study of atherectomy specimens from patients with and without diabetes, coronary tissue from diabetics contained a greater amount of lipid-rich atheroma, more macrophage infiltration, both of which are associated with a greater risk for plaque rupture, and a higher incidence of thrombosis [",
"    <a class=\"abstract\" href=\"UTD.htm?26/37/27226/abstract/108\">",
"     108",
"    </a>",
"    ]. However, plaques from younger patients with type 1 diabetes at autopsy were characterized by dense fibrous tissue and few foam cells, which should enhance plaque stability [",
"    <a class=\"abstract\" href=\"UTD.htm?26/37/27226/abstract/109\">",
"     109",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/7/25721?source=see_link\">",
"     \"The role of the vulnerable plaque in acute coronary syndromes\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26\">",
"    <span class=\"h1\">",
"     MULTIFACTORIAL RISK FACTOR REDUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Risk factor reduction is effective for the secondary prevention of cardiovascular disease. This is relevant to patients with diabetes since, as mentioned above, the National Cholesterol Education Program report considered diabetes to be a CHD equivalent [",
"    <a class=\"abstract\" href=\"UTD.htm?26/37/27226/abstract/2\">",
"     2",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/60/40906?source=see_link\">",
"     \"Secondary prevention of cardiovascular disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The different components and efficacy of risk factor reduction in diabetic patients, including the importance of glycemic control, are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/38/36458?source=see_link&amp;anchor=H17#H17\">",
"     \"Overview of medical care in adults with diabetes mellitus\", section on 'Multifactorial risk factor reduction'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?7/25/7578?source=see_link\">",
"     \"Glycemic control and vascular complications in type 2 diabetes mellitus\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?11/34/11817?source=see_link\">",
"     \"Glycemic control and vascular complications in type 1 diabetes mellitus\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/45/21210?source=see_link\">",
"     \"Treatment of hypertension in patients with diabetes mellitus\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Beyond the Basics topics (see",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?35/26/36259?source=see_link\">",
"       \"Patient information: Diabetes mellitus type 1: Overview (Beyond the Basics)\"",
"      </a>",
"      and",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?9/22/9572?source=see_link\">",
"       \"Patient information: Diabetes mellitus type 2: Overview (Beyond the Basics)\"",
"      </a>",
"      and",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?40/1/40980?source=see_link\">",
"       \"Patient information: Preventing complications in diabetes mellitus (Beyond the Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/37/27226/abstract/1\">",
"      Grundy SM, Benjamin IJ, Burke GL, et al. Diabetes and cardiovascular disease: a statement for healthcare professionals from the American Heart Association. Circulation 1999; 100:1134.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/37/27226/abstract/2\">",
"      National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. Circulation 2002; 106:3143.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/37/27226/abstract/3\">",
"      De Backer G, Ambrosioni E, Borch-Johnsen K, et al. European guidelines on cardiovascular disease prevention in clinical practice: third joint task force of European and other societies on cardiovascular disease prevention in clinical practice (constituted by representatives of eight societies and by invited experts). Eur J Cardiovasc Prev Rehabil 2003; 10:S1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/37/27226/abstract/4\">",
"      Haffner SM, Lehto S, R&ouml;nnemaa T, et al. Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction. N Engl J Med 1998; 339:229.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/37/27226/abstract/5\">",
"      Kannel WB, McGee DL. Diabetes and cardiovascular risk factors: the Framingham study. Circulation 1979; 59:8.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/37/27226/abstract/6\">",
"      Stamler J, Vaccaro O, Neaton JD, Wentworth D. Diabetes, other risk factors, and 12-yr cardiovascular mortality for men screened in the Multiple Risk Factor Intervention Trial. Diabetes Care 1993; 16:434.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/37/27226/abstract/7\">",
"      Emerging Risk Factors Collaboration, Sarwar N, Gao P, et al. Diabetes mellitus, fasting blood glucose concentration, and risk of vascular disease: a collaborative meta-analysis of 102 prospective studies. Lancet 2010; 375:2215.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/37/27226/abstract/8\">",
"      Krolewski AS, Kosinski EJ, Warram JH, et al. Magnitude and determinants of coronary artery disease in juvenile-onset, insulin-dependent diabetes mellitus. Am J Cardiol 1987; 59:750.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/37/27226/abstract/9\">",
"      Barrett-Connor E, Orchard TJ. Insulin-dependent diabetes mellitus and ischemic heart disease. Diabetes Care 1985; 8 Suppl 1:65.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/37/27226/abstract/10\">",
"      Booth GL, Kapral MK, Fung K, Tu JV. Relation between age and cardiovascular disease in men and women with diabetes compared with non-diabetic people: a population-based retrospective cohort study. Lancet 2006; 368:29.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/37/27226/abstract/11\">",
"      Robertson WB, Strong JP. Atherosclerosis in persons with hypertension and diabetes mellitus. Lab Invest 1968; 18:538.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/37/27226/abstract/12\">",
"      Waller BF, Palumbo PJ, Lie JT, Roberts WC. Status of the coronary arteries at necropsy in diabetes mellitus with onset after age 30 years. Analysis of 229 diabetic patients with and without clinical evidence of coronary heart disease and comparison to 183 control subjects. Am J Med 1980; 69:498.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/37/27226/abstract/13\">",
"      Pajunen P, Taskinen MR, Nieminen MS, Syv&auml;nne M. Angiographic severity and extent of coronary artery disease in patients with type 1 diabetes mellitus. Am J Cardiol 2000; 86:1080.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/37/27226/abstract/14\">",
"      Stein B, Weintraub WS, Gebhart SP, et al. Influence of diabetes mellitus on early and late outcome after percutaneous transluminal coronary angioplasty. Circulation 1995; 91:979.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/37/27226/abstract/15\">",
"      Granger CB, Califf RM, Young S, et al. Outcome of patients with diabetes mellitus and acute myocardial infarction treated with thrombolytic agents. The Thrombolysis and Angioplasty in Myocardial Infarction (TAMI) Study Group. J Am Coll Cardiol 1993; 21:920.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/37/27226/abstract/16\">",
"      Mueller HS, Cohen LS, Braunwald E, et al. Predictors of early morbidity and mortality after thrombolytic therapy of acute myocardial infarction. Analyses of patient subgroups in the Thrombolysis in Myocardial Infarction (TIMI) trial, phase II. Circulation 1992; 85:1254.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/37/27226/abstract/17\">",
"      Natali A, Vichi S, Landi P, et al. Coronary atherosclerosis in Type II diabetes: angiographic findings and clinical outcome. Diabetologia 2000; 43:632.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/37/27226/abstract/18\">",
"      Melidonis A, Dimopoulos V, Lempidakis E, et al. Angiographic study of coronary artery disease in diabetic patients in comparison with nondiabetic patients. Angiology 1999; 50:997.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/37/27226/abstract/19\">",
"      Pajunen P, Nieminen MS, Taskinen MR, Syv&auml;nne M. Quantitative comparison of angiographic characteristics of coronary artery disease in patients with noninsulin-dependent diabetes mellitus compared with matched nondiabetic control subjects. Am J Cardiol 1997; 80:550.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/37/27226/abstract/20\">",
"      Scognamiglio R, Negut C, Ramondo A, et al. Detection of coronary artery disease in asymptomatic patients with type 2 diabetes mellitus. J Am Coll Cardiol 2006; 47:65.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/37/27226/abstract/21\">",
"      Fox CS, Coady S, Sorlie PD, et al. Trends in cardiovascular complications of diabetes. JAMA 2004; 292:2495.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/37/27226/abstract/22\">",
"      Gu K, Cowie CC, Harris MI. Diabetes and decline in heart disease mortality in US adults. JAMA 1999; 281:1291.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/37/27226/abstract/23\">",
"      Yusuf S, Hawken S, Ounpuu S, et al. Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): case-control study. Lancet 2004; 364:937.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/37/27226/abstract/24\">",
"      Lee CD, Folsom AR, Pankow JS, et al. Cardiovascular events in diabetic and nondiabetic adults with or without history of myocardial infarction. Circulation 2004; 109:855.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/37/27226/abstract/25\">",
"      Juutilainen A, Lehto S, R&ouml;nnemaa T, et al. Type 2 diabetes as a \"coronary heart disease equivalent\": an 18-year prospective population-based study in Finnish subjects. Diabetes Care 2005; 28:2901.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/37/27226/abstract/26\">",
"      Hu G, Jousilahti P, Qiao Q, et al. The gender-specific impact of diabetes and myocardial infarction at baseline and during follow-up on mortality from all causes and coronary heart disease. J Am Coll Cardiol 2005; 45:1413.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/37/27226/abstract/27\">",
"      Abaci A, Ouzhan A, Kahraman S, et al. Effect of diabetes mellitus on formation of coronary collateral vessels. Circulation 1999; 99:2239.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/37/27226/abstract/28\">",
"      Anand DV, Lim E, Lahiri A, Bax JJ. The role of non-invasive imaging in the risk stratification of asymptomatic diabetic subjects. Eur Heart J 2006; 27:905.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/37/27226/abstract/29\">",
"      Yokoyama I, Momomura S, Ohtake T, et al. Reduced myocardial flow reserve in non-insulin-dependent diabetes mellitus. J Am Coll Cardiol 1997; 30:1472.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/37/27226/abstract/30\">",
"      Di Carli MF, Bianco-Batlles D, Landa ME, et al. Effects of autonomic neuropathy on coronary blood flow in patients with diabetes mellitus. Circulation 1999; 100:813.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/37/27226/abstract/31\">",
"      Niakan E, Harati Y, Rolak LA, et al. Silent myocardial infarction and diabetic cardiovascular autonomic neuropathy. Arch Intern Med 1986; 146:2229.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/37/27226/abstract/32\">",
"      Faerman I, Faccio E, Milei J, et al. Autonomic neuropathy and painless myocardial infarction in diabetic patients. Histologic evidence of their relationship. Diabetes 1977; 26:1147.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/37/27226/abstract/33\">",
"      Langer A, Freeman MR, Josse RG, Armstrong PW. Metaiodobenzylguanidine imaging in diabetes mellitus: assessment of cardiac sympathetic denervation and its relation to autonomic dysfunction and silent myocardial ischemia. J Am Coll Cardiol 1995; 25:610.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/37/27226/abstract/34\">",
"      Watkins PJ, Mackay JD. Cardiac denervation in diabetic neuropathy. Ann Intern Med 1980; 92:304.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/37/27226/abstract/35\">",
"      Stevens MJ, Raffel DM, Allman KC, et al. Cardiac sympathetic dysinnervation in diabetes: implications for enhanced cardiovascular risk. Circulation 1998; 98:961.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/37/27226/abstract/36\">",
"      Ranjadayalan K, Umachandran V, Ambepityia G, et al. Prolonged anginal perceptual threshold in diabetes: effects on exercise capacity and myocardial ischemia. J Am Coll Cardiol 1990; 16:1120.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/37/27226/abstract/37\">",
"      Kannel WB. Lipids, diabetes, and coronary heart disease: insights from the Framingham Study. Am Heart J 1985; 110:1100.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/37/27226/abstract/38\">",
"      Margolis JR, Kannel WS, Feinleib M, et al. Clinical features of unrecognized myocardial infarction--silent and symptomatic. Eighteen year follow-up: the Framingham study. Am J Cardiol 1973; 32:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/37/27226/abstract/39\">",
"      Shlipak MG, Elmouchi DA, Herrington DM, et al. The incidence of unrecognized myocardial infarction in women with coronary heart disease. Ann Intern Med 2001; 134:1043.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/37/27226/abstract/40\">",
"      Norhammar A, Tenerz A, Nilsson G, et al. Glucose metabolism in patients with acute myocardial infarction and no previous diagnosis of diabetes mellitus: a prospective study. Lancet 2002; 359:2140.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/37/27226/abstract/41\">",
"      Hu FB, Stampfer MJ, Haffner SM, et al. Elevated risk of cardiovascular disease prior to clinical diagnosis of type 2 diabetes. Diabetes Care 2002; 25:1129.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/37/27226/abstract/42\">",
"      Coutinho M, Gerstein HC, Wang Y, Yusuf S. The relationship between glucose and incident cardiovascular events. A metaregression analysis of published data from 20 studies of 95,783 individuals followed for 12.4 years. Diabetes Care 1999; 22:233.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/37/27226/abstract/43\">",
"      Qiao Q, Py&ouml;r&auml;l&auml; K, Py&ouml;r&auml;l&auml; M, et al. Two-hour glucose is a better risk predictor for incident coronary heart disease and cardiovascular mortality than fasting glucose. Eur Heart J 2002; 23:1267.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/37/27226/abstract/44\">",
"      Singer DE, Nathan DM, Anderson KM, et al. Association of HbA1c with prevalent cardiovascular disease in the original cohort of the Framingham Heart Study. Diabetes 1992; 41:202.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/37/27226/abstract/45\">",
"      DECODE Study Group, the European Diabetes Epidemiology Group.. Glucose tolerance and cardiovascular mortality: comparison of fasting and 2-hour diagnostic criteria. Arch Intern Med 2001; 161:397.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/37/27226/abstract/46\">",
"      Levitan EB, Song Y, Ford ES, Liu S. Is nondiabetic hyperglycemia a risk factor for cardiovascular disease? A meta-analysis of prospective studies. Arch Intern Med 2004; 164:2147.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/37/27226/abstract/47\">",
"      Khaw KT, Wareham N, Bingham S, et al. Association of hemoglobin A1c with cardiovascular disease and mortality in adults: the European prospective investigation into cancer in Norfolk. Ann Intern Med 2004; 141:413.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/37/27226/abstract/48\">",
"      Sui X, Lavie CJ, Hooker SP, et al. A prospective study of fasting plasma glucose and risk of stroke in asymptomatic men. Mayo Clin Proc 2011; 86:1042.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/37/27226/abstract/49\">",
"      Selvin E, Coresh J, Golden SH, et al. Glycemic control and coronary heart disease risk in persons with and without diabetes: the atherosclerosis risk in communities study. Arch Intern Med 2005; 165:1910.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/37/27226/abstract/50\">",
"      Meigs JB, Nathan DM, D'Agostino RB Sr, et al. Fasting and postchallenge glycemia and cardiovascular disease risk: the Framingham Offspring Study. Diabetes Care 2002; 25:1845.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/37/27226/abstract/51\">",
"      Blake DR, Meigs JB, Muller DC, et al. Impaired glucose tolerance, but not impaired fasting glucose, is associated with increased levels of coronary heart disease risk factors: results from the Baltimore Longitudinal Study on Aging. Diabetes 2004; 53:2095.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/37/27226/abstract/52\">",
"      Hammoud T, Tanguay JF, Bourassa MG. Management of coronary artery disease: therapeutic options in patients with diabetes. J Am Coll Cardiol 2000; 36:355.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/37/27226/abstract/53\">",
"      Taegtmeyer H, McNulty P, Young ME. Adaptation and maladaptation of the heart in diabetes: Part I: general concepts. Circulation 2002; 105:1727.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/37/27226/abstract/54\">",
"      Haffner SM, Mykk&auml;nen L, Festa A, et al. Insulin-resistant prediabetic subjects have more atherogenic risk factors than insulin-sensitive prediabetic subjects: implications for preventing coronary heart disease during the prediabetic state. Circulation 2000; 101:975.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/37/27226/abstract/55\">",
"      Mogensen CE, Hansen KW, Pedersen MM, Christensen CK. Renal factors influencing blood pressure threshold and choice of treatment for hypertension in IDDM. Diabetes Care 1991; 14 Suppl 4:13.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/37/27226/abstract/56\">",
"      Adler AI, Stratton IM, Neil HA, et al. Association of systolic blood pressure with macrovascular and microvascular complications of type 2 diabetes (UKPDS 36): prospective observational study. BMJ 2000; 321:412.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/37/27226/abstract/57\">",
"      Chobanian AV, Bakris GL, Black HR, et al. The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report. JAMA 2003; 289:2560.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/37/27226/abstract/58\">",
"      Garg A, Grundy SM. Management of dyslipidemia in NIDDM. Diabetes Care 1990; 13:153.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/37/27226/abstract/59\">",
"      O'Brien T, Nguyen TT, Zimmerman BR. Hyperlipidemia and diabetes mellitus. Mayo Clin Proc 1998; 73:969.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/37/27226/abstract/60\">",
"      Lipid and lipoprotein levels in patients with IDDM diabetes control and complication. Trial experience. The DCCT Research Group. Diabetes Care 1992; 15:886.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/37/27226/abstract/61\">",
"      P&eacute;rez A, W&auml;gner AM, Carreras G, et al. Prevalence and phenotypic distribution of dyslipidemia in type 1 diabetes mellitus: effect of glycemic control. Arch Intern Med 2000; 160:2756.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/37/27226/abstract/62\">",
"      Haffner SM, Stern MP, Hazuda HP, et al. Cardiovascular risk factors in confirmed prediabetic individuals. Does the clock for coronary heart disease start ticking before the onset of clinical diabetes? JAMA 1990; 263:2893.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/37/27226/abstract/63\">",
"      Sacks FM, Tonkin AM, Craven T, et al. Coronary heart disease in patients with low LDL-cholesterol: benefit of pravastatin in diabetics and enhanced role for HDL-cholesterol and triglycerides as risk factors. Circulation 2002; 105:1424.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/37/27226/abstract/64\">",
"      Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial. Lancet 2002; 360:7.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/37/27226/abstract/65\">",
"      Lu W, Resnick HE, Jablonski KA, et al. Non-HDL cholesterol as a predictor of cardiovascular disease in type 2 diabetes: the strong heart study. Diabetes Care 2003; 26:16.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/37/27226/abstract/66\">",
"      Selvin E, Marinopoulos S, Berkenblit G, et al. Meta-analysis: glycosylated hemoglobin and cardiovascular disease in diabetes mellitus. Ann Intern Med 2004; 141:421.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/37/27226/abstract/67\">",
"      Ravipati G, Aronow WS, Ahn C, et al. Association of hemoglobin A(1c) level with the severity of coronary artery disease in patients with diabetes mellitus. Am J Cardiol 2006; 97:968.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/37/27226/abstract/68\">",
"      Huxley R, Barzi F, Woodward M. Excess risk of fatal coronary heart disease associated with diabetes in men and women: meta-analysis of 37 prospective cohort studies. BMJ 2006; 332:73.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/37/27226/abstract/69\">",
"      Gerstein HC, Mann JF, Yi Q, et al. Albuminuria and risk of cardiovascular events, death, and heart failure in diabetic and nondiabetic individuals. JAMA 2001; 286:421.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/37/27226/abstract/70\">",
"      Wachtell K, Ibsen H, Olsen MH, et al. Albuminuria and cardiovascular risk in hypertensive patients with left ventricular hypertrophy: the LIFE study. Ann Intern Med 2003; 139:901.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/37/27226/abstract/71\">",
"      Adler AI, Stevens RJ, Manley SE, et al. Development and progression of nephropathy in type 2 diabetes: the United Kingdom Prospective Diabetes Study (UKPDS 64). Kidney Int 2003; 63:225.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/37/27226/abstract/72\">",
"      Ninomiya T, Perkovic V, de Galan BE, et al. Albuminuria and kidney function independently predict cardiovascular and renal outcomes in diabetes. J Am Soc Nephrol 2009; 20:1813.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/37/27226/abstract/73\">",
"      Gregg EW, Gerzoff RB, Caspersen CJ, et al. Relationship of walking to mortality among US adults with diabetes. Arch Intern Med 2003; 163:1440.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/37/27226/abstract/74\">",
"      Hu G, Eriksson J, Barengo NC, et al. Occupational, commuting, and leisure-time physical activity in relation to total and cardiovascular mortality among Finnish subjects with type 2 diabetes. Circulation 2004; 110:666.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/37/27226/abstract/75\">",
"      Ajani UA, Gaziano JM, Lotufo PA, et al. Alcohol consumption and risk of coronary heart disease by diabetes status. Circulation 2000; 102:500.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/37/27226/abstract/76\">",
"      Solomon CG, Hu FB, Stampfer MJ, et al. Moderate alcohol consumption and risk of coronary heart disease among women with type 2 diabetes mellitus. Circulation 2000; 102:494.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/37/27226/abstract/77\">",
"      Hoogeveen EK, Kostense PJ, Jakobs C, et al. Hyperhomocysteinemia increases risk of death, especially in type 2 diabetes : 5-year follow-up of the Hoorn Study. Circulation 2000; 101:1506.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/37/27226/abstract/78\">",
"      Eckel RH, Wassef M, Chait A, et al. Prevention Conference VI: Diabetes and Cardiovascular Disease: Writing Group II: pathogenesis of atherosclerosis in diabetes. Circulation 2002; 105:e138.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/37/27226/abstract/79\">",
"      Clarkson P, Celermajer DS, Donald AE, et al. Impaired vascular reactivity in insulin-dependent diabetes mellitus is related to disease duration and low density lipoprotein cholesterol levels. J Am Coll Cardiol 1996; 28:573.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/37/27226/abstract/80\">",
"      M&auml;kimattila S, Virkam&auml;ki A, Groop PH, et al. Chronic hyperglycemia impairs endothelial function and insulin sensitivity via different mechanisms in insulin-dependent diabetes mellitus. Circulation 1996; 94:1276.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/37/27226/abstract/81\">",
"      Di Carli MF, Janisse J, Grunberger G, Ager J. Role of chronic hyperglycemia in the pathogenesis of coronary microvascular dysfunction in diabetes. J Am Coll Cardiol 2003; 41:1387.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/37/27226/abstract/82\">",
"      Miura H, Wachtel RE, Loberiza FR Jr, et al. Diabetes mellitus impairs vasodilation to hypoxia in human coronary arterioles: reduced activity of ATP-sensitive potassium channels. Circ Res 2003; 92:151.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/37/27226/abstract/83\">",
"      Nitenberg A, Paycha F, Ledoux S, et al. Coronary artery responses to physiological stimuli are improved by deferoxamine but not by L-arginine in non-insulin-dependent diabetic patients with angiographically normal coronary arteries and no other risk factors. Circulation 1998; 97:736.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/37/27226/abstract/84\">",
"      Kawano H, Motoyama T, Hirashima O, et al. Hyperglycemia rapidly suppresses flow-mediated endothelium-dependent vasodilation of brachial artery. J Am Coll Cardiol 1999; 34:146.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/37/27226/abstract/85\">",
"      Qui&ntilde;ones MJ, Hernandez-Pampaloni M, Schelbert H, et al. Coronary vasomotor abnormalities in insulin-resistant individuals. Ann Intern Med 2004; 140:700.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/37/27226/abstract/86\">",
"      Hsueh WA, Lyon CJ, Qui&ntilde;ones MJ. Insulin resistance and the endothelium. Am J Med 2004; 117:109.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/37/27226/abstract/87\">",
"      Mather KJ, Verma S, Anderson TJ. Improved endothelial function with metformin in type 2 diabetes mellitus. J Am Coll Cardiol 2001; 37:1344.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/37/27226/abstract/88\">",
"      Mullen MJ, Wright D, Donald AE, et al. Atorvastatin but not L-arginine improves endothelial function in type I diabetes mellitus: a double-blind study. J Am Coll Cardiol 2000; 36:410.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/37/27226/abstract/89\">",
"      Skyrme-Jones RA, O'Brien RC, Berry KL, Meredith IT. Vitamin E supplementation improves endothelial function in type I diabetes mellitus: a randomized, placebo-controlled study. J Am Coll Cardiol 2000; 36:94.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/37/27226/abstract/90\">",
"      Winocour PD. Platelet abnormalities in diabetes mellitus. Diabetes 1992; 41 Suppl 2:26.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/37/27226/abstract/91\">",
"      Dav&igrave; G, Catalano I, Averna M, et al. Thromboxane biosynthesis and platelet function in type II diabetes mellitus. N Engl J Med 1990; 322:1769.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/37/27226/abstract/92\">",
"      Calverley DC, Hacker MR, Loda KA, et al. Increased platelet Fc receptor expression as a potential contributing cause of platelet hypersensitivity to collagen in diabetes mellitus. Br J Haematol 2003; 121:139.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/37/27226/abstract/93\">",
"      Dav&igrave; G, Ciabattoni G, Consoli A, et al. In vivo formation of 8-iso-prostaglandin f2alpha and platelet activation in diabetes mellitus: effects of improved metabolic control and vitamin E supplementation. Circulation 1999; 99:224.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/37/27226/abstract/94\">",
"      Rosove MH, Frank HJ, Harwig SS. Plasma beta-thromboglobulin, platelet factor 4, fibrinopeptide A, and other hemostatic functions during improved, short-term glycemic control in diabetes mellitus. Diabetes Care 1984; 7:174.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/37/27226/abstract/95\">",
"      Shechter M, Merz CN, Paul-Labrador MJ, Kaul S. Blood glucose and platelet-dependent thrombosis in patients with coronary artery disease. J Am Coll Cardiol 2000; 35:300.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/37/27226/abstract/96\">",
"      Kwaan HC. Changes in blood coagulation, platelet function, and plasminogen-plasmin system in diabetes. Diabetes 1992; 41 Suppl 2:32.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/37/27226/abstract/97\">",
"      Ostermann H, van de Loo J. Factors of the hemostatic system in diabetic patients. A survey of controlled studies. Haemostasis 1986; 16:386.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/37/27226/abstract/98\">",
"      Saito I, Folsom AR, Brancati FL, et al. Nontraditional risk factors for coronary heart disease incidence among persons with diabetes: the Atherosclerosis Risk in Communities (ARIC) Study. Ann Intern Med 2000; 133:81.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/37/27226/abstract/99\">",
"      Stec JJ, Silbershatz H, Tofler GH, et al. Association of fibrinogen with cardiovascular risk factors and cardiovascular disease in the Framingham Offspring Population. Circulation 2000; 102:1634.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/37/27226/abstract/100\">",
"      Badawi H, el-Sawy M, Mikhail M, et al. Platelets, coagulation and fibrinolysis in diabetic and non-diabetic patients with quiescent coronary heart disease. Angiology 1970; 21:511.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/37/27226/abstract/101\">",
"      Small M, Lowe GD, MacCuish AC, Forbes CD. Thrombin and plasmin activity in diabetes mellitus and their association with glycaemic control. Q J Med 1987; 65:1025.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/37/27226/abstract/102\">",
"      Gray RP, Patterson DL, Yudkin JS. Plasminogen activator inhibitor activity in diabetic and nondiabetic survivors of myocardial infarction. Arterioscler Thromb 1993; 13:415.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/37/27226/abstract/103\">",
"      McGill JB, Schneider DJ, Arfken CL, et al. Factors responsible for impaired fibrinolysis in obese subjects and NIDDM patients. Diabetes 1994; 43:104.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/37/27226/abstract/104\">",
"      Sobel BE, Woodcock-Mitchell J, Schneider DJ, et al. Increased plasminogen activator inhibitor type 1 in coronary artery atherectomy specimens from type 2 diabetic compared with nondiabetic patients: a potential factor predisposing to thrombosis and its persistence. Circulation 1998; 97:2213.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/37/27226/abstract/105\">",
"      Zhang J, Ren S, Sun D, Shen GX. Influence of glycation on LDL-induced generation of fibrinolytic regulators in vascular endothelial cells. Arterioscler Thromb Vasc Biol 1998; 18:1140.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/37/27226/abstract/106\">",
"      Nordt TK, Schneider DJ, Sobel BE. Augmentation of the synthesis of plasminogen activator inhibitor type-1 by precursors of insulin. A potential risk factor for vascular disease. Circulation 1994; 89:321.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/37/27226/abstract/107\">",
"      Sambola A, Osende J, Hathcock J, et al. Role of risk factors in the modulation of tissue factor activity and blood thrombogenicity. Circulation 2003; 107:973.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/37/27226/abstract/108\">",
"      Moreno PR, Murcia AM, Palacios IF, et al. Coronary composition and macrophage infiltration in atherectomy specimens from patients with diabetes mellitus. Circulation 2000; 102:2180.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/37/27226/abstract/109\">",
"      Mautner SL, Lin F, Roberts WC. Composition of atherosclerotic plaques in the epicardial coronary arteries in juvenile (type I) diabetes mellitus. Am J Cardiol 1992; 70:1264.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 1542 Version 8.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0605-83.177.194.223-190351C039-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f26_37_27226=[""].join("\n");
var outline_f26_37_27226=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      PREVALENCE",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Diabetes as a CHD equivalent",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      - Extent of coronary disease",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      - Temporal trends",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Myocardial infarction",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Asymptomatic CHD",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      - Silent ischemia and infarction",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      CHD before diabetes",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      RISK FACTORS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Hypertension",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Dyslipidemia",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Smoking",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Hyperglycemia",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      - Effect of glycemic control",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Sex",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      Microalbuminuria",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      Exercise",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      Lack of moderate alcohol intake",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      Hyperhomocysteinemia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      MECHANISMS OF INCREASED RISK",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      Endothelial dysfunction",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      Platelet activation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      Coagulation abnormalities",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      Plaque composition",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H26\">",
"      MULTIFACTORIAL RISK FACTOR REDUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"CARD/1542\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"CARD/1542|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?34/1/34845\" title=\"figure 1\">",
"      Diabetes increases coronary mortality",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?26/52/27469\" title=\"figure 2\">",
"      Systolic BP in type 2 diabetes",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"CARD/1542|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?34/17/35100\" title=\"table 1A\">",
"      Eval risk factor CHD DM I",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?15/47/16124\" title=\"table 1B\">",
"      Eval risk factor CHD DM II",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?34/41/35484\" title=\"table 2\">",
"      Classification and management of blood pressure",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?10/46/10989\" title=\"table 3\">",
"      Proposed ATPIII LDL goals",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?10/56/11147\" title=\"table 4\">",
"      NCEP very high risk",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/33/31258?source=related_link\">",
"      Cardiovascular benefits and risks of moderate alcohol consumption",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?36/51/37685?source=related_link\">",
"      Cardiovascular risks of hypertension",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/15/30970?source=related_link\">",
"      Coronary artery revascularization in patients with diabetes mellitus and multivessel coronary artery disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/57/28570?source=related_link\">",
"      Determinants and management of cardiovascular risk in women",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?8/46/8938?source=related_link\">",
"      Diabetic autonomic neuropathy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?43/20/44361?source=related_link\">",
"      Epidemiology of coronary heart disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?14/28/14793?source=related_link\">",
"      Exercise and fitness in the prevention of cardiovascular disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?11/34/11817?source=related_link\">",
"      Glycemic control and vascular complications in type 1 diabetes mellitus",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?7/25/7578?source=related_link\">",
"      Glycemic control and vascular complications in type 2 diabetes mellitus",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?43/33/44567?source=related_link\">",
"      Glycemic control for acute myocardial infarction in patients with and without diabetes mellitus",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?20/16/20745?source=related_link\">",
"      High albuminuria (microalbuminuria) and cardiovascular disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?2/59/3002?source=related_link\">",
"      Intensity of lipid lowering therapy in secondary prevention of coronary heart disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?41/49/42777?source=related_link\">",
"      Microalbuminuria in type 1 diabetes mellitus",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?38/33/39449?source=related_link\">",
"      Microalbuminuria in type 2 diabetes mellitus",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?18/37/19034?source=related_link\">",
"      Overview of homocysteine",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?35/38/36458?source=related_link\">",
"      Overview of medical care in adults with diabetes mellitus",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?38/59/39866?source=related_link\">",
"      Overview of the risk equivalents and established risk factors for cardiovascular disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?35/26/36259?source=related_link\">",
"      Patient information: Diabetes mellitus type 1: Overview (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?9/22/9572?source=related_link\">",
"      Patient information: Diabetes mellitus type 2: Overview (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?40/1/40980?source=related_link\">",
"      Patient information: Preventing complications in diabetes mellitus (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?18/20/18761?source=related_link\">",
"      Screening for coronary heart disease in patients with diabetes mellitus",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?39/60/40906?source=related_link\">",
"      Secondary prevention of cardiovascular disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/33/28180?source=related_link\">",
"      Silent myocardial ischemia: Diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?5/4/5189?source=related_link\">",
"      Smoking and cardiovascular risk in diabetes mellitus",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?32/11/32954?source=related_link\">",
"      The metabolic syndrome (insulin resistance syndrome or syndrome X)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?25/7/25721?source=related_link\">",
"      The role of the vulnerable plaque in acute coronary syndromes",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?40/20/41289?source=related_link\">",
"      Treatment of acute myocardial infarction in diabetes mellitus",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?20/45/21210?source=related_link\">",
"      Treatment of hypertension in patients with diabetes mellitus",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?25/32/26122?source=related_link\">",
"      Treatment of lipids (including hypercholesterolemia) in secondary prevention",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f26_37_27227="AIP HISORt criteria";
var content_f26_37_27227=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=GAST%2F74331&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=GAST%2F74331&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Summary of criteria for diagnosing autoimmune pancreatitis (revised HISORt criteria)",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td>",
"        <strong>",
"         <span class=\"red\">",
"          (H)",
"         </span>",
"         Histology",
"        </strong>",
"        suggestive of autoimmine pancreatitis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <strong>",
"         <span class=\"red\">",
"          (I)",
"         </span>",
"        </strong>",
"        Pancreatic",
"        <strong>",
"         imaging",
"        </strong>",
"        suggestive of autoimmine pancreatitis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <strong>",
"         <span class=\"red\">",
"          (S)",
"         </span>",
"         Serology",
"        </strong>",
"        (IgG4 &ge;2 times the upper limit of normal)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <strong>",
"         <span class=\"red\">",
"          (O)",
"         </span>",
"        </strong>",
"        <strong>",
"         Other",
"        </strong>",
"        organ involvement",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent2\">",
"        Biliary strictures, parotid/lacrimal gland involvement, mediastinal lymphadenopathy, retroperitoneal fibrosis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <strong>",
"         <span class=\"red\">",
"          (Rt)",
"         </span>",
"         &nbsp;Response to steroid treatment",
"        </strong>",
"        &nbsp;- Resolution/marked improvement of pancreatic and extrapancreatic manifestations",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Adapted from: Chari ST, Takahashi N, Levy MJ, et al. A diagnostic strategy to distinguish autoimmune pancreatitis from pancreatic cancer. Clin Gastroenterol Hepatol 2009; 7:1097.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f26_37_27227=[""].join("\n");
var outline_f26_37_27227=null;
var title_f26_37_27228="IPSS in MDS";
var content_f26_37_27228=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=HEME%2F50634&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=HEME%2F50634&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    International prognosis scoring system (IPSS) in myelodysplastic syndrome",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\" rowspan=\"2\">",
"        Variable",
"       </td>",
"       <td class=\"subtitle1\" colspan=\"5\">",
"        Score",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2\">",
"        0",
"       </td>",
"       <td class=\"subtitle2\">",
"        0.5",
"       </td>",
"       <td class=\"subtitle2\">",
"        1.0",
"       </td>",
"       <td class=\"subtitle2\">",
"        1.5",
"       </td>",
"       <td class=\"subtitle2\">",
"        2.0",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\">",
"        Bone marrow blasts (percent)",
"       </td>",
"       <td>",
"        &lt;5",
"       </td>",
"       <td>",
"        5 to 10",
"       </td>",
"       <td>",
"        -",
"       </td>",
"       <td>",
"        11 to 20",
"       </td>",
"       <td>",
"        21 to 30",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\">",
"        Karyotype*",
"       </td>",
"       <td>",
"        Good",
"       </td>",
"       <td>",
"        Intermediate",
"       </td>",
"       <td>",
"        Poor",
"       </td>",
"       <td>",
"        -",
"       </td>",
"       <td>",
"        -",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\">",
"        Cytopenias",
"        <sup>",
"         &bull;",
"        </sup>",
"       </td>",
"       <td>",
"        0/1",
"       </td>",
"       <td>",
"        2/3",
"       </td>",
"       <td>",
"        -",
"       </td>",
"       <td>",
"        -",
"       </td>",
"       <td>",
"        -",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Risk group",
"       </td>",
"       <td class=\"subtitle1\" colspan=\"5\">",
"        IPSS score",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Low",
"       </td>",
"       <td colspan=\"5\">",
"        0",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Intermediate-1",
"       </td>",
"       <td colspan=\"5\">",
"        0.5 to 1.0",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Intermediate-2",
"       </td>",
"       <td colspan=\"5\">",
"        1.5 to 2.0",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        High",
"       </td>",
"       <td colspan=\"5\">",
"        2.5 to 3.5",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <strong>",
"     Scoring system:",
"    </strong>",
"    A score from zero to two is determined for each of the three variables; the three values are added obtain the IPSS score. Thus, a patient with 12 percent bone marrow blasts (score 1.5), complex chromosomal changes (poor karyotype score 1.0), neutrophil count of 1000/microL, and platelet count of 50,000/microL (two cytopenias, score 0.5) would have an IPSS score of 3.0 (ie, high risk).",
"    <div class=\"footnotes\">",
"     * Karytope definitions:",
"     <br>",
"      Good: Normal;-Y; del (5q); del (20q)",
"      <br>",
"       Poor: Complex (&ge;3 abnormalities); abnormal chromosome 7",
"       <br>",
"        Intermediate: All others",
"        <br>",
"         &bull; Cytopenia definitions:",
"         <br>",
"          Red blood cells: Hemoglobin &lt;10 g/dL (100 g/L)",
"          <br>",
"           White blood cells: Absolute neutrophil count &lt;1800/microL",
"           <br>",
"            Platelets: Platelet count &lt;100,000/microL",
"           </br>",
"          </br>",
"         </br>",
"        </br>",
"       </br>",
"      </br>",
"     </br>",
"    </div>",
"    <div class=\"reference\">",
"     Adapted from:&nbsp;Greenberg P, Cox C, LeBeau MM, et al. International scoring system for evaluating prognosis in myelodysplastic syndromes. Blood 1997; 89:2079. Erratum in Blood 1998; 91:1100.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f26_37_27228=[""].join("\n");
var outline_f26_37_27228=null;
var title_f26_37_27229="Drug causes of AUR";
var content_f26_37_27229=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PC%2F75763&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PC%2F75763&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Pharmacologic agents associated with urinary retention",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tr>",
"      <td class=\"subtitle1_single\">",
"       Sympathomimelics (alpha-adrenergic agents)",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Ephedrine sulfate (Marax, Tedral)",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Phenylephrine HCl (Neo-Synephrine)",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Phenylpropanolamine HCL (Conlac)",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Pseudoephedrine HCl (Sudafed, Actifed)",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"subtitle1_single\">",
"       Sympathomimetics (beta-adrenergic agents)",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Isoproterenol",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Metaproterenol",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Terbutaline",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"subtitle1_single\">",
"       Antidepressants",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Imipramine (Tofranil)",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Nortriptyline (Aventyl)",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Amitriptyline (Elavil)",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Doxepin (Adapin)",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Amoxepine (Asendin)",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Maprotiline (Ludiomil)",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"subtitle1_single\">",
"       Antiarrhythmics",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Quinidine",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Procainamide",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Disopyramide",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"subtitle1_single\">",
"       Anticholinergics (selected)",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Atropine",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Scopolamine hydrobromide",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Clidinium bromide (Quarzan)",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Glycopyrrolate (Robinul)",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Mepenzolate bromide (Cantil)",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Oxybutynin (Ditropan)",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Flavoxate HCl (Urispas)",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Hyoscyamine sulfate (Anaspaz)",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Belladonna",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Homatropine methylbromide",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Propantheline bromide (Probanthine)",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Dicyclomine HCl (Bentyl)",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"subtitle1_single\">",
"       Antiparkinsonian agents",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Trihexyphenidyl HCl (Arlane)",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Benztropine Mesylate (Cogentin)",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Amantadine HCl (Symmetrel)",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Levodopa (Sinemet)",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Bromocriptine Mesylate (Parlodel)",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"subtitle1_single\">",
"       Hormonal agents",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Progesterone",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Estrogen",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Testosterone",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"subtitle1_single\">",
"       Antipsychotics",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Haloperidol (Haldol)",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Thiothixene (Navane)",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Thioridizine (Mellaril)",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Chlorpromazine (Thorazine)",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Fluphenazine (Prolixin)",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Prochlorperazine (Compazine)",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"subtitle1_single\">",
"       Antihistamines (selected)",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Diphenhydramine HCl (Benadryl)",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Chlorpheniramine (Chlor-Trimeton)",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Brompheniramine (Dimetane)",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Cyproheptadine (Periactin)",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Hydroxyzine (Atarax, Vistaril)",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"subtitle1_single\">",
"       Antihypertensives",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Hydralazine (Apresoline)",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Nifedipine (Procardia)",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"subtitle1_single\">",
"       Muscle relaxants",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Diazepam (Valium)",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Baclofen (Lioresal)",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Cyclobenzaprine (Flexeril)",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"subtitle1_single\">",
"       Miscellaneous",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Indomethacin (Indocin)",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Carbamazepine (Tegretol)",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Amphetamines",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Dopamine",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Vincristine",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Morphine sulfate and other opioids",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Anesthetic agents",
"      </td>",
"     </tr>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Curtis, LA, Dolan, TS, Cespedes, RD. Acute urinary retention and urinary incontinence. Emergency Medicine Clinics of North America 2001; 19:591. Copyright &copy;2001 Elsevier.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f26_37_27229=[""].join("\n");
var outline_f26_37_27229=null;
var title_f26_37_27230="Skin in eosinophilic fasciitis";
var content_f26_37_27230=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=RHEUM%2F65829&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=RHEUM%2F65829&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Eosinophilic fasciitis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 437px; height: 207px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    \"Peau d'orange\" changes in a patient with eosinophilic fasciitis. These changes are similar to those observed in patients with morphea.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Carol M Black, MD, FRCP.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f26_37_27230=[""].join("\n");
var outline_f26_37_27230=null;
var title_f26_37_27231="Diet diary PI";
var content_f26_37_27231=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PI%2F58605&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PI%2F58605&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 619px\">",
"   <div class=\"ttl\">",
"    Diet diary",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 599px; height: 788px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f26_37_27231=[""].join("\n");
var outline_f26_37_27231=null;
